{"docstore/data": {"9fe0fe7f-eabb-4cd7-8b9d-05d8aee52bd1": {"__data__": {"id_": "9fe0fe7f-eabb-4cd7-8b9d-05d8aee52bd1", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f19edc3-78bd-4060-b083-6d0421f272b0", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. "}, "hash": "314e8a2ea8d6d4852bf948aef3a276ee144301d36278b09f75215c90ea1e8191", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion. ", "start_char_idx": 0, "end_char_idx": 540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f19edc3-78bd-4060-b083-6d0421f272b0": {"__data__": {"id_": "9f19edc3-78bd-4060-b083-6d0421f272b0", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fe0fe7f-eabb-4cd7-8b9d-05d8aee52bd1", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9980b1930f5c514239a0d8a3a040ce4dd720066c0026420edb07d4d37faa03b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86206a4c-9249-496c-a68f-057d20eb3cae", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter. "}, "hash": "dad9ce87fc11f5ae490fe3f41c15ab411c7435c67524c35e93f0c6a27d0ea757", "class_name": "RelatedNodeInfo"}}, "text": "On the basis of U.S. ", "start_char_idx": 540, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86206a4c-9249-496c-a68f-057d20eb3cae": {"__data__": {"id_": "86206a4c-9249-496c-a68f-057d20eb3cae", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f19edc3-78bd-4060-b083-6d0421f272b0", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021. ", "original_text": "On the basis of U.S. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17300085cccb29a7f30349a3efe35ec868164866bd8f949a2360235193e3f838", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7310391-fadf-4911-822c-44ad0d3f2b2e", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n"}, "hash": "95c6c7e6e222bbfd8d5d6e794d014c3dd1d59d009a92a5b229536fd1884decf0", "class_name": "RelatedNodeInfo"}}, "text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter. ", "start_char_idx": 561, "end_char_idx": 735, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7310391-fadf-4911-822c-44ad0d3f2b2e": {"__data__": {"id_": "d7310391-fadf-4911-822c-44ad0d3f2b2e", "embedding": null, "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86206a4c-9249-496c-a68f-057d20eb3cae", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "original_text": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7663bcc2207cc58194879399e77db21471bf318a7113e3f2f489a6d2a900e17b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e8526d6-be8e-485d-956e-f3c08e0dbccb", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. "}, "hash": "3bd80058d40d5b1928714a55a5fbaf0df9a59ec766dc88a4952069575584a984", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "start_char_idx": 735, "end_char_idx": 883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e8526d6-be8e-485d-956e-f3c08e0dbccb": {"__data__": {"id_": "8e8526d6-be8e-485d-956e-f3c08e0dbccb", "embedding": null, "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7310391-fadf-4911-822c-44ad0d3f2b2e", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "original_text": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b68b44eebe5075c5a7ef8537e741e21c04929e4c0cc15eaaf4c0395ace747b39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3002e3-b2a8-413b-bb08-1ae8412447ed", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. "}, "hash": "564f4cd4aafd6d97153812c2af1c1e7e3cbf69583588fb455bf3bef896ad919a", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "start_char_idx": 883, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3002e3-b2a8-413b-bb08-1ae8412447ed": {"__data__": {"id_": "dc3002e3-b2a8-413b-bb08-1ae8412447ed", "embedding": null, "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e8526d6-be8e-485d-956e-f3c08e0dbccb", "node_type": "1", "metadata": {"window": "On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "original_text": "AmerisourceBergen is updating its outlook for fiscal year 2021. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "951512d05f75672656a39ed9ba0d8ffba3dc641b2e75698edc176b8851e019a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e7cd1ad-7035-4d60-99d3-4ba7d6905783", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n"}, "hash": "82d4141cc9a2517a8e2ac5ae30905c85353c452babe4673a7b3a6aa3c18d998a", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "start_char_idx": 947, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e7cd1ad-7035-4d60-99d3-4ba7d6905783": {"__data__": {"id_": "9e7cd1ad-7035-4d60-99d3-4ba7d6905783", "embedding": null, "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3002e3-b2a8-413b-bb08-1ae8412447ed", "node_type": "1", "metadata": {"window": "generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "original_text": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1381909fbb2d66c706ddb8cc2c08777549839b1f817a862ce8207e0a3c9a3dba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ad34148-97db-4a90-930f-b939088580a7", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued. ", "original_text": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. "}, "hash": "5d0778a7edc5aa18558b3f1cf051b715dffc31951ba930549d806049f40a8edc", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "start_char_idx": 1071, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ad34148-97db-4a90-930f-b939088580a7": {"__data__": {"id_": "4ad34148-97db-4a90-930f-b939088580a7", "embedding": null, "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued. ", "original_text": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e7cd1ad-7035-4d60-99d3-4ba7d6905783", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "original_text": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3daaa469b1277059ec466dcc7b48ae3fa0594ca9c95413b74be77c9102ec55a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaa6ba74-7051-4cd0-a331-f655b65f9305", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "original_text": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n"}, "hash": "7b2d6157d8b728e1fb2e00c3be502d94c6740a87c50002a764310830d72e9766", "class_name": "RelatedNodeInfo"}}, "text": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "start_char_idx": 1268, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaa6ba74-7051-4cd0-a331-f655b65f9305": {"__data__": {"id_": "aaa6ba74-7051-4cd0-a331-f655b65f9305", "embedding": null, "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "original_text": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ad34148-97db-4a90-930f-b939088580a7", "node_type": "1", "metadata": {"window": "AmerisourceBergen is updating its outlook for fiscal year 2021.  The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued. ", "original_text": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3b05efd7689cc2b6f7d27497d123293873247f0c1782f401fb6a31de3ed7106", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. "}, "hash": "c08f5ae9c5db2af2bb1f3e0a62eb0f1f47613650f2370ef27e21c7f68c46c36f", "class_name": "RelatedNodeInfo"}}, "text": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "start_char_idx": 1615, "end_char_idx": 1811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3": {"__data__": {"id_": "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3", "embedding": null, "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaa6ba74-7051-4cd0-a331-f655b65f9305", "node_type": "1", "metadata": {"window": "The Company does not provide forward-looking guidance on a\nGAAP basis, as discussed below in Fiscal Year 2021 Expectations.  Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "original_text": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "58090854145de67e537007c9fce86aa732c180d7725b0c8e724289251965c3e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "551a1d30-2603-4420-9f57-65b20c4c4495", "node_type": "1", "metadata": {"window": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Collis continued. "}, "hash": "3be8d28995f7ff56204d61090f85d164b1478a663960202b06d6a7f5e9600590", "class_name": "RelatedNodeInfo"}}, "text": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "start_char_idx": 1811, "end_char_idx": 2005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "551a1d30-2603-4420-9f57-65b20c4c4495": {"__data__": {"id_": "551a1d30-2603-4420-9f57-65b20c4c4495", "embedding": null, "metadata": {"window": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3", "node_type": "1", "metadata": {"window": "Adjusted diluted EPS guidance has been raised from the previous\nrange of $8.90 to $9.10 to a range of $9.15 to $9.30, reflecting growth of 16 percent to 18 percent versus the previous fiscal year.\n \"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de8bfab214670d1f00d591cc6d6304de0cea119b5bc633f2f5a7704dedfbd01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff643fb8-bb2a-4238-9a28-dd91d0155cc4", "node_type": "1", "metadata": {"window": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n"}, "hash": "efa178238f01bb12c3c4079527a893eef0946e02ce0f7a5f6c0a5e420a53f2eb", "class_name": "RelatedNodeInfo"}}, "text": "Collis continued. ", "start_char_idx": 2005, "end_char_idx": 2023, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff643fb8-bb2a-4238-9a28-dd91d0155cc4": {"__data__": {"id_": "ff643fb8-bb2a-4238-9a28-dd91d0155cc4", "embedding": null, "metadata": {"window": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "551a1d30-2603-4420-9f57-65b20c4c4495", "node_type": "1", "metadata": {"window": "\"During the third quarter, AmerisourceBergen continued to capitalize on our differentiated, pharmaceutical-centric value\nproposition and successfully executed on our key strategic initiatives including completing the acquisition of Alliance Healthcare,\"\nsaid Steven H. Collis, Chairman, President and Chief Executive Officer of AmerisourceBergen.  \"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Collis continued. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac5f26894659748dd0f79fd8fe5bb18242b31c1db25a350836bf755a0f35a3a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0139868c-d1b6-4659-844e-111de542b94c", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1"}, "hash": "a328c7dd716db057ba44a13689674007ab8743caf08d9f3081a30385b5dbea0a", "class_name": "RelatedNodeInfo"}}, "text": "\"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "start_char_idx": 2023, "end_char_idx": 2372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0139868c-d1b6-4659-844e-111de542b94c": {"__data__": {"id_": "0139868c-d1b6-4659-844e-111de542b94c", "embedding": null, "metadata": {"window": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a0286359936eef879ee73da7a65c524188a8cd8b7ec55220a49649af6b4a2287", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff643fb8-bb2a-4238-9a28-dd91d0155cc4", "node_type": "1", "metadata": {"window": "\"We are proud of the execution by our\nteams to deliver these results and pleased to increase financial guidance for fiscal 2021 to reflect the continued strong performance\nacross our businesses.\"\n \"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "\"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80cc1fdaba267e3b0c0c93801af0585e769ceff5a73a683874855a9988309c7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5f7487c-b63e-4090-a96d-74fb12a20122", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. "}, "hash": "d958cc93047016fe8f0d79155575955522ea573d1baee39850b637071dc6eb37", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "start_char_idx": 2372, "end_char_idx": 2626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5f7487c-b63e-4090-a96d-74fb12a20122": {"__data__": {"id_": "c5f7487c-b63e-4090-a96d-74fb12a20122", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0139868c-d1b6-4659-844e-111de542b94c", "node_type": "1", "metadata": {"window": "\"AmerisourceBergen's purpose-driven teams continue to provide critical pharmaceutical distribution services and innovative\npharmaceutical services to customers across our global footprint,\" Mr.  Collis continued.  \"By providing differentiated value to our\nstakeholders, focusing on our customers, expanding on our leadership in specialty distribution, and executing, innovating, and\nsupporting pharmaceutical innovation globally, we are well positioned to create long-term stakeholder value as we remain united in\nour responsibility to create healthier futures.\"\n Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "original_text": "Third Quar ter Fiscal Y ear 2021 Summar y Results\n\u00a0 GAAP Adjust ed (Non-GAAP)\nRevenue $53.4B $53.4B\nGross Pr ofit $1.9B $1.6B\nOperating Expenses $1,267M $996M\nOperating Income $621M $631M\nInterest Expense, Net $51M $51M\nEffectiv e Tax Rat e 48.5% 21.0%\n1", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b60266eb2027ff66a1b2a3e77d98600d851a33b8ce58618351dff65c53512cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a3b634a-a999-43e5-9c81-797b25bd8c60", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. "}, "hash": "b9a64531c44aafbb6f682401acd8d8d26631076c670dea6986f351d872775ea1", "class_name": "RelatedNodeInfo"}}, "text": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "start_char_idx": 0, "end_char_idx": 247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a3b634a-a999-43e5-9c81-797b25bd8c60": {"__data__": {"id_": "7a3b634a-a999-43e5-9c81-797b25bd8c60", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5f7487c-b63e-4090-a96d-74fb12a20122", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c929f95a0e8e8114e39d72950369d07a2a72faf7583304e81603d804ea26fdcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85faab7a-2559-43f1-8102-97614f834458", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n"}, "hash": "2c920715d368b0b0d7e849e8dbefacfa0f0381336644d1e960c82bb52c27ce96", "class_name": "RelatedNodeInfo"}}, "text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "start_char_idx": 247, "end_char_idx": 339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85faab7a-2559-43f1-8102-97614f834458": {"__data__": {"id_": "85faab7a-2559-43f1-8102-97614f834458", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a3b634a-a999-43e5-9c81-797b25bd8c60", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "original_text": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c96519a45e869f4a41a05c61c214ac4ba8cc5e59277e2f6cbef130e8dc06b49", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3c20500-a9a9-4072-bacc-768c963048f6", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "7a6149f349a8edeef45ba4ff312e18757d4ea58d44763c1e11b5f7b5268c2743", "class_name": "RelatedNodeInfo"}}, "text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "start_char_idx": 339, "end_char_idx": 561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3c20500-a9a9-4072-bacc-768c963048f6": {"__data__": {"id_": "d3c20500-a9a9-4072-bacc-768c963048f6", "embedding": null, "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85faab7a-2559-43f1-8102-97614f834458", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "original_text": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "639846699befe8e702d0abb9b56045985b3f8155acdf2532a63e7cfeb620c878", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2e93779-4977-4c64-9347-7d24c70bdf54", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. "}, "hash": "0c3348143cde37bcf68b4422ea16896a5f2e385f0382fe2372a50749f20ed7d2", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 561, "end_char_idx": 944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2e93779-4977-4c64-9347-7d24c70bdf54": {"__data__": {"id_": "c2e93779-4977-4c64-9347-7d24c70bdf54", "embedding": null, "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3c20500-a9a9-4072-bacc-768c963048f6", "node_type": "1", "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "original_text": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2a4929964cc3d9efd1ec6d8c4be55c92c08b7c8a319b0e73f1e329971283480", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7030fe7-1f1f-4a4d-993f-d03045062c93", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. "}, "hash": "d6367b379de07b66c8602a98891be597d8aeaaac72b7f1799e3120042cb40264", "class_name": "RelatedNodeInfo"}}, "text": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "start_char_idx": 944, "end_char_idx": 1107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7030fe7-1f1f-4a4d-993f-d03045062c93": {"__data__": {"id_": "f7030fe7-1f1f-4a4d-993f-d03045062c93", "embedding": null, "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2e93779-4977-4c64-9347-7d24c70bdf54", "node_type": "1", "metadata": {"window": "In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "original_text": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a19fc7a8e457ecdd884d887338a42b8e2570362d89da20b80f485f05d396ca40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "514e0001-f72e-410c-8a84-6915524d8bd0", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n"}, "hash": "31036a17381f751712f296694649ad75752ca4208892ae2bac41c6fd922242eb", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "start_char_idx": 1107, "end_char_idx": 1385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "514e0001-f72e-410c-8a84-6915524d8bd0": {"__data__": {"id_": "514e0001-f72e-410c-8a84-6915524d8bd0", "embedding": null, "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7030fe7-1f1f-4a4d-993f-d03045062c93", "node_type": "1", "metadata": {"window": "For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "original_text": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bb307beae84b1b4e52eb5459ca74bea64c5036919dc6f1961fd5e97e3872263d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "316d2dd3-e6f9-4249-8bd0-02b09f8a6650", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. "}, "hash": "e1313f3491440b33648eef9f3df5ad08b5874040e6d868a65d7d2f3f292a5728", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "start_char_idx": 1385, "end_char_idx": 1700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "316d2dd3-e6f9-4249-8bd0-02b09f8a6650": {"__data__": {"id_": "316d2dd3-e6f9-4249-8bd0-02b09f8a6650", "embedding": null, "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "514e0001-f72e-410c-8a84-6915524d8bd0", "node_type": "1", "metadata": {"window": "Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "original_text": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ced11b5bbb4dcf20b585945b965a8cf6773304df98121ea466ca1542d5c45461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13947e16-3f92-4418-ac00-24e61c66190a", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "original_text": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. "}, "hash": "fe5083931ce05816656c45956e803164f4220d0989733a99b3352b6d4a8a73bb", "class_name": "RelatedNodeInfo"}}, "text": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "start_char_idx": 1700, "end_char_idx": 1870, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13947e16-3f92-4418-ac00-24e61c66190a": {"__data__": {"id_": "13947e16-3f92-4418-ac00-24e61c66190a", "embedding": null, "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "original_text": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "316d2dd3-e6f9-4249-8bd0-02b09f8a6650", "node_type": "1", "metadata": {"window": "Gross Profit:  Gross profit in the third quarter of fiscal 2021 was $1.9 billion, a 54.0 percent increase compared to the same\nperiod in the previous fiscal year.  Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "original_text": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4419940bfd365883f01b5dbf969de7a599b0ea4159c975cb5779da2d5eb94674", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c260ad0-9f08-4d28-8869-8f0ed8538a01", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n"}, "hash": "e3de508c492a8b9f858a524b61266982e46255256bd9819e98157b712cbd1eb5", "class_name": "RelatedNodeInfo"}}, "text": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "start_char_idx": 1870, "end_char_idx": 2036, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c260ad0-9f08-4d28-8869-8f0ed8538a01": {"__data__": {"id_": "1c260ad0-9f08-4d28-8869-8f0ed8538a01", "embedding": null, "metadata": {"window": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13947e16-3f92-4418-ac00-24e61c66190a", "node_type": "1", "metadata": {"window": "Gross profit was favorably impacted by increases in gross profit in Pharmaceutical\nDistribution Services and Other, a LIFO credit in the current year quarter in comparison to a LIFO expense in the prior year\nquarter and increases in gains from antitrust litigation settlements.  Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "original_text": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0e88ee21aa6f0b5b47d5770042e0d8a0175bec3a41ed3395962dfe2e8f550ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c410088b-f0df-46c1-b82b-548d821e5b85", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "original_text": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n"}, "hash": "cec046312681ec0c310ee9f8f9aa9c93b9771dd124a5c3e4358062f6921c5ba0", "class_name": "RelatedNodeInfo"}}, "text": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "start_char_idx": 2036, "end_char_idx": 2251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c410088b-f0df-46c1-b82b-548d821e5b85": {"__data__": {"id_": "c410088b-f0df-46c1-b82b-548d821e5b85", "embedding": null, "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "original_text": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c260ad0-9f08-4d28-8869-8f0ed8538a01", "node_type": "1", "metadata": {"window": "Gross profit as a percentage of revenue was 3.54%, an\nincrease of 84 basis points from the prior year quarter primarily driven by the acquisition of Alliance Healthcare, an increase in\nsales of specialty products in Pharmaceutical Distribution Services and growth in some of the Company's higher margin\nbusinesses.\n Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ce46196b3ff216520c083f854be12703894d6f2249370fd3e4b53180804e0d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78087d40-938e-4da0-9bf3-7bc66069f434", "node_type": "1", "metadata": {"window": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "original_text": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n"}, "hash": "c745abd8391990d96cc116a32d80642c507df48b32185249eb352e82d33f68c9", "class_name": "RelatedNodeInfo"}}, "text": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "start_char_idx": 2251, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78087d40-938e-4da0-9bf3-7bc66069f434": {"__data__": {"id_": "78087d40-938e-4da0-9bf3-7bc66069f434", "embedding": null, "metadata": {"window": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "original_text": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c410088b-f0df-46c1-b82b-548d821e5b85", "node_type": "1", "metadata": {"window": "Operating Expenses:  In the third quarter of fiscal 2021, operating expenses were $1,267.5 million, a 54.4 percent increase\ncompared to the same period last fiscal year.  The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "original_text": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ac0a766bcdf237a1a46df756bc8b720a5f87e1bcbd1d8a628ea34c3550ea8c3f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b73b946-0c6d-4420-9809-531de5d60a28", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n"}, "hash": "3d11a63794173ffd72c5128d3a54cb2a16c338b264f9e032b55310f05d12b6c8", "class_name": "RelatedNodeInfo"}}, "text": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "start_char_idx": 2370, "end_char_idx": 2659, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b73b946-0c6d-4420-9809-531de5d60a28": {"__data__": {"id_": "7b73b946-0c6d-4420-9809-531de5d60a28", "embedding": null, "metadata": {"window": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78087d40-938e-4da0-9bf3-7bc66069f434", "node_type": "1", "metadata": {"window": "The increase in operating expenses was primarily due to the acquisition of\nAlliance Healthcare and a $124.3 million accrual related to opioid settlement discussions.  Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "original_text": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "202bf679649b8bcc70eccbc3bb9cdb856e00f654a5f090fba3e8d54d9c75c6a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. "}, "hash": "7f78b4ac196303e1bdd94ffcac51c467b83ad114b636de1aeb22f1a233022415", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "start_char_idx": 2659, "end_char_idx": 2897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c": {"__data__": {"id_": "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c", "embedding": null, "metadata": {"window": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b73b946-0c6d-4420-9809-531de5d60a28", "node_type": "1", "metadata": {"window": "Operating expenses as a percentage\nof revenue in the fiscal 2021 third quarter were 2.37 percent, compared to 1.81 percent for the same period in the previous\nfiscal year primarily due to the items mentioned above.\n Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "original_text": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d74aaa05144940c6b769f5af59309778112c1aede607a9181c620f4330bf95e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c846acd-3fff-4317-ae6a-1f8ed8970998", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n"}, "hash": "7be352e97f3cb23241137ada6a1d9fd694c3b4c41def1815f892c89b64980335", "class_name": "RelatedNodeInfo"}}, "text": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "start_char_idx": 2897, "end_char_idx": 3046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c846acd-3fff-4317-ae6a-1f8ed8970998": {"__data__": {"id_": "1c846acd-3fff-4317-ae6a-1f8ed8970998", "embedding": null, "metadata": {"window": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c", "node_type": "1", "metadata": {"window": "Operating Income:  In the fiscal 2021 third quarter, operating income increased to $620.7 million from $404.8 million.\n Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa22fb175274c0422c83af51c28adc2622c952c30d54da683da4af445ac4a951", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "639ec7ed-917e-45ef-9e1a-9d42b41a8b64", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n"}, "hash": "a0822aa7ab9c0304456dbc4b2dc79ab90c134267588be2bbc2bf540b4207afae", "class_name": "RelatedNodeInfo"}}, "text": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "start_char_idx": 3046, "end_char_idx": 3159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "639ec7ed-917e-45ef-9e1a-9d42b41a8b64": {"__data__": {"id_": "639ec7ed-917e-45ef-9e1a-9d42b41a8b64", "embedding": null, "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c846acd-3fff-4317-ae6a-1f8ed8970998", "node_type": "1", "metadata": {"window": "Operating income as a percentage of revenue was 1.16 percent in the third quarter of fiscal 2021, compared to 0.89 percent\nfor the same period in the previous fiscal year primarily due to the acquisition of Alliance Healthcare and growth in some of\nthe Company's higher margin businesses.\n Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "original_text": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a7855e4177ccfacfab0e42d2e3f1c6b27d67885eb497c37b51bb2bfa9192abb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a7d36bc-24a5-4269-a4d2-a277c7a99357", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "2829eb1ea827311800fb04bb36212dc2948e489f4fef44a0457aa6c282e981b3", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "start_char_idx": 3159, "end_char_idx": 3324, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a7d36bc-24a5-4269-a4d2-a277c7a99357": {"__data__": {"id_": "8a7d36bc-24a5-4269-a4d2-a277c7a99357", "embedding": null, "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "639ec7ed-917e-45ef-9e1a-9d42b41a8b64", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  In the fiscal 2021 third quarter, net interest expense of $51.3 million was up 36.0 percent versus the\nprior year quarter due to the issuance of debt to finance a portion of the acquisition of Alliance Healthcare.\n Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aef55112c39fe975ab3baaf775d76c685979549ef379682279f0fc9c26b0899d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af65e123-f5ae-4883-9494-dacd8d927cd1", "node_type": "1", "metadata": {"window": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. "}, "hash": "d5e1dbe9ee63dde63cc9eba4df528f71437e761790100692e67c113cfcbacf3d", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 3324, "end_char_idx": 3697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af65e123-f5ae-4883-9494-dacd8d927cd1": {"__data__": {"id_": "af65e123-f5ae-4883-9494-dacd8d927cd1", "embedding": null, "metadata": {"window": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a7d36bc-24a5-4269-a4d2-a277c7a99357", "node_type": "1", "metadata": {"window": "Effective Tax Rate:  The effective tax rate was 48.5 percent for the third quarter of fiscal 2021 primarily due to tax reform in the\nUnited Kingdom.  This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef6736f7459395dc00456c14879958b3ee3d849a9b5b999fa86200e5b9c3ca75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f10c2628-e07c-46a1-bf04-ec088088aca7", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2"}, "hash": "d98679bc57a93b330033941d3b5257e65be8ff845ae55295435f332529974e0b", "class_name": "RelatedNodeInfo"}}, "text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "start_char_idx": 3697, "end_char_idx": 3814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f10c2628-e07c-46a1-bf04-ec088088aca7": {"__data__": {"id_": "f10c2628-e07c-46a1-bf04-ec088088aca7", "embedding": null, "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "09171313-4b13-48bb-9d5b-29c9710fa0be", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2377624f9e1fcf431d12978d538b59aa3a4dd376dd5c9132c1cf199eea0d78c9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af65e123-f5ae-4883-9494-dacd8d927cd1", "node_type": "1", "metadata": {"window": "This compares to 16.5 percent in the prior year quarter, which was favorably impacted by a discrete tax\nbenefit.\n Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98fbf80a739c4af25d8ed7e9edb691e29362521ffddfda779c94496d34312a41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "128b0472-8710-467f-95d8-e4ef4dfe131e", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "original_text": "June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "4d2f6f945c7c79a7ae7115c271ebe99403d667af7a8ca23c39e2f8edf18bb1fd", "class_name": "RelatedNodeInfo"}}, "text": "In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "start_char_idx": 3814, "end_char_idx": 4114, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "128b0472-8710-467f-95d8-e4ef4dfe131e": {"__data__": {"id_": "128b0472-8710-467f-95d8-e4ef4dfe131e", "embedding": null, "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "original_text": "June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f10c2628-e07c-46a1-bf04-ec088088aca7", "node_type": "1", "metadata": {"window": "Diluted Earnings Per Share:  Diluted earnings per share was $1.40 in the third quarter of fiscal 2021 compared to $1.41 in the\nprevious fiscal year\u2019s third quarter.\n Diluted Shares Outstanding:  Diluted weighted average shares outstanding for the third quarter of fiscal 2021 were 208.9\nmillion, a 1.6 percent increase versus the prior fiscal year third quarter resulting from stock option exercises, restricted stock\nvesting, and the issuance of 2 million Company shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Third Quar ter Adjust ed (non-GAAP) R esults\nRevenue:  No adjustments were made to the GAAP presentation of revenue.  In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "original_text": "In the third quarter of fiscal 2021, revenue was\n$53.4 billion, up 17.7 percent compared to the same quarter in the previous fiscal year, reflecting a 13.2 percent increase in\nPharmaceutical Distribution Services revenue and an 128.0 percent increase in revenue within Other primarily driven by the\n2", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cafc74d1598f391f7eb2a37693c32bdf4dcdbb3dfcdfd6effde3f515ed82d8b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a12841f1-6f65-49df-ba17-79b79f7c2052", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other. "}, "hash": "984a407b772cf0f083bee7f8cb1a02bf494b208ae4b628adaf09ff122639f10b", "class_name": "RelatedNodeInfo"}}, "text": "June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 0, "end_char_idx": 46, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a12841f1-6f65-49df-ba17-79b79f7c2052": {"__data__": {"id_": "a12841f1-6f65-49df-ba17-79b79f7c2052", "embedding": null, "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "128b0472-8710-467f-95d8-e4ef4dfe131e", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "original_text": "June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb96719b5f55fec47b8a90aeeeb3c6eff67865f2ae72fcfcc187296a0ad48d1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n"}, "hash": "81471ae4db827a834047777e37ed5fc435f668820b4344f84304255fbf887c46", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other. ", "start_char_idx": 46, "end_char_idx": 349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9": {"__data__": {"id_": "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9", "embedding": null, "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a12841f1-6f65-49df-ba17-79b79f7c2052", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "00158ee50cec97861c3ac91ce724137a2b9f758d385bbaaf5b4ae80a4ddb6566", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c599e1c4-b7c8-498f-8242-550494ad53cd", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. "}, "hash": "43ab56503841f36b30d916757d20c6a14c64111896835986e6724194fe885927", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n", "start_char_idx": 349, "end_char_idx": 722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c599e1c4-b7c8-498f-8242-550494ad53cd": {"__data__": {"id_": "c599e1c4-b7c8-498f-8242-550494ad53cd", "embedding": null, "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "original_text": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "727d44267656c6fa83b5687f2187475084bce64058d3dd4f9bf8fcfd15c0c0fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e652466-8a21-446d-b4af-6429e203e9af", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n"}, "hash": "9fa5fafdff25cb3b048caf5af2fd3820489aae9ba73b2c96bef5174c2e404721", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "start_char_idx": 722, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e652466-8a21-446d-b4af-6429e203e9af": {"__data__": {"id_": "6e652466-8a21-446d-b4af-6429e203e9af", "embedding": null, "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c599e1c4-b7c8-498f-8242-550494ad53cd", "node_type": "1", "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "original_text": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2f5da5ae5e604588083ac93428de34c41c54482099a56a202d2a06101e092fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c062dfb-dc89-41f2-a5c0-a46be6d28acd", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. "}, "hash": "16de4ca59ec93cba671f36a7e447f888c6bc5fc79d8d3b151cd0b1ecb51acadf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "start_char_idx": 1079, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c062dfb-dc89-41f2-a5c0-a46be6d28acd": {"__data__": {"id_": "7c062dfb-dc89-41f2-a5c0-a46be6d28acd", "embedding": null, "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e652466-8a21-446d-b4af-6429e203e9af", "node_type": "1", "metadata": {"window": "Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "original_text": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f44f4e58f6fe79f6133fe1ab393919ebfc01952e0a544fd4db6936364913cda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n"}, "hash": "d4e136ebbd6bc1453a0602e77706ac1c9f5c500a59312511d9177fcf41016844", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "start_char_idx": 1313, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a": {"__data__": {"id_": "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a", "embedding": null, "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c062dfb-dc89-41f2-a5c0-a46be6d28acd", "node_type": "1", "metadata": {"window": "Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1d9a903a95b1917a35a7dbe57d5ae0a83437f177df7bed1e5a2b080d1f15011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2", "node_type": "1", "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. "}, "hash": "9e4e1f868d4df28c0da1d420afb24344c16964c316499ff100260f8e0002c795", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "start_char_idx": 1621, "end_char_idx": 1878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2": {"__data__": {"id_": "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2", "embedding": null, "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a", "node_type": "1", "metadata": {"window": "Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth.  Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "original_text": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b01474214cd0dd3b43abbb5b802ce228899e19800c5cd7badf517d924b28006a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d33c8f13-f5f2-45a5-988d-456703b26f7d", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n"}, "hash": "d70c492f727b23fefd59058fa6fa45f43cff0942e3036afdf638a30807456779", "class_name": "RelatedNodeInfo"}}, "text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "start_char_idx": 1878, "end_char_idx": 1977, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d33c8f13-f5f2-45a5-988d-456703b26f7d": {"__data__": {"id_": "d33c8f13-f5f2-45a5-988d-456703b26f7d", "embedding": null, "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2", "node_type": "1", "metadata": {"window": "Adjusted operating\nexpenses as a percentage of revenue in the fiscal 2021 third quarter was 1.87 percent, an increase of 27 basis points when\ncompared to the prior year quarter primarily due to the acquisition of Alliance Healthcare.\n Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "original_text": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37489d22d494319adec296a18d3e8c5458e4ff255a963903bb6097a155e21232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87036aad-6ff2-44d3-a023-40589f58e4a3", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n"}, "hash": "6612dd80399aafd528b9b5814e7764973eda3d419519b014b0cd3ccee394bb13", "class_name": "RelatedNodeInfo"}}, "text": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "start_char_idx": 1977, "end_char_idx": 2191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87036aad-6ff2-44d3-a023-40589f58e4a3": {"__data__": {"id_": "87036aad-6ff2-44d3-a023-40589f58e4a3", "embedding": null, "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d33c8f13-f5f2-45a5-988d-456703b26f7d", "node_type": "1", "metadata": {"window": "Adjusted Operating Income:  In the fiscal 2021 third quarter, adjusted operating income of $630.6 million increased 24.3\npercent from the prior year quarter due to a 13.4 percent increase in Pharmaceutical Distribution Services' operating income\nand a 77.2 percent increase in operating income within Other.  Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "original_text": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d55876727a8070faa5fc4e7b04f11a7e1cc785e6e8b2b2e16a00ebb40d67172e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee62b8c6-e3a9-4776-baff-f53fc71f1a04", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n"}, "hash": "0dc8699c19c4d53732b42a34b13429fb20aa15e295681147906daf4c347d4eab", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "start_char_idx": 2191, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee62b8c6-e3a9-4776-baff-f53fc71f1a04": {"__data__": {"id_": "ee62b8c6-e3a9-4776-baff-f53fc71f1a04", "embedding": null, "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87036aad-6ff2-44d3-a023-40589f58e4a3", "node_type": "1", "metadata": {"window": "Adjusted operating income as a percentage of revenue was\n1.18 percent in the fiscal 2021 third quarter, an increase of 6 basis points when compared to the prior year quarter due to the\nAlliance Healthcare acquisition and growth in higher margin businesses.\n Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4945e3ec3f036aa6d0366e3134b435d6a37b6fa004620366bcfcdb83a3a12496", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43f3fbd6-b089-4af8-9176-c9b13e2022e8", "node_type": "1", "metadata": {"window": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. "}, "hash": "8f79b12837f2cd4cec832074dcc700a844044f57a8c75aad341922bad05a1c5a", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "start_char_idx": 2401, "end_char_idx": 2767, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43f3fbd6-b089-4af8-9176-c9b13e2022e8": {"__data__": {"id_": "43f3fbd6-b089-4af8-9176-c9b13e2022e8", "embedding": null, "metadata": {"window": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee62b8c6-e3a9-4776-baff-f53fc71f1a04", "node_type": "1", "metadata": {"window": "Interest Expense, Net:  No adjustments were made to the GAAP presentation of net interest expense.  In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "original_text": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af4ff24074396fdb952fab049ed1d2337b0bee535a8dc3ae4ebb8a31a309e8b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ebc3a1c-00f2-4afb-90ee-42b87299409c", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "619cf349a9563c98344921ddbe6d0057fe597b2689f0484a27f6586daef6715d", "class_name": "RelatedNodeInfo"}}, "text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "start_char_idx": 2767, "end_char_idx": 2877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ebc3a1c-00f2-4afb-90ee-42b87299409c": {"__data__": {"id_": "0ebc3a1c-00f2-4afb-90ee-42b87299409c", "embedding": null, "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43f3fbd6-b089-4af8-9176-c9b13e2022e8", "node_type": "1", "metadata": {"window": "In the fiscal 2021 third\nquarter, net interest expense of $51.3 million was up 36.0 percent versus the prior year quarter due to the issuance of debt to\nfinance a portion of the acquisition of Alliance Healthcare.\n Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "original_text": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20775c3cda4dc8add2a377d4dcd20b040bb7081ef4b4af75023e0788af70d7d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce11fdd8-d125-4428-bd77-de5ac414e1e6", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. "}, "hash": "d724e4002e5d53c43a4ad493ab8fa59a4020453a9d691702773b395db3d00142", "class_name": "RelatedNodeInfo"}}, "text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 2877, "end_char_idx": 3221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce11fdd8-d125-4428-bd77-de5ac414e1e6": {"__data__": {"id_": "ce11fdd8-d125-4428-bd77-de5ac414e1e6", "embedding": null, "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ebc3a1c-00f2-4afb-90ee-42b87299409c", "node_type": "1", "metadata": {"window": "Adjusted Effective Tax Rate:  The adjusted effective tax rate was 21.0 percent for the third quarter of fiscal 2021 compared to\n18.8 percent in the prior year quarter, which benefited from a discrete tax item.\n Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "original_text": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d90067de52d012cdecb5dc1a9ea0b537d03723091f83787367696dd5abe1b91f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ad3fa7-adbb-4894-9aea-5d23bd02a7da", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). "}, "hash": "a90b297a097421dc9b8abf29cad0fb30e9fcae0e68a393c29c08e20f7fc633ba", "class_name": "RelatedNodeInfo"}}, "text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "start_char_idx": 3221, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ad3fa7-adbb-4894-9aea-5d23bd02a7da": {"__data__": {"id_": "73ad3fa7-adbb-4894-9aea-5d23bd02a7da", "embedding": null, "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce11fdd8-d125-4428-bd77-de5ac414e1e6", "node_type": "1", "metadata": {"window": "Adjusted Diluted Earnings Per Share:  Adjusted diluted earnings per share was up 16.8 percent to $2.16 in the third quarter of\nfiscal 2021 compared to $1.85 in the previous fiscal year\u2019s third quarter, driven by the increase in adjusted operating income\nand partially offset by higher interest expense, a higher effective tax rate, and a higher diluted share count.\n Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "original_text": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d0eff07ad22b9e882a83490a4f03f0c8d0d4355f94c7dc0d4a6c165ed9369802", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a55f9745-0850-4d8f-bc71-b4cc8a85e552", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n"}, "hash": "15a6448f46669fad01fe5fb9a0d025d7c519c098376b6548173e7ab659532b3d", "class_name": "RelatedNodeInfo"}}, "text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "start_char_idx": 3553, "end_char_idx": 3780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a55f9745-0850-4d8f-bc71-b4cc8a85e552": {"__data__": {"id_": "a55f9745-0850-4d8f-bc71-b4cc8a85e552", "embedding": null, "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ad3fa7-adbb-4894-9aea-5d23bd02a7da", "node_type": "1", "metadata": {"window": "Diluted Shares Outstanding:  No adjustments were made to the GAAP presentation of diluted shares outstanding.  Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "original_text": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare). ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ecb4ab41fde05f3b0f3fdb3a601ac2c0ab868e85418039131f059f0d4bca6d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca9babee-8aeb-472f-953b-7a44b03cbd28", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. "}, "hash": "2db45f136b0d0792781329c24166bac9dae4e9daffe126bb8a48ed76f109f0aa", "class_name": "RelatedNodeInfo"}}, "text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "start_char_idx": 3780, "end_char_idx": 3925, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca9babee-8aeb-472f-953b-7a44b03cbd28": {"__data__": {"id_": "ca9babee-8aeb-472f-953b-7a44b03cbd28", "embedding": null, "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a55f9745-0850-4d8f-bc71-b4cc8a85e552", "node_type": "1", "metadata": {"window": "Diluted\nweighted average shares outstanding for the third quarter of fiscal 2021 were 208.9 million, a 1.6 percent increase versus the\nprior fiscal year third quarter resulting from stock option exercises, restricted stock vesting, and the issuance of 2 million\nCompany shares to Walgreens for the June 2021 acquisition of Alliance Healthcare.\n Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "721bab1f1b68db82302d0a0838cbaf438ad218fec63595ee12ad92d57f93c830", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56338974-c21b-43bd-8b88-b54a4846df2d", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n"}, "hash": "38f0ea9f89e334ffc65dc3b62c71b234c4fecbab21ee1fbc8da5e2575feee95c", "class_name": "RelatedNodeInfo"}}, "text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "start_char_idx": 3925, "end_char_idx": 4266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56338974-c21b-43bd-8b88-b54a4846df2d": {"__data__": {"id_": "56338974-c21b-43bd-8b88-b54a4846df2d", "embedding": null, "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca9babee-8aeb-472f-953b-7a44b03cbd28", "node_type": "1", "metadata": {"window": "Segment Discussion\nThe Company's operations are comprised of the Pharmaceutical Distribution Services reportable segment and other operating\nsegments that are not significant enough to require separate reportable segment disclosure and, therefore, have been included in\nOther for the purpose of the reportable segment presentation.  Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth. ", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "daad4b95069911acd1d3445200ab7258fb57b982610c0dbcc8f2d33db40d3f6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfd924ba-fedd-4a32-bd33-92a3feaf897a", "node_type": "1", "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Other\n3"}, "hash": "3a232bcf4e3f6e7fc085b3bec72ac232a5dccb691f6784ca669616a01ca5a1b3", "class_name": "RelatedNodeInfo"}}, "text": "Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "start_char_idx": 4266, "end_char_idx": 4539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfd924ba-fedd-4a32-bd33-92a3feaf897a": {"__data__": {"id_": "dfd924ba-fedd-4a32-bd33-92a3feaf897a", "embedding": null, "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Other\n3", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ed807259-1b19-4feb-a664-384450cebb90", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35567e9222a875c21e722fd23decc1a9cebcbb6976eb041a937ee72b87d4280d", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56338974-c21b-43bd-8b88-b54a4846df2d", "node_type": "1", "metadata": {"window": "Other consists of operating segments that focus on global\ncommercialization services, animal health (MWI Animal Health or \"MWI\"), and international pharmaceutical wholesale and related\nservice operations (Alliance Healthcare).  The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2cd32a1d38b1329f4e586fd53e000b3024081798b140015200171dec26d02cf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a5de5de-c080-448b-86ba-7618e50ab122", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "original_text": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS. "}, "hash": "ff8c3a1681b650a93365dc78065defbef9e7be15bcb874294def997159f3d1ed", "class_name": "RelatedNodeInfo"}}, "text": "Other\n3", "start_char_idx": 4539, "end_char_idx": 4546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a5de5de-c080-448b-86ba-7618e50ab122": {"__data__": {"id_": "1a5de5de-c080-448b-86ba-7618e50ab122", "embedding": null, "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "original_text": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfd924ba-fedd-4a32-bd33-92a3feaf897a", "node_type": "1", "metadata": {"window": "The operating segments that focus on global commercialization services include\nAmerisourceBergen Consulting Services (\"ABCS\") and World Courier.\n Pharmaceutical Distribution Services Segment\nPharmaceutical Distribution Services revenue was $49.3 billion in the third quarter of fiscal 2021, an increase of 13.2 percent\ncompared to the same quarter in the prior fiscal year primarily due to increased sales of specialty products, including COVID-19\ntreatments, and overall market growth.  Segment operating income of $483.9 million in the third quarter of fiscal 2021 was up 13.4\npercent compared to the same period in the previous fiscal year as a result of strong performance across our distribution businesses\nincluding increased sales of specialty products.\n Other\n3", "original_text": "Other\n3", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "27e08299ac9600e3374553dc455f9808577f24cffd97a6d2835f3d41fc9b0216", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71357bbb-c077-4ced-b88c-b783967484ec", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n"}, "hash": "317851cb634455effde941cae95aefdf5e6548a3340b13f31b28836a846b59bc", "class_name": "RelatedNodeInfo"}}, "text": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS. ", "start_char_idx": 0, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71357bbb-c077-4ced-b88c-b783967484ec": {"__data__": {"id_": "71357bbb-c077-4ced-b88c-b783967484ec", "embedding": null, "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a5de5de-c080-448b-86ba-7618e50ab122", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "original_text": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "712eddf8b42d41c25d3283b453e5f7b00017b208b687e27532adc59a2eefd7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c80bd36-d297-4699-889e-12a6725b7d1c", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses. "}, "hash": "9b718b2f5e5b8c8bbab23f2ff144c2c79b9b13cba81458e6f8a91b3d1dc9c9cb", "class_name": "RelatedNodeInfo"}}, "text": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n", "start_char_idx": 283, "end_char_idx": 479, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c80bd36-d297-4699-889e-12a6725b7d1c": {"__data__": {"id_": "1c80bd36-d297-4699-889e-12a6725b7d1c", "embedding": null, "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71357bbb-c077-4ced-b88c-b783967484ec", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "original_text": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2992824178ab5fafa6ed8cfe875f4ffc8ec7e279e70c0234a0eeeef8400d49ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5d17a5b-0263-4508-b859-b1333f03418f", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n"}, "hash": "d1373a12b3db378068c5f6efa6fef17112014ef4c586cff51086708bd402a500", "class_name": "RelatedNodeInfo"}}, "text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses. ", "start_char_idx": 479, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5d17a5b-0263-4508-b859-b1333f03418f": {"__data__": {"id_": "e5d17a5b-0263-4508-b859-b1333f03418f", "embedding": null, "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c80bd36-d297-4699-889e-12a6725b7d1c", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S. ", "original_text": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed7caa3625984a9bfd0f2b14387d048e0aa5ac72da37502ca7d51950e12811aa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f47fcdd9-123e-46ed-8bc6-973368750ac4", "node_type": "1", "metadata": {"window": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. "}, "hash": "d6fdf881dcfbd016ed43914ddc7ed3adba715a48e5a7a989f22c3137788b8427", "class_name": "RelatedNodeInfo"}}, "text": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "start_char_idx": 660, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f47fcdd9-123e-46ed-8bc6-973368750ac4": {"__data__": {"id_": "f47fcdd9-123e-46ed-8bc6-973368750ac4", "embedding": null, "metadata": {"window": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5d17a5b-0263-4508-b859-b1333f03418f", "node_type": "1", "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study. ", "original_text": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e07892b8bfcc9c1382a404d21822899d3175a339570e2e51694f9e0ea63889ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae0c417-79ae-42db-9e14-488c20f59635", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "original_text": "Power 2020 U.S. "}, "hash": "0ced7080c9d72bb0af158d4cd76741ec52ed4133960431fcccaf5baae1db8626", "class_name": "RelatedNodeInfo"}}, "text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "start_char_idx": 824, "end_char_idx": 1021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae0c417-79ae-42db-9e14-488c20f59635": {"__data__": {"id_": "3ae0c417-79ae-42db-9e14-488c20f59635", "embedding": null, "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "original_text": "Power 2020 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f47fcdd9-123e-46ed-8bc6-973368750ac4", "node_type": "1", "metadata": {"window": "Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "original_text": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25e9367f60b9000d434935f5096a6a8fb8bde5cd0c466d02e68d565078a1043", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd0f6610-475d-4452-b02e-049f3ed68a82", "node_type": "1", "metadata": {"window": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "original_text": "Pharmacy Study. "}, "hash": "5b4364e89767f7a36b1771d3d709ec9946221e84019e845fd179dcac2ba4241b", "class_name": "RelatedNodeInfo"}}, "text": "Power 2020 U.S. ", "start_char_idx": 1021, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd0f6610-475d-4452-b02e-049f3ed68a82": {"__data__": {"id_": "fd0f6610-475d-4452-b02e-049f3ed68a82", "embedding": null, "metadata": {"window": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "original_text": "Pharmacy Study. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae0c417-79ae-42db-9e14-488c20f59635", "node_type": "1", "metadata": {"window": "Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "original_text": "Power 2020 U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3b4228be62310f56c2004a6c4b2d417170237f1a8804d1058f13ee420e66de2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3dfcc09-c925-445b-b293-aa61380ed76d", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers. ", "original_text": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n"}, "hash": "78fe841b4101377bdc47598b4af1af18a2fb30df261a907d9a17d2ef81d6e9e2", "class_name": "RelatedNodeInfo"}}, "text": "Pharmacy Study. ", "start_char_idx": 1037, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3dfcc09-c925-445b-b293-aa61380ed76d": {"__data__": {"id_": "a3dfcc09-c925-445b-b293-aa61380ed76d", "embedding": null, "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers. ", "original_text": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd0f6610-475d-4452-b02e-049f3ed68a82", "node_type": "1", "metadata": {"window": "The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "original_text": "Pharmacy Study. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7b2b48cc14d4771fb45a1a10a5c568964d8d0938160bdf5e797c4aa5fea830ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f89555d-156a-4383-9bea-803750c1b62d", "node_type": "1", "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "original_text": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. "}, "hash": "53fa1dca3ba6c91b5c4bd73b7777d502992f244557694b973c115bc767b47eea", "class_name": "RelatedNodeInfo"}}, "text": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "start_char_idx": 1053, "end_char_idx": 1156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f89555d-156a-4383-9bea-803750c1b62d": {"__data__": {"id_": "2f89555d-156a-4383-9bea-803750c1b62d", "embedding": null, "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "original_text": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3dfcc09-c925-445b-b293-aa61380ed76d", "node_type": "1", "metadata": {"window": "Good Neighbor Pharmacy, AmerisourceBergen\u2019s national independent pharmacy network, announced that it has been ranked\n\u201cHighest in Customer Satisfaction with Chain Drug Store Pharmacies\u201d in the J.D.  Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers. ", "original_text": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "415a8c54396974ec313bf8a73c34ea2489436512114318d2658dffcf9214bafb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0432da5b-1c0e-40a5-a443-09db63078961", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. "}, "hash": "f3be3a49f62e6ecde68489b4e5cb5e90b428d19bd97ff7cff674e31b0818f153", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "start_char_idx": 1156, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0432da5b-1c0e-40a5-a443-09db63078961": {"__data__": {"id_": "0432da5b-1c0e-40a5-a443-09db63078961", "embedding": null, "metadata": {"window": "Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f89555d-156a-4383-9bea-803750c1b62d", "node_type": "1", "metadata": {"window": "Power 2020 U.S.  Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "original_text": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1219c81fb80a18dccb0cb332f83112336f1adeb258f97296a3fd905401ffb121", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18", "node_type": "1", "metadata": {"window": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "employers. "}, "hash": "0644affe4042068811b9511e68f0c1afd3da77b4af354f4d87f59a9ec710325b", "class_name": "RelatedNodeInfo"}}, "text": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "start_char_idx": 1232, "end_char_idx": 1341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18": {"__data__": {"id_": "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18", "embedding": null, "metadata": {"window": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "employers. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0432da5b-1c0e-40a5-a443-09db63078961", "node_type": "1", "metadata": {"window": "Pharmacy Study.  This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "original_text": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21234a19d06693eadfc5afbb581dba63eddb0b1444ab717b03899935a6d77978", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a335c69-0bd6-455a-a1ef-2d0b5f4da801", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "original_text": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n"}, "hash": "3b4d68cb66410deaf51522021d1ba7e2f76f50355615f5a387a0eee53b00d057", "class_name": "RelatedNodeInfo"}}, "text": "employers. ", "start_char_idx": 1341, "end_char_idx": 1352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a335c69-0bd6-455a-a1ef-2d0b5f4da801": {"__data__": {"id_": "8a335c69-0bd6-455a-a1ef-2d0b5f4da801", "embedding": null, "metadata": {"window": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "original_text": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18", "node_type": "1", "metadata": {"window": "This marks\nthe tenth time that Good Neighbor Pharmacy has earned the achievement in the last 12 years.\n AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "original_text": "employers. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7caa145c8aa9eaf091d80a8192c4409792dba180113f3394e980f44bb0a26f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ca69835-2155-43c9-a4c9-cefdedf40ac6", "node_type": "1", "metadata": {"window": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. "}, "hash": "3d3a656aaa7adbb8fb83d84abfcdea4268ce8c8f7860256ae2951b40ee14f55e", "class_name": "RelatedNodeInfo"}}, "text": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "start_char_idx": 1352, "end_char_idx": 1539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ca69835-2155-43c9-a4c9-cefdedf40ac6": {"__data__": {"id_": "0ca69835-2155-43c9-a4c9-cefdedf40ac6", "embedding": null, "metadata": {"window": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a335c69-0bd6-455a-a1ef-2d0b5f4da801", "node_type": "1", "metadata": {"window": "AmerisourceBergen was named 8th on the 2021 DiversityInc Philanthropy list.  Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "original_text": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ce999a3772e5b850c6d42a387fdb2472df3723d2e191093e974534125ec33c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2", "node_type": "1", "metadata": {"window": "employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n"}, "hash": "79f4c92065d7d01c133c6c994aba4133668ccce107f9c513087a16fbc2c58716", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "start_char_idx": 1539, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2": {"__data__": {"id_": "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2", "embedding": null, "metadata": {"window": "employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ca69835-2155-43c9-a4c9-cefdedf40ac6", "node_type": "1", "metadata": {"window": "Launched in 2001, the survey is the most\ncomprehensive, data-driven D&I analysis of some of the largest U.S.  employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "original_text": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4998c4a4ae88626921d4f36753bd62ef28a611bd52f4381c5d9ea50ad8bc1e2f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38179bd7-3014-45eb-9ee9-1efa25757c7e", "node_type": "1", "metadata": {"window": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n"}, "hash": "873b2a2eff5ebe789886630f170766b850168e655a11fee53ba9425e4fdb9129", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "start_char_idx": 1783, "end_char_idx": 1915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38179bd7-3014-45eb-9ee9-1efa25757c7e": {"__data__": {"id_": "38179bd7-3014-45eb-9ee9-1efa25757c7e", "embedding": null, "metadata": {"window": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2", "node_type": "1", "metadata": {"window": "employers.  The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "original_text": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "018a98c5f1fd1d0dcda6f5ee637fb5b1ea8ba68b0f1e2ed4f2884f7ed2a01197", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50922714-fc3f-46a0-bcca-1e42eb4f8544", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. "}, "hash": "a6e3ccf45ad95416e7dc961757583e9d5816938b21b0cbbba87e6a3f35fddf5b", "class_name": "RelatedNodeInfo"}}, "text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "start_char_idx": 1915, "end_char_idx": 2421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50922714-fc3f-46a0-bcca-1e42eb4f8544": {"__data__": {"id_": "50922714-fc3f-46a0-bcca-1e42eb4f8544", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38179bd7-3014-45eb-9ee9-1efa25757c7e", "node_type": "1", "metadata": {"window": "The assessment collects data across six key\nareas: Leadership Accountability, Human Capital Diversity Metrics, Talent Programs, Workforce Practices, Supplier Diversity,\nand Philanthropy.\n Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "original_text": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "457ba0586468f7217de7ec391724dda4bbf963387958cd25876af90536271677", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce2aa9d1-cb77-4db0-bbce-03129c71266a", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n"}, "hash": "14234b8e30d33c0bbbf5d9c518d6aa68391ecc953b1d4711968dae444f5bedf6", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "start_char_idx": 2421, "end_char_idx": 2572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce2aa9d1-cb77-4db0-bbce-03129c71266a": {"__data__": {"id_": "ce2aa9d1-cb77-4db0-bbce-03129c71266a", "embedding": null, "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50922714-fc3f-46a0-bcca-1e42eb4f8544", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations\nThe Company does not provide forward-looking guidance on a GAAP basis as certain financial information, the probable\nsignificance of which cannot be determined, is not available or cannot be reasonably estimated.  Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "original_text": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae83ad109c2954af1f728facf813d719eee91da4e0ee1230eec1d3d2b68836d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aec0db3f-3cff-4fa1-98a1-7d34968f12ce", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n"}, "hash": "fe42d7da2a57f8996154df5cbb46e298468a35a44918b8ec6a75a0b1da784588", "class_name": "RelatedNodeInfo"}}, "text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "start_char_idx": 2572, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aec0db3f-3cff-4fa1-98a1-7d34968f12ce": {"__data__": {"id_": "aec0db3f-3cff-4fa1-98a1-7d34968f12ce", "embedding": null, "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce2aa9d1-cb77-4db0-bbce-03129c71266a", "node_type": "1", "metadata": {"window": "Please refer to the Supplemental\nInformation Regarding Non-GAAP Financial Measures following the tables for additional information.\n Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4c49062e5bd4883d3751f0d1c5c705f1ce0f39e8183a5939c257a5f0be3d70f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8b605f03-1350-4802-8fc9-0c2d5f358d07", "node_type": "1", "metadata": {"window": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n"}, "hash": "58271a4c9874a2e9694cf220946f2b14f4dcd4f3e65c032c2786e5c150ec4921", "class_name": "RelatedNodeInfo"}}, "text": "Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "start_char_idx": 2706, "end_char_idx": 3465, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8b605f03-1350-4802-8fc9-0c2d5f358d07": {"__data__": {"id_": "8b605f03-1350-4802-8fc9-0c2d5f358d07", "embedding": null, "metadata": {"window": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aec0db3f-3cff-4fa1-98a1-7d34968f12ce", "node_type": "1", "metadata": {"window": "Fiscal Y ear 2021 Expectations on an Adjust ed (non-GAAP) Basis\nIn June 2021, AmerisourceBergen updated its fiscal year 2021 financial guidance for revenue, adjusted diluted EPS and weighted\naverage shares following the closing of the Alliance Healthcare acquisition to reflect the expected contribution from Alliance\nHealthcare and the weighted average share count impact of the 2 million shares of AmerisourceBergen common stock that the\nCompany delivered to Walgreens at the closing of the transaction.\n AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c9637a115125fba2b9cfe41bd10a2b326f702d475fd47820c062d047d62d961", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f15c82a-be3a-476c-9d50-8ea2bef0c257", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Dividend Declaration\n4"}, "hash": "0d4b766940f751ea45bd1cef36d88a74fa21dfa0e68bf2808071806aa068edfe", "class_name": "RelatedNodeInfo"}}, "text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "start_char_idx": 3465, "end_char_idx": 3593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f15c82a-be3a-476c-9d50-8ea2bef0c257": {"__data__": {"id_": "9f15c82a-be3a-476c-9d50-8ea2bef0c257", "embedding": null, "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Dividend Declaration\n4", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "97c40641-d845-4a7e-abff-6500dad1dd3a", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c25ff9d61f83c99f2648fe6e38578dc8502a040f4068062db2aeecd076412766", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8b605f03-1350-4802-8fc9-0c2d5f358d07", "node_type": "1", "metadata": {"window": "AmerisourceBergen is now updating its fiscal year 2021 financial guidance to reflect the Company\u2019s continued strong performance\nacross its businesses.  The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a05a8d87f2da5cb65621b8b3b863b856a2fbd8e15d9aff69f205cfa85d4a59c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e0c2ed28-5ca9-492a-82db-f3ed6bd5da29", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021. ", "original_text": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n"}, "hash": "42f0d609567da554616345ee5a262c207c27b39ba910fdde037508909b3754a9", "class_name": "RelatedNodeInfo"}}, "text": "Dividend Declaration\n4", "start_char_idx": 3593, "end_char_idx": 3615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e0c2ed28-5ca9-492a-82db-f3ed6bd5da29": {"__data__": {"id_": "e0c2ed28-5ca9-492a-82db-f3ed6bd5da29", "embedding": null, "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021. ", "original_text": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f15c82a-be3a-476c-9d50-8ea2bef0c257", "node_type": "1", "metadata": {"window": "The Company now expects:\nAdjusted Diluted EPS to be in the range of $9.15 to $9.30, raised from the previous range of $8.90 to $9.10.\n Additional expectations now include:\nAdjusted operating expense to be approximately $3.9 billion, up from growth in the high-single digit percent range;\nAdjusted operating income to be approximately $2.6 billion, up from growth in the high-single digit percent range;\nPharmaceutical Distribution Services operating income growth to be in the low-double digit percent range, up from\ngrowth in the high-single digit percent range;\nOther, which is comprised of Alliance Healthcare and the Global Commercialization Services & Animal Health\nbusinesses, operating income to be approximately $610 to $620 million, up from growth in the low-double digit\npercent range; and\nAdjusted free cash flow to be approximately $1.7 billion, up from approximately $1.5 billion.\n All other previously communicated aspects of the Company's fiscal year 2021 financial guidance and assumptions remain the same.\n Dividend Declaration\n4", "original_text": "Dividend Declaration\n4", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0da57e2daa841117ae7cf699459a520db816ccfe97037a99c9a787262da4d3cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "982011cd-f125-4304-be01-15f6299cb210", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n"}, "hash": "9ea0100cdb6adeacbcae5a247cdb42cb9aa6398317fe5d21d4edfc8593be1d12", "class_name": "RelatedNodeInfo"}}, "text": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n", "start_char_idx": 0, "end_char_idx": 193, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "982011cd-f125-4304-be01-15f6299cb210": {"__data__": {"id_": "982011cd-f125-4304-be01-15f6299cb210", "embedding": null, "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e0c2ed28-5ca9-492a-82db-f3ed6bd5da29", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021. ", "original_text": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "594662c32a8cbf3d3a94521ea7bbd80d30538cda14b02488b3086ea845677787", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ad63680-be79-4528-b649-28a1333e17fb", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. "}, "hash": "2971d60c6392e9dec5663e003822bc2cfb9a73a43a18ea7b298ba4fb5bcc7649", "class_name": "RelatedNodeInfo"}}, "text": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n", "start_char_idx": 193, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ad63680-be79-4528-b649-28a1333e17fb": {"__data__": {"id_": "8ad63680-be79-4528-b649-28a1333e17fb", "embedding": null, "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "982011cd-f125-4304-be01-15f6299cb210", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "original_text": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09aeb98dd483766a3c6e00af12c28526c3b011e4da5295fb72c7aa6d6738b1ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c39e25-8de7-49a4-bfd6-8aa744f8d482", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on August 4, 2021. "}, "hash": "34f3f6c6c67b7fbffeca9b9b542a2b5932635e257d9d446bee0e43d1f8587673", "class_name": "RelatedNodeInfo"}}, "text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "start_char_idx": 545, "end_char_idx": 660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c39e25-8de7-49a4-bfd6-8aa744f8d482": {"__data__": {"id_": "c5c39e25-8de7-49a4-bfd6-8aa744f8d482", "embedding": null, "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on August 4, 2021. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ad63680-be79-4528-b649-28a1333e17fb", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "original_text": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33037a4f19d6c01af80482a0de50b6c8055a27cd6ecb98d1bca4dd2438cd62a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "500703b2-b343-4c03-abc6-fe62c708fb10", "node_type": "1", "metadata": {"window": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . "}, "hash": "42ccc7bbb0fea7a468a5b21ebec756f3672152aa4c7fc7b87e4d5057420704fd", "class_name": "RelatedNodeInfo"}}, "text": "ET on August 4, 2021. ", "start_char_idx": 660, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "500703b2-b343-4c03-abc6-fe62c708fb10": {"__data__": {"id_": "500703b2-b343-4c03-abc6-fe62c708fb10", "embedding": null, "metadata": {"window": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c39e25-8de7-49a4-bfd6-8aa744f8d482", "node_type": "1", "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282. ", "original_text": "ET on August 4, 2021. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fa5f74f37f5452c98d5ffbf91c9e2fb989eba590be311b9388ee75aa2dc5684", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bd51752-d7c2-4c42-9a80-16f64e068c21", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. "}, "hash": "995201ea28cada16691e75f2c2e308e8347cf09f1ac11950180c6b7c69b82acf", "class_name": "RelatedNodeInfo"}}, "text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "start_char_idx": 682, "end_char_idx": 799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bd51752-d7c2-4c42-9a80-16f64e068c21": {"__data__": {"id_": "4bd51752-d7c2-4c42-9a80-16f64e068c21", "embedding": null, "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "500703b2-b343-4c03-abc6-fe62c708fb10", "node_type": "1", "metadata": {"window": "Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired. ", "original_text": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "665514e35898d5acda0da2fa2560333ec34c1b4cca882468c00e8e775486ca1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07c77af4-420b-43bc-a2b5-6070fd72963b", "node_type": "1", "metadata": {"window": "ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. "}, "hash": "9ade6b7eb2a93ef6dffb9ef117488358455dba20c43741edec0e7263efa1dc63", "class_name": "RelatedNodeInfo"}}, "text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "start_char_idx": 799, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07c77af4-420b-43bc-a2b5-6070fd72963b": {"__data__": {"id_": "07c77af4-420b-43bc-a2b5-6070fd72963b", "embedding": null, "metadata": {"window": "ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bd51752-d7c2-4c42-9a80-16f64e068c21", "node_type": "1", "metadata": {"window": "Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "original_text": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0374da85b0611b552de850365b0d6a4287f6d7a366f2d3188a8d7b046bd5110e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. "}, "hash": "420f03afd459a3d22f1d22a40d9e7c652109039eb230596ff305024f29b10bfd", "class_name": "RelatedNodeInfo"}}, "text": "From outside the United States, dial +1 (412) 317-5282. ", "start_char_idx": 1038, "end_char_idx": 1094, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9": {"__data__": {"id_": "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9", "embedding": null, "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07c77af4-420b-43bc-a2b5-6070fd72963b", "node_type": "1", "metadata": {"window": "ET on August 4, 2021.  A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "original_text": "From outside the United States, dial +1 (412) 317-5282. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b5dbe10a76b39441df3cddc3403e73126094568bdd2cb834da128d38e9a01c0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "865a0a79-2c50-477e-8be7-95a45a732c97", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . "}, "hash": "c8ebaa055d627d00b7ff9e142184196236c96c3a5a483769d01d10eb9efc4b86", "class_name": "RelatedNodeInfo"}}, "text": "No access code is\nrequired. ", "start_char_idx": 1094, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "865a0a79-2c50-477e-8be7-95a45a732c97": {"__data__": {"id_": "865a0a79-2c50-477e-8be7-95a45a732c97", "embedding": null, "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9", "node_type": "1", "metadata": {"window": "A slide presentation for investors\nhas also been posted on the Company's website at investor.amerisourcebergen.com .  Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast. ", "original_text": "No access code is\nrequired. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33aa052332ca04a6778fd2c7dbd8276efe42d3f77431b22dfe0b6803b4ccc123", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "454e9184-0d20-4a23-a671-505044e0aaab", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n"}, "hash": "977e52b469423f96d46f5da5cce93b4e56c7a608fe5b6815a463b36b0c95f305", "class_name": "RelatedNodeInfo"}}, "text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "start_char_idx": 1122, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "454e9184-0d20-4a23-a671-505044e0aaab": {"__data__": {"id_": "454e9184-0d20-4a23-a671-505044e0aaab", "embedding": null, "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "865a0a79-2c50-477e-8be7-95a45a732c97", "node_type": "1", "metadata": {"window": "Participating in the conference call will be:\nSteven H. Collis, Chairman, President & Chief Executive Officer\nJames F. Cleary, Executive Vice President & Chief Financial Officer\nThe dial-in number for the live call will be (844) 808-6694.  From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "original_text": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com . ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61aa0d3e0a7f8bb66badcde087c7cdf2b3f18f214aa089b1355a024d70a342fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. "}, "hash": "a785338c29e966735e941039c52688d2834afbc610b23b145bbdf354a4b80e19", "class_name": "RelatedNodeInfo"}}, "text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "start_char_idx": 1219, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9": {"__data__": {"id_": "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9", "embedding": null, "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "454e9184-0d20-4a23-a671-505044e0aaab", "node_type": "1", "metadata": {"window": "From outside the United States, dial +1 (412) 317-5282.  No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "original_text": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de3ee89beb2d4f086fca5ab1ad0bd46389596dab6629c3604e19e0af2967f300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. "}, "hash": "dfa62d043018eabe2b73c0f5a741fd437ad6219af065d177bfeef0d158127e1c", "class_name": "RelatedNodeInfo"}}, "text": "Replays of the call will be made available via telephone and webcast. ", "start_char_idx": 1342, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa": {"__data__": {"id_": "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa", "embedding": null, "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9", "node_type": "1", "metadata": {"window": "No access code is\nrequired.  The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529. ", "original_text": "Replays of the call will be made available via telephone and webcast. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "984f2f1b38e1be2fa31b399694de777cd8e1db48cf9d29cfe4f2baf0ce01130e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "847614e7-e5de-41d0-b83c-ef77877a9627", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. "}, "hash": "ed68e8fd717353b7f09af06aefbedf950b43b4b04274a32f1c1af039221032fd", "class_name": "RelatedNodeInfo"}}, "text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "start_char_idx": 1412, "end_char_idx": 1582, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "847614e7-e5de-41d0-b83c-ef77877a9627": {"__data__": {"id_": "847614e7-e5de-41d0-b83c-ef77877a9627", "embedding": null, "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa", "node_type": "1", "metadata": {"window": "The live call will also be webcast via the Company\u2019s website at investor.amerisourcebergen.com .  Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658. ", "original_text": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b844710df4d79f562bac772d057d5ff91a1e5a9930cd53d92249d8e24c298452", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d2b5319-7dcd-447e-a56c-7c136e0d83a1", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. "}, "hash": "482e43fa4b51562d5b38c4af78a80ffd4b76f0fa2f0e0b9eeff623bf94801fb6", "class_name": "RelatedNodeInfo"}}, "text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "start_char_idx": 1582, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d2b5319-7dcd-447e-a56c-7c136e0d83a1": {"__data__": {"id_": "8d2b5319-7dcd-447e-a56c-7c136e0d83a1", "embedding": null, "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "847614e7-e5de-41d0-b83c-ef77877a9627", "node_type": "1", "metadata": {"window": "Users are encouraged to\nlog on to the webcast approximately 10 minutes in advance of the scheduled start time of the call.\n Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "original_text": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5191ec5bf3d1ffd08fd7cc9c57a65b508c0cd29c52add7d4bbd8eccc831d5529", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fee81e8d-c164-4439-b7c0-e7f85da19d47", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. "}, "hash": "11fe3aa5101139725391fb4d224d2f5e0a69796ffbc454de5ee041e3e274d857", "class_name": "RelatedNodeInfo"}}, "text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "start_char_idx": 1724, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fee81e8d-c164-4439-b7c0-e7f85da19d47": {"__data__": {"id_": "fee81e8d-c164-4439-b7c0-e7f85da19d47", "embedding": null, "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d2b5319-7dcd-447e-a56c-7c136e0d83a1", "node_type": "1", "metadata": {"window": "Replays of the call will be made available via telephone and webcast.  A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n", "original_text": "To access the telephone replay from within the U.S., dial (877) 344-7529. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c715e744688343f444365f76dfe1bf72b80b9ddd76fea3e400995217e87d16f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2f3df2a9-7ed2-431f-9580-e870332f52c9", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. "}, "hash": "5f4cd1442b066054284ba18893b0bd0ad1a8f2125ee61cc0cbede4596d07e228", "class_name": "RelatedNodeInfo"}}, "text": "From Canada, dial +1 (855) 669-9658. ", "start_char_idx": 1798, "end_char_idx": 1835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2f3df2a9-7ed2-431f-9580-e870332f52c9": {"__data__": {"id_": "2f3df2a9-7ed2-431f-9580-e870332f52c9", "embedding": null, "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fee81e8d-c164-4439-b7c0-e7f85da19d47", "node_type": "1", "metadata": {"window": "A replay of the webcast will be posted on\ninvestor.amerisourcebergen.com  approximately one hour after the completion of the call and will remain available for one year.  The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "original_text": "From Canada, dial +1 (855) 669-9658. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37df8be813d8baa5ba45f91e19d2a75f430a8c590c8011d7feccdc9e36da64b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "269d6890-d057-4e2d-9757-3636f4e4f970", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "The access code for the replay is 10157948.\n"}, "hash": "7f1e5bb3ab9bf9c838459a2385e5c9697edfa91c631b228757dda11a88bfdf4e", "class_name": "RelatedNodeInfo"}}, "text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "start_char_idx": 1835, "end_char_idx": 1902, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "269d6890-d057-4e2d-9757-3636f4e4f970": {"__data__": {"id_": "269d6890-d057-4e2d-9757-3636f4e4f970", "embedding": null, "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "The access code for the replay is 10157948.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2f3df2a9-7ed2-431f-9580-e870332f52c9", "node_type": "1", "metadata": {"window": "The\ntelephone replay will also be available approximately one hour after the completion of the call and will remain available for seven\ndays.  To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "original_text": "From outside\nthe United States and Canada, dial +1 (412) 317-0088. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "239a213f6c941f5a27a140851491a70d2f593a33dc50782932fd31baafa0d518", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4f0061-815c-40a6-a5f0-33dcbeaccda2", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. "}, "hash": "3dd801781f66366b49961bbff3e02d827e05754c1e7aa9f2f372c6e5b356bc42", "class_name": "RelatedNodeInfo"}}, "text": "The access code for the replay is 10157948.\n", "start_char_idx": 1902, "end_char_idx": 1946, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4f0061-815c-40a6-a5f0-33dcbeaccda2": {"__data__": {"id_": "0d4f0061-815c-40a6-a5f0-33dcbeaccda2", "embedding": null, "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "269d6890-d057-4e2d-9757-3636f4e4f970", "node_type": "1", "metadata": {"window": "To access the telephone replay from within the U.S., dial (877) 344-7529.  From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "original_text": "The access code for the replay is 10157948.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5839074fa718cf6a67a470ecbf4c99b35f8ccce6b23c9e57cc05bce99bc3443c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef618df9-57d6-468b-a759-d0d703ebe523", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. "}, "hash": "07fb4a952c805f573eb246dfaa95c8215c743d49d8fca3ba07e04a7afa8a4680", "class_name": "RelatedNodeInfo"}}, "text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "start_char_idx": 1946, "end_char_idx": 2159, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef618df9-57d6-468b-a759-d0d703ebe523": {"__data__": {"id_": "ef618df9-57d6-468b-a759-d0d703ebe523", "embedding": null, "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4f0061-815c-40a6-a5f0-33dcbeaccda2", "node_type": "1", "metadata": {"window": "From Canada, dial +1 (855) 669-9658.  From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "original_text": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94f6a6159329c1b1514c1f155fef922d46ad7bc8046460ee55422fcd7606883d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989", "node_type": "1", "metadata": {"window": "The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. "}, "hash": "15e8b549e7ae94f17f3384ab911e6fcfd24811bb56930a0207a5da016c9fb985", "class_name": "RelatedNodeInfo"}}, "text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "start_char_idx": 2159, "end_char_idx": 2394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989": {"__data__": {"id_": "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989", "embedding": null, "metadata": {"window": "The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef618df9-57d6-468b-a759-d0d703ebe523", "node_type": "1", "metadata": {"window": "From outside\nthe United States and Canada, dial +1 (412) 317-0088.  The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n", "original_text": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3a3f7fcd26ca7201519c6d9b17e1a55ebe91f66dfce78e618732211c65cdc202", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8ab4c5a-71b1-4e67-8978-4be77bb04790", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. "}, "hash": "cb9d2df014b32560a5a2a4ecfb72034d58a3ef62882d7f2b39aa5bef302dc2ae", "class_name": "RelatedNodeInfo"}}, "text": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "start_char_idx": 2394, "end_char_idx": 2509, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8ab4c5a-71b1-4e67-8978-4be77bb04790": {"__data__": {"id_": "b8ab4c5a-71b1-4e67-8978-4be77bb04790", "embedding": null, "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989", "node_type": "1", "metadata": {"window": "The access code for the replay is 10157948.\n About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "original_text": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4d49a33d8d4678c3ba29a229d6d1be20bedeb60458e47560f2a198eb58533c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58a092dc-d649-46de-abee-5e42d06efe84", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n"}, "hash": "9faa8c1a25958b8f6971f27ca180f095bac263a9bab2b27ce56b6f17114bc59d", "class_name": "RelatedNodeInfo"}}, "text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "start_char_idx": 2509, "end_char_idx": 2606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58a092dc-d649-46de-abee-5e42d06efe84": {"__data__": {"id_": "58a092dc-d649-46de-abee-5e42d06efe84", "embedding": null, "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8ab4c5a-71b1-4e67-8978-4be77bb04790", "node_type": "1", "metadata": {"window": "About Amerisour ceBer gen\nAmerisourceBergen fosters a positive impact on the health of people and communities around the world by advancing the\ndevelopment and delivery of pharmaceuticals and healthcare products.  As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "original_text": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ff6de7d1d3d574bf716e43c5ef0da78c8d1627c428d45ee4b21621535acc74eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be123ccd-fd45-4045-a4b7-ba65f4d3758a", "node_type": "1", "metadata": {"window": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). "}, "hash": "3b52c5741f6e9de4af7612fe70a86af523df9b32e01a31cd8132692e1969b551", "class_name": "RelatedNodeInfo"}}, "text": "Learn more at investor.amerisourcebergen.com .\n", "start_char_idx": 2606, "end_char_idx": 2653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be123ccd-fd45-4045-a4b7-ba65f4d3758a": {"__data__": {"id_": "be123ccd-fd45-4045-a4b7-ba65f4d3758a", "embedding": null, "metadata": {"window": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58a092dc-d649-46de-abee-5e42d06efe84", "node_type": "1", "metadata": {"window": "As a leading global healthcare company, with a foundation\nin pharmaceutical distribution and solutions for manufacturers, pharmacies and providers, we create unparalleled access, efficiency\nand reliability for human and animal health.  Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "original_text": "Learn more at investor.amerisourcebergen.com .\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "032e566dddde8c866a470113fc2f66d234fe2cd231b4d337a3950a1d97e4a757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df2e76a7-a758-480c-b71d-e353fc22a2d7", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. "}, "hash": "5872fe4925eed3a028f62f63bc8bbad64c81bf57ae6527e6170f4decdeeb78ba", "class_name": "RelatedNodeInfo"}}, "text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "start_char_idx": 2653, "end_char_idx": 3000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df2e76a7-a758-480c-b71d-e353fc22a2d7": {"__data__": {"id_": "df2e76a7-a758-480c-b71d-e353fc22a2d7", "embedding": null, "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be123ccd-fd45-4045-a4b7-ba65f4d3758a", "node_type": "1", "metadata": {"window": "Our 41,000 global team members power our purpose: We are united in our\nresponsibility to create healthier futures.  AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "original_text": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\"). ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8315ef574a5aa96d9a30e91dcaca252daed59093d8fd1e5a34721ddad00c7368", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a879545-b589-4a25-84d6-f2e769414b47", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. "}, "hash": "b4533078324bd01bdb6d40d3527f1050de3b5643b52c7cc81d52742d1fe5ba6d", "class_name": "RelatedNodeInfo"}}, "text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "start_char_idx": 3000, "end_char_idx": 3349, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a879545-b589-4a25-84d6-f2e769414b47": {"__data__": {"id_": "1a879545-b589-4a25-84d6-f2e769414b47", "embedding": null, "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df2e76a7-a758-480c-b71d-e353fc22a2d7", "node_type": "1", "metadata": {"window": "AmerisourceBergen is ranked #8 on the Fortune 500 with more than $200 billion in annual\nrevenue.  Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "664ab1ab2870821b3aec1c8a414bfb5863d0eef895e136ef53c94b7352da052d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5408e699-cc5b-4597-8a3a-2212d7e64433", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. "}, "hash": "a082534b3cb42eaa10c5a33a1fcec39fcf5b233106bb56568d7308079a2cf67f", "class_name": "RelatedNodeInfo"}}, "text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "start_char_idx": 3349, "end_char_idx": 3511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5408e699-cc5b-4597-8a3a-2212d7e64433": {"__data__": {"id_": "5408e699-cc5b-4597-8a3a-2212d7e64433", "embedding": null, "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a879545-b589-4a25-84d6-f2e769414b47", "node_type": "1", "metadata": {"window": "Learn more at investor.amerisourcebergen.com .\n Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f34e83e3fc8b65616354c540ed5f9c584afe289991f0257697c20a80083e97bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "066d3668-8bd9-4138-93e4-f136c3cacf3d", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5"}, "hash": "b6f0cb6e3d50edfe75517d1044a4fffa1aef584adb12dd44f70f5724a5e9ff42", "class_name": "RelatedNodeInfo"}}, "text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "start_char_idx": 3511, "end_char_idx": 3710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "066d3668-8bd9-4138-93e4-f136c3cacf3d": {"__data__": {"id_": "066d3668-8bd9-4138-93e4-f136c3cacf3d", "embedding": null, "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3935c4c8f7af5f653f5f07b77bd116df0e40c0afc44d0897e2becc9711e963b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5408e699-cc5b-4597-8a3a-2212d7e64433", "node_type": "1", "metadata": {"window": "Amerisour ceBer gen's Cautionar y Not e Regarding For ward-Looking S tatements\nCertain of the statements contained in this press release are \"forward-looking statements\" within the meaning of Section 27A of the\nSecurities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the \"Securities Exchange\nAct\").  Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated. ", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "89396b48142e01c91bcfb0409d044a082513962355d0e75acfc182bbe1a4c4f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16bddad9-31b4-439c-9c21-d55e7b2356bf", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. "}, "hash": "139e70b057f985e9f465097a655d1dbea629ead06744e7b64b62fe04575e90e7", "class_name": "RelatedNodeInfo"}}, "text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "start_char_idx": 3710, "end_char_idx": 4303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16bddad9-31b4-439c-9c21-d55e7b2356bf": {"__data__": {"id_": "16bddad9-31b4-439c-9c21-d55e7b2356bf", "embedding": null, "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "066d3668-8bd9-4138-93e4-f136c3cacf3d", "node_type": "1", "metadata": {"window": "Words such as \"expect,\" \"likely,\" \"outlook,\" \"forecast,\" \"would,\" \"could,\" \"should,\" \"can,\" \"project,\" \"intend,\" \"plan,\" \"continue,\"\n\"sustain,\" \"synergy,\" \"on track,\" \"believe,\" \"seek,\" \"estimate,\" \"anticipate,\" \"may,\" \"possible,\" \"assume,\" variations of such words, and\nsimilar expressions are intended to identify such forward-looking statements.  These statements are based on management's current\nexpectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof.  These statements\nare not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause\nactual results to vary materially from those indicated.  Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "original_text": "Among the factors that could cause actual results to differ materially from\nthose projected, anticipated, or implied are the following: unfavorable trends in brand and generic pharmaceutical pricing, including\nin rate or frequency of price inflation or deflation; competition and industry consolidation of both customers and suppliers resulting\nin increasing pressure to reduce prices for our products and services; changes in the United States healthcare and regulatory\nenvironment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing\n5", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ebc598b8d6d31fc08f329dd5dc5dae673b5440fa02e5390270c89b30fd1c1d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a70d733-ef47-4a31-84b9-b2ed4fe25edb", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S. "}, "hash": "ff54a815443f3844e025880930c1097559f2dbeefbd9e9887a37dbff0c61e009", "class_name": "RelatedNodeInfo"}}, "text": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "start_char_idx": 0, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a70d733-ef47-4a31-84b9-b2ed4fe25edb": {"__data__": {"id_": "1a70d733-ef47-4a31-84b9-b2ed4fe25edb", "embedding": null, "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16bddad9-31b4-439c-9c21-d55e7b2356bf", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a961fc948372e9ff83e8b34902b36bcd6efb112aef56a8e8df0fd51dd73b191", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5166528-bef8-4d08-b33a-dea7f72c82e7", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. "}, "hash": "bcaffe7bc808a9afd91bc32c18a47ed9720ff45afe6294a36caff5817c1f3d79", "class_name": "RelatedNodeInfo"}}, "text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S. ", "start_char_idx": 2384, "end_char_idx": 2595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5166528-bef8-4d08-b33a-dea7f72c82e7": {"__data__": {"id_": "d5166528-bef8-4d08-b33a-dea7f72c82e7", "embedding": null, "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a70d733-ef47-4a31-84b9-b2ed4fe25edb", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "original_text": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7418a6ecc43f5fe410f97a2d7a3a13f79315dcbf16607c5538c4b299217722f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. "}, "hash": "a96bf36abc18373019da6deb13f7f7882123f35dab91fc34fac48472261aa3ee", "class_name": "RelatedNodeInfo"}}, "text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "start_char_idx": 2595, "end_char_idx": 4251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e": {"__data__": {"id_": "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e", "embedding": null, "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5166528-bef8-4d08-b33a-dea7f72c82e7", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8cc838dd8e8d40bf0790f79e989d3c1eaeecf0aa5f430bbf7a8948fbb49fe874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e33daa0e-8845-478a-b62a-7fe1f5c392fd", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n"}, "hash": "0e54dc0c3f73ff1ca199c022a02cd20ac5d77598e0b0221f9fe44dc1c5cf0c95", "class_name": "RelatedNodeInfo"}}, "text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "start_char_idx": 4251, "end_char_idx": 4666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e33daa0e-8845-478a-b62a-7fe1f5c392fd": {"__data__": {"id_": "e33daa0e-8845-478a-b62a-7fe1f5c392fd", "embedding": null, "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e", "node_type": "1", "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0ae0abd05446d60fc0a14b9d752b3cd613627cf8b23239a40f0ee58e2ced9ad1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "298e2635-81f6-4460-806e-8eede25c6a07", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6"}, "hash": "6c108330bd0566ec0ce6fe91d5183d797e13aea12970327bd1f0fb9213724914", "class_name": "RelatedNodeInfo"}}, "text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "start_char_idx": 4666, "end_char_idx": 4815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "298e2635-81f6-4460-806e-8eede25c6a07": {"__data__": {"id_": "298e2635-81f6-4460-806e-8eede25c6a07", "embedding": null, "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "80df82db-d2f4-4b2e-8063-0906751b03f3", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "61eb64f719ce463505511d0706c88576f64a430c77eaa80adf7c7d4522094416", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e33daa0e-8845-478a-b62a-7fe1f5c392fd", "node_type": "1", "metadata": {"window": "and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dd824e87f586cb5ee2e0ad8da6d625f75739cbcdf0d6fc78c307d2cf266aa87c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "758fea22-bf78-423f-8bcb-f806429549c6", "node_type": "1", "metadata": {"window": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7"}, "hash": "3d42f241f1db780819472abfcc68a78986c3b23e8a0d3102daa8e30f6b123dc1", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "start_char_idx": 4815, "end_char_idx": 5100, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "758fea22-bf78-423f-8bcb-f806429549c6": {"__data__": {"id_": "758fea22-bf78-423f-8bcb-f806429549c6", "embedding": null, "metadata": {"window": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a03e3911-7a61-4832-b633-f79cfb15c989", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d53d81ce1475b2d68256bc7c3dbe2a659598a3f70b582fbf0da7033c9c0722fb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "298e2635-81f6-4460-806e-8eede25c6a07", "node_type": "1", "metadata": {"window": "Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act.  The Company\nundertakes no obligation to publicly update or revise any forward-looking statements, except as required by the federal securities\nlaws.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Three \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0\u00a0 \u00a0$45,366,777 \u00a0\u00a0\u00a0 \u00a017.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n6", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25eddcbc13afafe20f2b2c399c8e11105078336dbc04de8c5b15aa6eefe233d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4348b828-f9c4-4b04-821d-7cdd2f4248f4", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "original_text": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021. "}, "hash": "a55d3c38b04c3a62dc21aa96a5788a77f43a8bcf358e09ee04d356759680640f", "class_name": "RelatedNodeInfo"}}, "text": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "start_char_idx": 0, "end_char_idx": 1250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4348b828-f9c4-4b04-821d-7cdd2f4248f4": {"__data__": {"id_": "4348b828-f9c4-4b04-821d-7cdd2f4248f4", "embedding": null, "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "original_text": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021. ", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "758fea22-bf78-423f-8bcb-f806429549c6", "node_type": "1", "metadata": {"window": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e62f4bb4b07e5ea760326d0db7530ee692faf153e4d0906e3fb782361fb8b294", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "749746c8-f7db-4d55-8c6a-99359e254a6d", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "original_text": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n"}, "hash": "dfeae5815c6a66ffb474d74d84a6e6a91ce2965c4ecb8e5594cb573d1000f824", "class_name": "RelatedNodeInfo"}}, "text": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021. ", "start_char_idx": 0, "end_char_idx": 418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "749746c8-f7db-4d55-8c6a-99359e254a6d": {"__data__": {"id_": "749746c8-f7db-4d55-8c6a-99359e254a6d", "embedding": null, "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "original_text": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4348b828-f9c4-4b04-821d-7cdd2f4248f4", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "original_text": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021. ", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "50c268b9fc5988c773778ce3956fe77bc6b854776b84c6c28d5d57bccd0f4d41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n"}, "hash": "5f95353251e9971455e5907c04409853ae1ee376cbffe6b4c848aa33241498ba", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n", "start_char_idx": 418, "end_char_idx": 496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b": {"__data__": {"id_": "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b", "embedding": null, "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "749746c8-f7db-4d55-8c6a-99359e254a6d", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "original_text": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e786fbd17a5ef3db1c98495bdad961092e1225e7df0a7e97ba0fcbb4c4e01ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2613502a-191e-4276-bdd7-5263dcef6522", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. "}, "hash": "21eda12d8f160c1ab7f01ac97701603ce4f7f123ca547a2a0fdc1b73e7034fa1", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "start_char_idx": 496, "end_char_idx": 591, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2613502a-191e-4276-bdd7-5263dcef6522": {"__data__": {"id_": "2613502a-191e-4276-bdd7-5263dcef6522", "embedding": null, "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "51111d75fd740a58017c56727d28022a5476f9840a016a00a755dd9764762e93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25492582-915f-49f6-8852-0c1e12f68d81", "node_type": "1", "metadata": {"window": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n"}, "hash": "8af60266d792dc1ce28b185efa4570b7845653166a312de13e1b5754a61f9676", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "start_char_idx": 591, "end_char_idx": 1046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25492582-915f-49f6-8852-0c1e12f68d81": {"__data__": {"id_": "25492582-915f-49f6-8852-0c1e12f68d81", "embedding": null, "metadata": {"window": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2613502a-191e-4276-bdd7-5263dcef6522", "node_type": "1", "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "original_text": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "936542f124cda60d8fd61e84859bf99c1c9bcacb560b0f0e87e283056d2fc7a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb106088-0256-4e24-8e25-4e6c3e23327f", "node_type": "1", "metadata": {"window": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n"}, "hash": "bd7c353eab513b975aaf735fdf37dd082ea415a3ceeeea93a077d4d5322bf31e", "class_name": "RelatedNodeInfo"}}, "text": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "start_char_idx": 1046, "end_char_idx": 1412, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb106088-0256-4e24-8e25-4e6c3e23327f": {"__data__": {"id_": "eb106088-0256-4e24-8e25-4e6c3e23327f", "embedding": null, "metadata": {"window": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25492582-915f-49f6-8852-0c1e12f68d81", "node_type": "1", "metadata": {"window": "Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f657395276a535b9e2f8b6f21e9d32c0785e0ff588149ead9bab18e77277cd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6c748b8-b2f0-4f08-904c-8c61111007dc", "node_type": "1", "metadata": {"window": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n"}, "hash": "1179db1b258e2fe2c3d181810aaf00666f28205054d590905dcd91bed4529323", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "start_char_idx": 1412, "end_char_idx": 1569, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6c748b8-b2f0-4f08-904c-8c61111007dc": {"__data__": {"id_": "b6c748b8-b2f0-4f08-904c-8c61111007dc", "embedding": null, "metadata": {"window": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb106088-0256-4e24-8e25-4e6c3e23327f", "node_type": "1", "metadata": {"window": "2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f88a5eb7a15aff5b01be4fec3c336bc1a79248b2159f48c2d995791081b1b0c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b94a360-0206-489d-87dd-c204d9748de1", "node_type": "1", "metadata": {"window": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8"}, "hash": "7a18fd3d3c89d7b7d75095d3446f6ec386c198e9e4bb35a6871a261e876752ed", "class_name": "RelatedNodeInfo"}}, "text": "5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "start_char_idx": 1569, "end_char_idx": 1730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b94a360-0206-489d-87dd-c204d9748de1": {"__data__": {"id_": "0b94a360-0206-489d-87dd-c204d9748de1", "embedding": null, "metadata": {"window": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc6e3b32162b39266ba25f0349239aba03aa006cadbdfd47a90d86e314c1585c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6c748b8-b2f0-4f08-904c-8c61111007dc", "node_type": "1", "metadata": {"window": "3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021.  Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f005d8cda40e53769bd9bc1c287b9a3d2a23bb8346f7affe169e2acd3ae2676", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93b972c7-0ab1-426b-8ff4-c57b5dc226ea", "node_type": "1", "metadata": {"window": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "original_text": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9"}, "hash": "8bf29de6362eca152a9976c84190a059ac565301d112e7e98d9d17871bafb05e", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "start_char_idx": 1730, "end_char_idx": 2095, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93b972c7-0ab1-426b-8ff4-c57b5dc226ea": {"__data__": {"id_": "93b972c7-0ab1-426b-8ff4-c57b5dc226ea", "embedding": null, "metadata": {"window": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "original_text": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "page_label": "9", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6631f107-6f9c-4aff-9248-1e2814044903", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "88db77f40d8a2c730f28cb002a8b8062731a99c7ce57e89d4d5078b5807db780", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b94a360-0206-489d-87dd-c204d9748de1", "node_type": "1", "metadata": {"window": "Includes $6.5 million of employee severance, $31.4 million of litigation costs\nrelated to legal fees in connection with opioid lawsuits and investigations, and $20.7 million of other costs in connection with\nbusiness transformation efforts, acquisition-related deal and integration costs, and other restructuring initiatives in the three months\nended June 30, 2020.\n 4 Includes $6.2 million of income on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform and $9.0 million of expense relating to Swiss tax reform in the three\nmonths ended June 30, 2021.\n AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "original_text": "AMERISOURCEBERGEN CORPORATION \n FINANCIAL SUMMARY \n (In thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine \nMonths Ended \nJune 30, 2021 \u00a0% of\nRevenue \u00a0Nine \nMonths Ended \nJune 30, 2020 \u00a0% of\nRevenue \u00a0%\nChange\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0\u00a0 \u00a0$140,649,158 \u00a0\u00a0\u00a0\u00a0 \u00a010.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nCost of goods sold \u00a0150,202,605 \u00a0\u00a0\u00a0\u00a0 \u00a0136,804,121 \u00a0\u00a0\u00a0\u00a0 \u00a09.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n8", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec4f473f7b1a605b15874dd19fb7f62bc11be71b31c532de18bc5f1c68ccd940", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "824dbe41-cb78-4353-9a70-c365c991dc75", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "original_text": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021. "}, "hash": "35a3c9b97d05d7b568da4cd1ded8d49f8ba2f341ffa4546f977d8f3b667ba479", "class_name": "RelatedNodeInfo"}}, "text": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "start_char_idx": 0, "end_char_idx": 1308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "824dbe41-cb78-4353-9a70-c365c991dc75": {"__data__": {"id_": "824dbe41-cb78-4353-9a70-c365c991dc75", "embedding": null, "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "original_text": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93b972c7-0ab1-426b-8ff4-c57b5dc226ea", "node_type": "1", "metadata": {"window": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "original_text": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "page_label": "9", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64354b40cfffc67889cac7e22928f77a6e108749213f90fad316eed3821aa48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62847867-7ce0-4f9d-857a-79a3dd09c318", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "original_text": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n"}, "hash": "e03f42a852bb80cb031a2691b2095a98ed77806a6e2c845ebdb5a16b46f0e223", "class_name": "RelatedNodeInfo"}}, "text": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021. ", "start_char_idx": 0, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62847867-7ce0-4f9d-857a-79a3dd09c318": {"__data__": {"id_": "62847867-7ce0-4f9d-857a-79a3dd09c318", "embedding": null, "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "original_text": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "824dbe41-cb78-4353-9a70-c365c991dc75", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "original_text": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56a2d7b53bc1e534b00b3d9e0f865b5bac729685ba87e5db8696fc46045b4bd6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n"}, "hash": "5564ea5e7647ae6e1be543d4e554de2511c59fd9d6ac94a39a31caf415793b34", "class_name": "RelatedNodeInfo"}}, "text": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n", "start_char_idx": 387, "end_char_idx": 589, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4": {"__data__": {"id_": "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4", "embedding": null, "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62847867-7ce0-4f9d-857a-79a3dd09c318", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "original_text": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3417da8d3b608fe8f3db7e3635216f6daf9f5aca40091b3fbd773752574b0ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23943697-d32a-40b3-891b-7043128dbbe5", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "original_text": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. "}, "hash": "1d669c68f8e0405aecf1f5a4c375f8520f8e9daa26f40b2b2a1b8fb25a59d84c", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n", "start_char_idx": 589, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23943697-d32a-40b3-891b-7043128dbbe5": {"__data__": {"id_": "23943697-d32a-40b3-891b-7043128dbbe5", "embedding": null, "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "original_text": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "original_text": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b54448823abccf48cb0bb24ecef49f1011fa168b32e5fa679ccc961ddd53fd0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5054753b-44bf-413a-8837-cede99b1b5f0", "node_type": "1", "metadata": {"window": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "original_text": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n"}, "hash": "a515c4b8827d9739fa8eeab0990284a1807a8dbb8ff17dd7647f13c343d9b1a8", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "start_char_idx": 853, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5054753b-44bf-413a-8837-cede99b1b5f0": {"__data__": {"id_": "5054753b-44bf-413a-8837-cede99b1b5f0", "embedding": null, "metadata": {"window": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "original_text": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23943697-d32a-40b3-891b-7043128dbbe5", "node_type": "1", "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "original_text": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "069daa56fc5fe5ef6d73fdeed9d983d72d7b5d97cc0f534c0089f1520bd28bf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "52d913c3-1688-4f77-883d-e3286369c5dd", "node_type": "1", "metadata": {"window": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n"}, "hash": "6cecaf290bb85509e19a028c69b2693b3af22a89d25809017e5039c4f62dac05", "class_name": "RelatedNodeInfo"}}, "text": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "start_char_idx": 1306, "end_char_idx": 1672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "52d913c3-1688-4f77-883d-e3286369c5dd": {"__data__": {"id_": "52d913c3-1688-4f77-883d-e3286369c5dd", "embedding": null, "metadata": {"window": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5054753b-44bf-413a-8837-cede99b1b5f0", "node_type": "1", "metadata": {"window": "Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "original_text": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6413ba3b49ea5c2c023ea62b477ee27e0d5c005b1398fe90cae63789a943bd5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02bd7576-3bfb-45ad-89be-ef63cc9574d3", "node_type": "1", "metadata": {"window": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. "}, "hash": "2cfeaac387825cf3dbfad1aed5dbe055b8613ea9b7f38dca3300265e7f176436", "class_name": "RelatedNodeInfo"}}, "text": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "start_char_idx": 1672, "end_char_idx": 1828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02bd7576-3bfb-45ad-89be-ef63cc9574d3": {"__data__": {"id_": "02bd7576-3bfb-45ad-89be-ef63cc9574d3", "embedding": null, "metadata": {"window": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "52d913c3-1688-4f77-883d-e3286369c5dd", "node_type": "1", "metadata": {"window": "2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "15bec04e8b82d49326b4ad79e2747769eecdc804aad0098e240031664550121a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09812a40-cfd0-4c1e-bf72-4859ef1dcea1", "node_type": "1", "metadata": {"window": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n"}, "hash": "31605f0bb9f1e0e9b6aadcc49eadfe84413fb109a13904d9fc33e91143a0805a", "class_name": "RelatedNodeInfo"}}, "text": "5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "start_char_idx": 1828, "end_char_idx": 2160, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09812a40-cfd0-4c1e-bf72-4859ef1dcea1": {"__data__": {"id_": "09812a40-cfd0-4c1e-bf72-4859ef1dcea1", "embedding": null, "metadata": {"window": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02bd7576-3bfb-45ad-89be-ef63cc9574d3", "node_type": "1", "metadata": {"window": "3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021.  Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575672f2eb1773c343971ffdd2fb6185ffad1c72c2ec6b6c8b530b04160eee4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14", "node_type": "1", "metadata": {"window": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10"}, "hash": "890dd43efa8218aa96f85af6b8cf02b341c73359a91bc23ff565549d04958272", "class_name": "RelatedNodeInfo"}}, "text": "Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "start_char_idx": 2160, "end_char_idx": 2356, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14": {"__data__": {"id_": "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14", "embedding": null, "metadata": {"window": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9e378987-9a65-464b-b917-f2bca2db10cd", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26031f2b0353f416d585cf35f41324d9bf2180e8ca7a2e6c3f81482ba0facbac", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09812a40-cfd0-4c1e-bf72-4859ef1dcea1", "node_type": "1", "metadata": {"window": "Includes $32.4 million of employee severance, $86.9 million of\nlitigation costs related to legal fees in connection with opioid lawsuits and investigations, and $46.4 million of other costs in\nconnection with business transformation efforts, other restructuring initiatives, and acquisition-related deal and integration costs in\nthe nine months ended June 30, 2020.\n 4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0e86b1201ffd7897e8bc4998f94316d1398bbb751afce1ba4d62409b611a1836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "99d5fcb03a5e9178e8462964f3ed1f2ab774549cf4d0693f189724419eb1d091", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "start_char_idx": 2356, "end_char_idx": 2841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f": {"__data__": {"id_": "a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ac7718c-3947-40a7-b13c-7abc741cf8dc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d42590492f5761c8048e7f046d317d62480bb964aa3a49fcc4ad87f34618c28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14", "node_type": "1", "metadata": {"window": "4 Includes a $1.1 million expense on the currency remeasurement of deferred tax assets relating to Swiss tax reform in the nine\nmonths ended June 30, 2021.\n 5 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $20.4\nmillion adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the permanent\nshutdown of the PharMEDium business in the nine months ended June 30, 2021.  Includes $741.0 million of discrete tax benefits\nprimarily attributable to the income tax deductions resulting from the shutdown of the PharMEDium business in the nine months\nended June 30, 2020.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2021 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,888,206 \u00a0\u00a0$1,267,479 \u00a0\u00a0$620,727 \u00a0\u00a0$573,530 \u00a0\u00a0$278,082 \u00a0\u00a0$(3,326 )\u00a0$292,122 \u00a0\u00a0$1.40 \u00a0\u00a0\n10", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26b3dd76423ca6f3c46475a88e86b99832c570dd1a138f546b8b4f4c32ba0faf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79eab791-fc24-4385-b6da-b9172ffc14b2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11"}, "hash": "8185ae2bb91116617eda477ad61b0267bf43d98abdb3b3273ef8e0d53e26dc9b", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79eab791-fc24-4385-b6da-b9172ffc14b2": {"__data__": {"id_": "79eab791-fc24-4385-b6da-b9172ffc14b2", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3ac7718c-3947-40a7-b13c-7abc741cf8dc", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d42590492f5761c8048e7f046d317d62480bb964aa3a49fcc4ad87f34618c28", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "508a2c438db64cd0827ecf1c657fc42538f9a882e9cda0e6d6bc138ed7c7f988", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b69928b-17a8-4db3-971a-a3ea5efd452e", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n"}, "hash": "a6dcd96462e0af502aa632c29fc52a30a8d8da9beccdc2c477da9b6eb8acee9d", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "start_char_idx": 820, "end_char_idx": 1037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b69928b-17a8-4db3-971a-a3ea5efd452e": {"__data__": {"id_": "0b69928b-17a8-4db3-971a-a3ea5efd452e", "embedding": null, "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dba5f8dd-9511-497a-98fb-43d691170379", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4e0df22fcdbf9f5b4171a2edb3e9ebaa24cdc19a0e1e6b46ea7d5b54b81e14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79eab791-fc24-4385-b6da-b9172ffc14b2", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8d7ed4883b976c446fb013a71fa1acef1cb3ec9c1a93f550ca27f4fc72b17fa8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9637a46f-34d4-4795-b962-8ea8187ec0fb", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n"}, "hash": "2837c61b7325edc0eb4e9237752f0d0c9456ec7c57d59c9dd9f16d748aed647c", "class_name": "RelatedNodeInfo"}}, "text": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n", "start_char_idx": 0, "end_char_idx": 145, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9637a46f-34d4-4795-b962-8ea8187ec0fb": {"__data__": {"id_": "9637a46f-34d4-4795-b962-8ea8187ec0fb", "embedding": null, "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dba5f8dd-9511-497a-98fb-43d691170379", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4e0df22fcdbf9f5b4171a2edb3e9ebaa24cdc19a0e1e6b46ea7d5b54b81e14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b69928b-17a8-4db3-971a-a3ea5efd452e", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c38f1204e8df70d195480aa7c7abd28b8c0d5e1d5092ddd6a0c99a0f1bf7ea6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b5f18f3-0caa-4033-a24c-e472a06b50f4", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "3 The sum of the components does not equal the total due to rounding.\n"}, "hash": "a7e40560157436512838a16e97ada4b7358892f277a3bf9978541ad9fdb8beb7", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n", "start_char_idx": 145, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b5f18f3-0caa-4033-a24c-e472a06b50f4": {"__data__": {"id_": "9b5f18f3-0caa-4033-a24c-e472a06b50f4", "embedding": null, "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "3 The sum of the components does not equal the total due to rounding.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dba5f8dd-9511-497a-98fb-43d691170379", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4e0df22fcdbf9f5b4171a2edb3e9ebaa24cdc19a0e1e6b46ea7d5b54b81e14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9637a46f-34d4-4795-b962-8ea8187ec0fb", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c08f55aee8d110308c608ba026f9341f30a9bbe34f330e373ea5da7e821f7068", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bba015a0-2c1c-4dff-8d65-a8b6cd263bce", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "eb958af0f56620759490aefcc8c08c23b11d735d7d8550ee180ccc45c17fed53", "class_name": "RelatedNodeInfo"}}, "text": "3 The sum of the components does not equal the total due to rounding.\n", "start_char_idx": 402, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bba015a0-2c1c-4dff-8d65-a8b6cd263bce": {"__data__": {"id_": "bba015a0-2c1c-4dff-8d65-a8b6cd263bce", "embedding": null, "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dba5f8dd-9511-497a-98fb-43d691170379", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4e0df22fcdbf9f5b4171a2edb3e9ebaa24cdc19a0e1e6b46ea7d5b54b81e14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b5f18f3-0caa-4033-a24c-e472a06b50f4", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "3 The sum of the components does not equal the total due to rounding.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf020adda0abff1163405de87dbde4d084d7c86d590f26bd8acef16d61637fbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f421cc4f-cdb9-4538-a2f2-b91016bbc77f", "node_type": "1", "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12"}, "hash": "9004e652d5f34b99e231219ce80c8bf4aeac1170ddd29aa1c2163c2b31fce9a0", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 472, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f421cc4f-cdb9-4538-a2f2-b91016bbc77f": {"__data__": {"id_": "f421cc4f-cdb9-4538-a2f2-b91016bbc77f", "embedding": null, "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dba5f8dd-9511-497a-98fb-43d691170379", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a4e0df22fcdbf9f5b4171a2edb3e9ebaa24cdc19a0e1e6b46ea7d5b54b81e14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bba015a0-2c1c-4dff-8d65-a8b6cd263bce", "node_type": "1", "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08f041b8ec2f59135c7899ebf9912fddc77908c68167b72ab69dd31b3aab9fcd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3", "node_type": "1", "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "24657eea8194125afadaedede2a4406071cad2454fb6f18f1e601d0629e58cb5", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "start_char_idx": 649, "end_char_idx": 1631, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3": {"__data__": {"id_": "d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3", "embedding": null, "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a3fea13-fa23-4c23-ad8a-0fab3e527b21", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a1ebef3fcfa685e629dc039c09e14cfcca13ff7de2cf4f684c068f45fe10c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f421cc4f-cdb9-4538-a2f2-b91016bbc77f", "node_type": "1", "metadata": {"window": "2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross\nProfit \u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income \n Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Net Loss (Income)\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed \n Earnings\nPer\nShare \u00a0\nGAAP \u00a0$1,225,716 \u00a0$820,885 \u00a0\u00a0$404,831 \u00a0$343,835 \u00a0$56,567 \u00a0\u00a0$ 2,171 \u00a0\u00a0$289,439 \u00a0\u00a0$1.41 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust litigation\nsettlements \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(15 )\u00a0\u2014 \u00a0\u00a015 \u00a0\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a06,061 \u00a0\u2014 \u00a0\u00a06,061 \u00a06,061 \u00a01,555 \u00a0\u00a0\u2014 \u00a0\u00a04,506 \u00a0\u00a00.02 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown costs \u00a0432 \u00a0(12,504 )\u00a012,936 \u00a012,936 \u00a03,264 \u00a0\u00a0\u2014 \u00a0 \u00a09,672 \u00a0\u00a00.05 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0(25,109 )\u00a025,109 \u00a025,109 \u00a06,276 \u00a0\u00a0(437 )\u00a018,396 \u00a0\u00a00.09 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\n12", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1e337714393ee95d296385cecf51bf7f0baf19898bc69d0de01c688f6dee687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be2e69d6-3882-4481-be54-a0d9c86a36d6", "node_type": "1", "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13"}, "hash": "b5e6f11bbb7985b84227fa4f23250ca841777d281105c498027f27766bd68fa5", "class_name": "RelatedNodeInfo"}}, "text": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be2e69d6-3882-4481-be54-a0d9c86a36d6": {"__data__": {"id_": "be2e69d6-3882-4481-be54-a0d9c86a36d6", "embedding": null, "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "6a3fea13-fa23-4c23-ad8a-0fab3e527b21", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "25a1ebef3fcfa685e629dc039c09e14cfcca13ff7de2cf4f684c068f45fe10c2", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3", "node_type": "1", "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "775fc85aafe5ae5c94923f90a1ff3c4dfa640a45bd9401fe15b819371ff5bec3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a884a4b-6796-4b8e-a64c-b11fe1233a4c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. "}, "hash": "d788d91abfdd7a1562ee7d9a22c5f5c3313561daaa9c18b7458b595e507666fe", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "start_char_idx": 889, "end_char_idx": 1077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a884a4b-6796-4b8e-a64c-b11fe1233a4c": {"__data__": {"id_": "4a884a4b-6796-4b8e-a64c-b11fe1233a4c", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "426cba76-db19-4101-9255-d4fb1858ebb2", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e330d1230f1c2f155b17b481f3061fad1c0521037c4c73a5db2912cc5b15ee6a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be2e69d6-3882-4481-be54-a0d9c86a36d6", "node_type": "1", "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c30b64420509b1f2e4acdb3e9f07f02722d33113656efacb42e391ed2907a90a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a35f55b3-475b-4a7e-80cb-da6f3dfb406b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14"}, "hash": "c47a108cf313417f673a48ace93d29f48ac5063def77668e873cfb25903f2bca", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "start_char_idx": 0, "end_char_idx": 1240, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a35f55b3-475b-4a7e-80cb-da6f3dfb406b": {"__data__": {"id_": "a35f55b3-475b-4a7e-80cb-da6f3dfb406b", "embedding": null, "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "426cba76-db19-4101-9255-d4fb1858ebb2", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e330d1230f1c2f155b17b481f3061fad1c0521037c4c73a5db2912cc5b15ee6a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a884a4b-6796-4b8e-a64c-b11fe1233a4c", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d76cd39482fb7776d65889f9841804497a9fe9c9753cb5e4bbb6c1c9eeacc6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6be0ccb8-531f-431d-8187-495bed6f57fd", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n"}, "hash": "3727e54b9ef9ce33c53f2e494ca70d53be9f1597fdf669a354a757f25d595e65", "class_name": "RelatedNodeInfo"}}, "text": "prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "start_char_idx": 1240, "end_char_idx": 1315, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6be0ccb8-531f-431d-8187-495bed6f57fd": {"__data__": {"id_": "6be0ccb8-531f-431d-8187-495bed6f57fd", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5ee18640419f933b156a2d0db78d41c15bea02c408ef220474d1af2f4dbe47b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a35f55b3-475b-4a7e-80cb-da6f3dfb406b", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ad5521facf59cf52ae9f0662bc27ebed168e5fd49c67e52fa2fb4aa0548266e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc9b2ac1-fdf8-4db1-b934-435c14c6a515", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n"}, "hash": "c257759ba38809d3415ada86f9503597ced61babed6beef4022bd3b6872a4cea", "class_name": "RelatedNodeInfo"}}, "text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n", "start_char_idx": 0, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc9b2ac1-fdf8-4db1-b934-435c14c6a515": {"__data__": {"id_": "cc9b2ac1-fdf8-4db1-b934-435c14c6a515", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5ee18640419f933b156a2d0db78d41c15bea02c408ef220474d1af2f4dbe47b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6be0ccb8-531f-431d-8187-495bed6f57fd", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80e8e03d0f9ce1e2e258bf1e9202868e769ab012491cf2a01aa1678b11923652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7c04171-35b3-4f82-a5dc-389219dfc5bb", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n"}, "hash": "600fa9cd748500abdf432ca12ccb34eb39de986e2dbbe1fc76f539d507f41990", "class_name": "RelatedNodeInfo"}}, "text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "start_char_idx": 287, "end_char_idx": 457, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7c04171-35b3-4f82-a5dc-389219dfc5bb": {"__data__": {"id_": "d7c04171-35b3-4f82-a5dc-389219dfc5bb", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5ee18640419f933b156a2d0db78d41c15bea02c408ef220474d1af2f4dbe47b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc9b2ac1-fdf8-4db1-b934-435c14c6a515", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "348015805861d9d8cf237c3fd7fba0b08ccc05a291c61e7cd34483e68490e47d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "521a7226-9b13-46f1-9fab-46b8c881187f", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "a41224658c1f3c11e5bca7e2e27ba113641a9a018ccc0c3051a1f2aab0c96046", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n", "start_char_idx": 457, "end_char_idx": 703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "521a7226-9b13-46f1-9fab-46b8c881187f": {"__data__": {"id_": "521a7226-9b13-46f1-9fab-46b8c881187f", "embedding": null, "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5ee18640419f933b156a2d0db78d41c15bea02c408ef220474d1af2f4dbe47b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7c04171-35b3-4f82-a5dc-389219dfc5bb", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "33005ecde5a7305a90567b75a554d23eeafb5517cc02c62cfa40335eea0665da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e9b4b43-6dec-4c66-abd5-895712cf8136", "node_type": "1", "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15"}, "hash": "60e9e8dc74d120cd4a654564e649e566c5d1016f1472659e60d7b6a874045c59", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 703, "end_char_idx": 880, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e9b4b43-6dec-4c66-abd5-895712cf8136": {"__data__": {"id_": "5e9b4b43-6dec-4c66-abd5-895712cf8136", "embedding": null, "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d5ee18640419f933b156a2d0db78d41c15bea02c408ef220474d1af2f4dbe47b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "521a7226-9b13-46f1-9fab-46b8c881187f", "node_type": "1", "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cd12435e50e0978b974b017e0e2131223b8c465bb2bae6d72d44c44d959c3a2e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3f376b3-078a-4c17-a082-10aaa482a11b", "node_type": "1", "metadata": {"window": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "original_text": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16"}, "hash": "f223e42c018341964b32a6a6013b383b001b626651a4c36ffc1f99188ea02467", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "start_char_idx": 880, "end_char_idx": 1677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3f376b3-078a-4c17-a082-10aaa482a11b": {"__data__": {"id_": "d3f376b3-078a-4c17-a082-10aaa482a11b", "embedding": null, "metadata": {"window": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "original_text": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "page_label": "16", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1f22f2bf-33b7-4b90-b536-cf1e31629f88", "node_type": "4", "metadata": {"page_label": "16", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c2003a8e8ff042af72dfea9132ea103af3c3462820160225149830995a6a4aa5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e9b4b43-6dec-4c66-abd5-895712cf8136", "node_type": "1", "metadata": {"window": "2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "original_text": "AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2020 \u00a0\n\u00a0 \u00a0Gross Pr ofit\u00a0Operating\nExpenses \u00a0Operating\nIncome \u00a0Income\nBefor e\nIncome\nTaxes \u00a0Income T ax\n(Benefit)\nExpense \u00a0Net Income\nAttributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Dilut ed\nEarnings\nPer\nShare \u00a0\nGAAP \u00a0$3,845,037 \u00a0\u00a0\u00a0$2,867,254 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0$849,626 \u00a0\u00a0\u00a0$(595,321 )\u00a0\u00a0$(7,591 )\u00a0\u00a0$1,437,356 \u00a0\u00a0\u00a0$6.95\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(8,546 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(8,546 )\u00a0\u00a0(8,546 )\u00a0\u00a0(2,100 )\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(6,446 )\u00a0\u00a0(0.03 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO expense \u00a043,195 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a043,195 \u00a0\u00a0\u00a010,614 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a032,581 \u00a0\u00a0\u00a00.16 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nPharMEDium\nshutdown\n15", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aed1c5bf1639b8eda798314b4c96e335af9e841031b99244355841f737ec6731", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e469e068-19d6-45b0-a8bf-4a3a260e6e99", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n"}, "hash": "9bcde4f8062615b3893a5861c80550c0b46f818f665115e86fa9604f30930c73", "class_name": "RelatedNodeInfo"}}, "text": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "start_char_idx": 0, "end_char_idx": 1169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e469e068-19d6-45b0-a8bf-4a3a260e6e99": {"__data__": {"id_": "e469e068-19d6-45b0-a8bf-4a3a260e6e99", "embedding": null, "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "421bfa304e63aecb2a47529f77283d915bd642ea4135fe19e1aa32846366549a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3f376b3-078a-4c17-a082-10aaa482a11b", "node_type": "1", "metadata": {"window": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "original_text": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "page_label": "16", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ea7c6e595da48dfbc4f9097a5a370fac601d8ba30b695b0221dfd494c293e549", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b28ba5c4-63c6-4286-9272-003d6f9a126d", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "3caf91e668882814d242897b8dc6ba1cece631184971a37303688e0226dbabf7", "class_name": "RelatedNodeInfo"}}, "text": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n", "start_char_idx": 0, "end_char_idx": 223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b28ba5c4-63c6-4286-9272-003d6f9a126d": {"__data__": {"id_": "b28ba5c4-63c6-4286-9272-003d6f9a126d", "embedding": null, "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "421bfa304e63aecb2a47529f77283d915bd642ea4135fe19e1aa32846366549a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e469e068-19d6-45b0-a8bf-4a3a260e6e99", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e84ea66431d668e4ec89b40642fe9ef7ba09ff6d413abd2e9644f23f4edd92d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f4b2768-b288-4a3e-b77d-0fc08fa33025", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17"}, "hash": "8a391b0edc438a8147c570d4fd6e4c57226f97e0ac1cdcabe4a295165bfad125", "class_name": "RelatedNodeInfo"}}, "text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 223, "end_char_idx": 400, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f4b2768-b288-4a3e-b77d-0fc08fa33025": {"__data__": {"id_": "3f4b2768-b288-4a3e-b77d-0fc08fa33025", "embedding": null, "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041", "node_type": "4", "metadata": {"page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "421bfa304e63aecb2a47529f77283d915bd642ea4135fe19e1aa32846366549a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b28ba5c4-63c6-4286-9272-003d6f9a126d", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7254dda95307ea4b85f60024effee9f5edad1f887a9fd7f43b25ab422dd1fe71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b71840d-7f4c-4773-9eba-8c98a9753df9", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "f586324f8dc08a32ce47e342ac0def967306793d0bd01737622105b39b6fb712", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "start_char_idx": 400, "end_char_idx": 1243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b71840d-7f4c-4773-9eba-8c98a9753df9": {"__data__": {"id_": "5b71840d-7f4c-4773-9eba-8c98a9753df9", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c780a895-f794-4666-8259-cada8c3ff3f5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a627b11dc856a9fd9b5306ef90a1f0fa2ddc70c072328319255ff09edbcbcaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f4b2768-b288-4a3e-b77d-0fc08fa33025", "node_type": "1", "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44d4aaaaed2755a2fe5b3ea6dd12b04b9bbe983063787a03403e8f4e52410c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1d4d66f-0993-4009-9755-d864305b3d74", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "18"}, "hash": "21e1c58ea800d208032f3a47d06d366c5c07cc9db901099072272a8f8dff7f5c", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1d4d66f-0993-4009-9755-d864305b3d74": {"__data__": {"id_": "d1d4d66f-0993-4009-9755-d864305b3d74", "embedding": null, "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c780a895-f794-4666-8259-cada8c3ff3f5", "node_type": "4", "metadata": {"page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a627b11dc856a9fd9b5306ef90a1f0fa2ddc70c072328319255ff09edbcbcaa", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b71840d-7f4c-4773-9eba-8c98a9753df9", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fac23c97885ba5848d9bbd138949d97e3d8d477626e34291d47f67ef47c6b228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1648d99d-e901-4f47-a595-19d87421fd7b", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19"}, "hash": "767d2862d5df06a4555834f7c68d8b468a9973d64aae2aa0c7e0b8b2f97ddcd2", "class_name": "RelatedNodeInfo"}}, "text": "18", "start_char_idx": 438, "end_char_idx": 440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1648d99d-e901-4f47-a595-19d87421fd7b": {"__data__": {"id_": "1648d99d-e901-4f47-a595-19d87421fd7b", "embedding": null, "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d1a231b-11f1-4500-9ed3-84383fc945ed", "node_type": "4", "metadata": {"page_label": "19", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f24d94c374a9e5a7b72dbca185472ff9e3858a0286bec3253c069d5772255ff9", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1d4d66f-0993-4009-9755-d864305b3d74", "node_type": "1", "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "18", "page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2698fca430e26c143ef9e9cf7ffe815596bffc8e90b115e723277b7f440bdd64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "070c2aed-83ea-4ecb-9047-3b74693a2626", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n"}, "hash": "b764b979b5b9d48f383fdb685d8df49ac8cb7c84019a334c9e20d8a678821e38", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "start_char_idx": 0, "end_char_idx": 1167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "070c2aed-83ea-4ecb-9047-3b74693a2626": {"__data__": {"id_": "070c2aed-83ea-4ecb-9047-3b74693a2626", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3484f2-8c0b-4b1d-92a2-d188850dc10d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8419105ab03af08046e0ab11880702ff7d0c4a9511287cdfb700626f6112142e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1648d99d-e901-4f47-a595-19d87421fd7b", "node_type": "1", "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4ef5d4c22cea9305234e21aead5f9a62371d1afdd56a431daead319e80aedfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbc53efc-6495-498a-be3f-b7cfbacb8360", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20"}, "hash": "49a19eda546878fd92109a3d1b1b4946071ff534a1028b32283f6d455eea7220", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "start_char_idx": 0, "end_char_idx": 877, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbc53efc-6495-498a-be3f-b7cfbacb8360": {"__data__": {"id_": "cbc53efc-6495-498a-be3f-b7cfbacb8360", "embedding": null, "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dd3484f2-8c0b-4b1d-92a2-d188850dc10d", "node_type": "4", "metadata": {"page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8419105ab03af08046e0ab11880702ff7d0c4a9511287cdfb700626f6112142e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "070c2aed-83ea-4ecb-9047-3b74693a2626", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa0d38df4b7d402450ac0e137055a3728159d9586992dae923c373a10b1d86b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e1deeb3-c6b7-4d52-a15a-794a00f514d9", "node_type": "1", "metadata": {"window": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "original_text": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21"}, "hash": "a34608db30c1aec93556abc5be2b22d22b04aff875850e6eca5310c623b8a23b", "class_name": "RelatedNodeInfo"}}, "text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "start_char_idx": 877, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e1deeb3-c6b7-4d52-a15a-794a00f514d9": {"__data__": {"id_": "7e1deeb3-c6b7-4d52-a15a-794a00f514d9", "embedding": null, "metadata": {"window": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "original_text": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3dfc97ef-e4e0-4ca9-842c-540aca825314", "node_type": "4", "metadata": {"page_label": "21", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a8e58461897227f3cb6dcd31f43b2407e382be436ec91dd66b8a14b7bef1203", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbc53efc-6495-498a-be3f-b7cfbacb8360", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "94fbb8f907d95aba795bc0a33a647f26ad6be1f6693e312d0e30035dc43eb8e1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51c7f25e-43f6-4deb-a450-be956a0a71e1", "node_type": "1", "metadata": {"window": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "original_text": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22"}, "hash": "cb7151865d657f95220758100e10e4355e0d3d994c52f815e7a3728d850d335f", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "start_char_idx": 0, "end_char_idx": 882, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51c7f25e-43f6-4deb-a450-be956a0a71e1": {"__data__": {"id_": "51c7f25e-43f6-4deb-a450-be956a0a71e1", "embedding": null, "metadata": {"window": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "original_text": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0f7a4cae-8fec-42b4-bd7a-d29f10ee3849", "node_type": "4", "metadata": {"page_label": "22", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6a1acb560cc2feadb83e4b650c1192d94fb278dfe71cda6dab7872ad72ba51e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e1deeb3-c6b7-4d52-a15a-794a00f514d9", "node_type": "1", "metadata": {"window": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "original_text": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddffd4e18d22e16ef503ee3185c018d89a34a7459d677d01c1aa6a228abd6213", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4707c0eb-b7e4-41ea-ba2a-30d86cc62287", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n"}, "hash": "87cfcf2e0cef1776da9e3861940ac8ffbb8029a1d2eccaf7088ecd74e8e32df1", "class_name": "RelatedNodeInfo"}}, "text": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "start_char_idx": 0, "end_char_idx": 1071, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4707c0eb-b7e4-41ea-ba2a-30d86cc62287": {"__data__": {"id_": "4707c0eb-b7e4-41ea-ba2a-30d86cc62287", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3a29bc947bb47972c05ce9231899c179175b7b835aea0fc79b789739f7cb02a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51c7f25e-43f6-4deb-a450-be956a0a71e1", "node_type": "1", "metadata": {"window": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "original_text": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45572e57d087a6386b52503e27bdcb5410ae5230d3aa883fa4676e60081f741c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a39f68e-7898-4978-b840-60071077090e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n"}, "hash": "5eb469ba69d06e4c3170a4a8cbbed10385d04734678fac62228c3edd1cd64ebe", "class_name": "RelatedNodeInfo"}}, "text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n", "start_char_idx": 0, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a39f68e-7898-4978-b840-60071077090e": {"__data__": {"id_": "7a39f68e-7898-4978-b840-60071077090e", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3a29bc947bb47972c05ce9231899c179175b7b835aea0fc79b789739f7cb02a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4707c0eb-b7e4-41ea-ba2a-30d86cc62287", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79017e04d43ba9a7e281285fc35c991b9b38fb50d004bc03cbc07b18a531aa62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3b437de-82fa-44f9-b58d-71755b7c72aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23"}, "hash": "757d4ee08818fae93dcb194f755f11a9502d5746ae5234a220ff44c835f73364", "class_name": "RelatedNodeInfo"}}, "text": "2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "start_char_idx": 1120, "end_char_idx": 1290, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3b437de-82fa-44f9-b58d-71755b7c72aa": {"__data__": {"id_": "d3b437de-82fa-44f9-b58d-71755b7c72aa", "embedding": null, "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3", "node_type": "4", "metadata": {"page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f3a29bc947bb47972c05ce9231899c179175b7b835aea0fc79b789739f7cb02a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a39f68e-7898-4978-b840-60071077090e", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cf3ae3c8e38f19a284c8d5c8b7b3c4132fb7b56a3e502fa64f4619e73eb31c13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36c35b28-cedc-4e26-88cd-76ecddd57d06", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n"}, "hash": "d62a55d5954d14ec127ff5bf0cd9a69f4d5753a80b8cce49571ee7ddd055e483", "class_name": "RelatedNodeInfo"}}, "text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "start_char_idx": 1290, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36c35b28-cedc-4e26-88cd-76ecddd57d06": {"__data__": {"id_": "36c35b28-cedc-4e26-88cd-76ecddd57d06", "embedding": null, "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3b437de-82fa-44f9-b58d-71755b7c72aa", "node_type": "1", "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46876527c2eeb2fa381425d3c99b769a17893dd5de0f099979ef20a2ff3a426a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0b3732d9-f301-45cf-8534-abb0db7c1b18", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. "}, "hash": "7c8ff19f467ec432bed3badff6e07c0c3d2b92ac7af32e77fe7246f0f3af8120", "class_name": "RelatedNodeInfo"}}, "text": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n", "start_char_idx": 0, "end_char_idx": 135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0b3732d9-f301-45cf-8534-abb0db7c1b18": {"__data__": {"id_": "0b3732d9-f301-45cf-8534-abb0db7c1b18", "embedding": null, "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36c35b28-cedc-4e26-88cd-76ecddd57d06", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "20c1d99e8ed9a6a775c778276a3e7afee534ca9f41bfef54bdbd27993b2f1ee7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66803499-28a2-4be4-9a75-6303460a167d", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. "}, "hash": "51fd67094c167f856a0aa01dd13c81958acbf67a919db8b318e334346e6a3224", "class_name": "RelatedNodeInfo"}}, "text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "start_char_idx": 135, "end_char_idx": 273, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66803499-28a2-4be4-9a75-6303460a167d": {"__data__": {"id_": "66803499-28a2-4be4-9a75-6303460a167d", "embedding": null, "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0b3732d9-f301-45cf-8534-abb0db7c1b18", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "original_text": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8cf56cb0eb478edf7253700df12446c218e091a692ed2e087f312d541711cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31bf0499-f754-4e46-b7a6-329f0f9e27a8", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. "}, "hash": "bea59840c6ca226f35279cb506a2ec3c65c0e906026e37c6ed94725ffad2c2c0", "class_name": "RelatedNodeInfo"}}, "text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "start_char_idx": 273, "end_char_idx": 388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31bf0499-f754-4e46-b7a6-329f0f9e27a8": {"__data__": {"id_": "31bf0499-f754-4e46-b7a6-329f0f9e27a8", "embedding": null, "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66803499-28a2-4be4-9a75-6303460a167d", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "original_text": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "719017dbd5bd5fd4190082ed4e3355b88c1176705ee2f9200c981d39edf0fb3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fffefa91-0a17-4e23-ba3a-4715eac1ced3", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n"}, "hash": "d7f41ea6e423d600cac2fbc4858ef319d95447153d4c26be00f5ad76552c02d8", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "start_char_idx": 388, "end_char_idx": 528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fffefa91-0a17-4e23-ba3a-4715eac1ced3": {"__data__": {"id_": "fffefa91-0a17-4e23-ba3a-4715eac1ced3", "embedding": null, "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31bf0499-f754-4e46-b7a6-329f0f9e27a8", "node_type": "1", "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "original_text": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78b0b455696c4270a822cdbe59d7b4643f5273bcc99784dc00860c3cda0b107e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. "}, "hash": "f5cf058a63c32666c5ff1239623854291d270a949959fb2bd63bc3d5ce3b0ac2", "class_name": "RelatedNodeInfo"}}, "text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "start_char_idx": 528, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab": {"__data__": {"id_": "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab", "embedding": null, "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fffefa91-0a17-4e23-ba3a-4715eac1ced3", "node_type": "1", "metadata": {"window": "SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "original_text": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dbd40a4dceaeb383214ad844bc81252fa726c222011b1d48e3d358637523200", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1fdf0dd-064a-4e86-8a1c-b22d206796ad", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. "}, "hash": "4660928a7e69c038d40a93afdb5e004132da8f44a448f0d15eb37e97d274a036", "class_name": "RelatedNodeInfo"}}, "text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "start_char_idx": 647, "end_char_idx": 866, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1fdf0dd-064a-4e86-8a1c-b22d206796ad": {"__data__": {"id_": "d1fdf0dd-064a-4e86-8a1c-b22d206796ad", "embedding": null, "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab", "node_type": "1", "metadata": {"window": "generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "original_text": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9c1dcf36a5a75a0c2c79904fe79245aac5c3c0a8a20d2b6a2faea7d0d65c6ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9afe04f-8167-4299-927c-d323f74b81f8", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. "}, "hash": "a28d89e4453f963a239b04a06896e990c43485f18bbce79d85c9ce2b443b6fb2", "class_name": "RelatedNodeInfo"}}, "text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "start_char_idx": 866, "end_char_idx": 1048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9afe04f-8167-4299-927c-d323f74b81f8": {"__data__": {"id_": "b9afe04f-8167-4299-927c-d323f74b81f8", "embedding": null, "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1fdf0dd-064a-4e86-8a1c-b22d206796ad", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP.  These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "original_text": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ea7fd064b4abf9ac876e210eed03d5e050a760df1da330260d6cdd3fb6568b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60e9fe26-5af6-4409-8648-b9374aa8c30e", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n"}, "hash": "22e007a4045010e12b3d6b9b9c9586169088eee19b7432577ad3d1c2798bf65a", "class_name": "RelatedNodeInfo"}}, "text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "start_char_idx": 1048, "end_char_idx": 1329, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60e9fe26-5af6-4409-8648-b9374aa8c30e": {"__data__": {"id_": "60e9fe26-5af6-4409-8648-b9374aa8c30e", "embedding": null, "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9afe04f-8167-4299-927c-d323f74b81f8", "node_type": "1", "metadata": {"window": "These supplemental measures may vary from, and may\nnot be comparable to, similarly titled measures by other companies.\n The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "original_text": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bf7f200160a1e71103e9f028a30485129820a04f43c069544496110d19748cd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b53d66d1-017c-4a2d-a409-5cde11d712d5", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. "}, "hash": "8c9f6b94cb238454982a42a0d03a5fd408e01adaa3505dedc6f0db4fc23a46de", "class_name": "RelatedNodeInfo"}}, "text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "start_char_idx": 1329, "end_char_idx": 1670, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b53d66d1-017c-4a2d-a409-5cde11d712d5": {"__data__": {"id_": "b53d66d1-017c-4a2d-a409-5cde11d712d5", "embedding": null, "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60e9fe26-5af6-4409-8648-b9374aa8c30e", "node_type": "1", "metadata": {"window": "The non-GAAP financial measures are presented because management uses non-GAAP financial measures to evaluate the\nCompany\u2019s operating performance, to perform financial planning, and to determine incentive compensation.  Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "original_text": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5d2862efef484647c0c3d3b34f57f642261b982152a131fd477fa54bbedfb48f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c293633-80d3-4936-befd-8fcaf47aa9ed", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n"}, "hash": "ea1d8ca9b1bea19bc780aac5f2f9c6478282d0f9d1fc5f4a8d740cb25de6fb68", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "start_char_idx": 1670, "end_char_idx": 1755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c293633-80d3-4936-befd-8fcaf47aa9ed": {"__data__": {"id_": "1c293633-80d3-4936-befd-8fcaf47aa9ed", "embedding": null, "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b53d66d1-017c-4a2d-a409-5cde11d712d5", "node_type": "1", "metadata": {"window": "Therefore, the\nCompany believes that the presentation of non-GAAP financial measures provides useful supplementary information to, and\nfacilitates additional analysis by, investors.  The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "original_text": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbac374c0598812914b28e46bef0b83afdb47ddf0c6a24cda2d25f30b234ca75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b3f3b03-e89f-49ef-954a-7650b4ce3a14", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. "}, "hash": "4ee2f651cc6a83746fdaccee280cd0d09df330f32f71c4371f087ded42b7dd5a", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "start_char_idx": 1755, "end_char_idx": 1912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b3f3b03-e89f-49ef-954a-7650b4ce3a14": {"__data__": {"id_": "6b3f3b03-e89f-49ef-954a-7650b4ce3a14", "embedding": null, "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c293633-80d3-4936-befd-8fcaf47aa9ed", "node_type": "1", "metadata": {"window": "The presented non-GAAP financial measures exclude items that management does not\nbelieve reflect the Company\u2019s core operating performance because such items are outside the control of the Company or are\ninherently unusual, non-operating, unpredictable, non-recurring, or non-cash.  We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "original_text": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c9794e86879398f0082a3074ffd810ed03eb07f4a70ab080632450e50ad22c7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6fafac4-6596-487d-a16c-f3a136557ec0", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. "}, "hash": "ca34a62b35003e4c3cb8164ef3800a274914c9341fbe436931b8b572b9e8a80c", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "start_char_idx": 1912, "end_char_idx": 2079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6fafac4-6596-487d-a16c-f3a136557ec0": {"__data__": {"id_": "f6fafac4-6596-487d-a16c-f3a136557ec0", "embedding": null, "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b3f3b03-e89f-49ef-954a-7650b4ce3a14", "node_type": "1", "metadata": {"window": "We have included the following non-GAAP earnings-\nrelated financial measures in this release:\nAdjusted gross profit and adjusted gross profit margin: Adjusted gross profit is a non-GAAP financial measure that excludes\ngains from antitrust litigation settlements, LIFO expense (credit), and certain PharMEDium shutdown and remediation costs.\n Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "original_text": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5645f80599f7573f60595bb46a084e9b34c90657e3af953e451f54326327eaf9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. "}, "hash": "d9f3a0292e7fc275e38ba6f70b83d32fee2b637a8ed4419f4ff2c3a4cb75ded2", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "start_char_idx": 2079, "end_char_idx": 2163, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4": {"__data__": {"id_": "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4", "embedding": null, "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6fafac4-6596-487d-a16c-f3a136557ec0", "node_type": "1", "metadata": {"window": "Adjusted gross profit margin is the ratio of adjusted gross profit to total revenue.  Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "original_text": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9945bc84ca2978692014934ae9d62a1ed2de1a6a5015db83416f97904e46bfc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68bac126-a580-41c1-9ac8-7b21e7d0bd7c", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. "}, "hash": "66aae53590aecc172814a04d54dc40fcce5cc095e2ba6d4a635f8cd13b89286c", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "start_char_idx": 2163, "end_char_idx": 2247, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68bac126-a580-41c1-9ac8-7b21e7d0bd7c": {"__data__": {"id_": "68bac126-a580-41c1-9ac8-7b21e7d0bd7c", "embedding": null, "metadata": {"window": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4", "node_type": "1", "metadata": {"window": "Management believes that these non-GAAP\nfinancial measures are useful to investors as a supplemental measure of the Company\u2019s ongoing operating performance.\n Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections. ", "original_text": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70da23f7fcc8d4b1463807cc99563a0639b319bece19c38d1b4e2e46f07de0d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "025c4c7f-9ed5-4187-bfef-c3e22b86bf89", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. "}, "hash": "cc15e3ffdc4fc5aff8268ab5e5656f26d65af247d2b8218e331bc947dc38bbbd", "class_name": "RelatedNodeInfo"}}, "text": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "start_char_idx": 2247, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "025c4c7f-9ed5-4187-bfef-c3e22b86bf89": {"__data__": {"id_": "025c4c7f-9ed5-4187-bfef-c3e22b86bf89", "embedding": null, "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68bac126-a580-41c1-9ac8-7b21e7d0bd7c", "node_type": "1", "metadata": {"window": "Gains from antitrust litigation settlements and LIFO expense (credit) are excluded because the Company cannot control the\namounts recognized or timing of these items.  PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "original_text": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dcb5ba03bf54ea700884234aaf0d0c3728871f46e7b3df3042dc9c7cb0a766f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. "}, "hash": "d6d680b3f3869b4ece97e40761be6456410e28489f44942cd85e05083d5ed4b9", "class_name": "RelatedNodeInfo"}}, "text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "start_char_idx": 2543, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b": {"__data__": {"id_": "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "025c4c7f-9ed5-4187-bfef-c3e22b86bf89", "node_type": "1", "metadata": {"window": "PharMEDium remediation costs are excluded because they were unpredictable\nexpenses.  PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "original_text": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ec40a0cae906b3cf8d75f196444374eec317e26f298e9c2cd2dcdbff8792c39", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59704da3-0b55-4c9f-8ed5-a70672a4ca7a", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. "}, "hash": "ac6bc27118151dd19420b223aae7c25160c6ff3f91b79c2ce2dbdccc0385cb7a", "class_name": "RelatedNodeInfo"}}, "text": "Food and Drug Administration inspections. ", "start_char_idx": 2667, "end_char_idx": 2709, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59704da3-0b55-4c9f-8ed5-a70672a4ca7a": {"__data__": {"id_": "59704da3-0b55-4c9f-8ed5-a70672a4ca7a", "embedding": null, "metadata": {"window": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs are excluded because they were unusual and non-recurring.  Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "original_text": "Food and Drug Administration inspections. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a217cf7e351b0fb2259016ca31a2ddc14e22dd558cae0bd91b584a8a68c423ce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ec40243-9deb-4ecb-951c-f691669e00d6", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n"}, "hash": "a3cdef101279a75d955d616a363c7c9ba7423228e9989ae25b98e493964eb8e0", "class_name": "RelatedNodeInfo"}}, "text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "start_char_idx": 2709, "end_char_idx": 2825, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ec40243-9deb-4ecb-951c-f691669e00d6": {"__data__": {"id_": "4ec40243-9deb-4ecb-951c-f691669e00d6", "embedding": null, "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59704da3-0b55-4c9f-8ed5-a70672a4ca7a", "node_type": "1", "metadata": {"window": "Gains from antitrust\nlitigation settlements relate to the settlement of lawsuits that have been filed against brand pharmaceutical manufacturers\nalleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs\nfrom entering the market.  The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "original_text": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4263498c82bf90afc4d1a1a302fdd7f29ab07c5a6ec71a50b6cf8862a09059ef", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50efce9d-4e95-4d06-8839-991b205eed1e", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. "}, "hash": "52882abbdb967e09440e0ad916455cd5a31025488d1379c95ef9c56265c29c3b", "class_name": "RelatedNodeInfo"}}, "text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "start_char_idx": 2825, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50efce9d-4e95-4d06-8839-991b205eed1e": {"__data__": {"id_": "50efce9d-4e95-4d06-8839-991b205eed1e", "embedding": null, "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ec40243-9deb-4ecb-951c-f691669e00d6", "node_type": "1", "metadata": {"window": "The PharMEDium remediation costs relate to costs incurred in connection with suspended\nproduction activities following U.S.  Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "original_text": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "792d2d2b5186c3aef78525ee3b29937ce848cf6eb90e7726710e57bc2d8a8245", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6c53c5b-b148-4c79-8a45-de56b842022f", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. "}, "hash": "8ed5bf7380abd6abacc36a7c9c136eca1e5448bd01995be86abcde3096a9ddb1", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "start_char_idx": 3007, "end_char_idx": 3364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6c53c5b-b148-4c79-8a45-de56b842022f": {"__data__": {"id_": "c6c53c5b-b148-4c79-8a45-de56b842022f", "embedding": null, "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50efce9d-4e95-4d06-8839-991b205eed1e", "node_type": "1", "metadata": {"window": "Food and Drug Administration inspections.  PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "original_text": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f149926ea1e7380b487d8e5cc47b714a28da9ab9588cb2723a139fe4b96209e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fed0e71-6c86-44eb-87f5-6433ca3a68fe", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. "}, "hash": "50103eb273fa30de70ee4f175cdcb9a91648490d43b2027b3539e5f9646cd8bf", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "start_char_idx": 3364, "end_char_idx": 3460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fed0e71-6c86-44eb-87f5-6433ca3a68fe": {"__data__": {"id_": "1fed0e71-6c86-44eb-87f5-6433ca3a68fe", "embedding": null, "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6c53c5b-b148-4c79-8a45-de56b842022f", "node_type": "1", "metadata": {"window": "PharMEDium shutdown costs were costs\nincurred in connection with the permanent shutdown of the PharMEDium business.  LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "original_text": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7ec1d2141fb11542ff0d262482067a7f4f6fde1cd2f7a35e0b8f2baa6f6892e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. "}, "hash": "6fbffaa33aaedefbf2f25fd25ba8d67a497c478a85551620b9f18991afa466a5", "class_name": "RelatedNodeInfo"}}, "text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "start_char_idx": 3460, "end_char_idx": 3622, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea": {"__data__": {"id_": "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea", "embedding": null, "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fed0e71-6c86-44eb-87f5-6433ca3a68fe", "node_type": "1", "metadata": {"window": "LIFO expense (credit) is affected by\nchanges in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and\nother external influences.\n Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "original_text": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1c18fd6305c9fcaa5016ea414291b0fd0716d5a9fd5e9f04796bd0510c656b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed2e65d4-795c-4fc0-a70b-4e0686807ae7", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. "}, "hash": "c98132ebd004ef082fbdc6bea9f75cd3793201d28c3c64a40d155c314e4a4164", "class_name": "RelatedNodeInfo"}}, "text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "start_char_idx": 3622, "end_char_idx": 3734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed2e65d4-795c-4fc0-a70b-4e0686807ae7": {"__data__": {"id_": "ed2e65d4-795c-4fc0-a70b-4e0686807ae7", "embedding": null, "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea", "node_type": "1", "metadata": {"window": "Adjusted operating expenses and adjusted operating expense margin: Adjusted operating expenses is a non-GAAP financial\nmeasure that excludes acquisition-related intangibles amortization, employee severance, litigation, and other, certain\nPharMEDium shutdown and remediation costs, impairment of PharMEDium assets, and a contingent consideration\nadjustment.  Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "original_text": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8022413b149b2826dc562fb4bd52d0f70450acc3848df0bd843777cc9693993e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n"}, "hash": "ccb6e289369ff395f56c56832d33d509062283d5de14716cbcab532ed94a679a", "class_name": "RelatedNodeInfo"}}, "text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "start_char_idx": 3734, "end_char_idx": 4119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f": {"__data__": {"id_": "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f", "embedding": null, "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed2e65d4-795c-4fc0-a70b-4e0686807ae7", "node_type": "1", "metadata": {"window": "Adjusted operating expense margin is the ratio of adjusted operating expenses to total revenue.  Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "original_text": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1e1a12158ea25cc09e8cc1a028020ebdf788068115efe2db87b1fce5c8d35ab6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e66ffe97-16ee-4933-978a-ea7720481782", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. "}, "hash": "695d6915923ef9bf3c64f936652c17c1b43f87b3942e4ff986371d5ecef45b56", "class_name": "RelatedNodeInfo"}}, "text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "start_char_idx": 4119, "end_char_idx": 4413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e66ffe97-16ee-4933-978a-ea7720481782": {"__data__": {"id_": "e66ffe97-16ee-4933-978a-ea7720481782", "embedding": null, "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f", "node_type": "1", "metadata": {"window": "Acquisition-\nrelated intangibles amortization is excluded because it is a non-cash item and does not reflect the operating performance of\nthe acquired companies.  We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "original_text": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "008ae12386d730df0a9f3d71300be134f76cc6212a7e098439fe2406d5de726c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d944e562-2afa-4197-96ad-ac896417dd38", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n"}, "hash": "164c00c398bdf5342448bbed480744e562de7d54404a10786db103305d7bbb1b", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "start_char_idx": 4413, "end_char_idx": 4662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d944e562-2afa-4197-96ad-ac896417dd38": {"__data__": {"id_": "d944e562-2afa-4197-96ad-ac896417dd38", "embedding": null, "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e66ffe97-16ee-4933-978a-ea7720481782", "node_type": "1", "metadata": {"window": "We exclude employee severance amounts that relate to unpredictable and/or non-recurring\nbusiness restructuring.  We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses. ", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c7c58bd191d407417803adfacf6d6077c1654e791ab4d6a1a439ff320a3794be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4834dd80-ae60-47af-8f81-15f9580b1a68", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n"}, "hash": "65c6f2d8ecacb405e6a41d7838ceb7a623b41cfd9dd8690c7a302cec86b94ea4", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "start_char_idx": 4662, "end_char_idx": 4755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4834dd80-ae60-47af-8f81-15f9580b1a68": {"__data__": {"id_": "4834dd80-ae60-47af-8f81-15f9580b1a68", "embedding": null, "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d944e562-2afa-4197-96ad-ac896417dd38", "node_type": "1", "metadata": {"window": "We exclude the amount of litigation settlements and other expenses, as well as PharMEDium\nshutdown and remediation costs, a contingent consideration adjustment and the impairment of PharMEDium assets, that are\nunusual, non-operating, unpredictable, non-recurring or non-cash in nature because we believe these exclusions facilitate the\nanalysis of our ongoing operational performance.  The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1c53edfc2eff7835f5db3f995bdb6625657eb696a91dc96c2582e89ae76bda4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af5aaf3a-b375-4561-bad1-24e4b4550e26", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24"}, "hash": "c01ee2d85c16dfca8c2ba0b45e188f6d157941595eba71cef75b6ef5ecc27d68", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "start_char_idx": 4755, "end_char_idx": 5002, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af5aaf3a-b375-4561-bad1-24e4b4550e26": {"__data__": {"id_": "af5aaf3a-b375-4561-bad1-24e4b4550e26", "embedding": null, "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c", "node_type": "4", "metadata": {"page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a269d7d93f7065e83ec16d1cae593e0a90586dd7c028322cf53100702d1deb8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4834dd80-ae60-47af-8f81-15f9580b1a68", "node_type": "1", "metadata": {"window": "The contingent consideration adjustment reflects an adjustment made by\none of the Company\u2019s non-wholly-owned subsidiaries, Profarma Distribuidora de Produtos Farmac\u00eauticos S.A., of its previous\nestimate of contingent consideration related to the purchase price of a prior business acquisition.\n Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "44eb1d85df20e1e54f590331fa693f9b7c2df69d841a399b2c9da3ca78438311", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbc99c99-570d-465d-b7d7-70dbf6450a33", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "the same items that are described above and excluded from adjusted operating income. "}, "hash": "657943eec2772392d3cb2865e1796e5f737f3249067f2e40074e74e859e534cb", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "start_char_idx": 5002, "end_char_idx": 5124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbc99c99-570d-465d-b7d7-70dbf6450a33": {"__data__": {"id_": "cbc99c99-570d-465d-b7d7-70dbf6450a33", "embedding": null, "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "the same items that are described above and excluded from adjusted operating income. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af5aaf3a-b375-4561-bad1-24e4b4550e26", "node_type": "1", "metadata": {"window": "Adjusted operating income and adjusted operating income margin: Adjusted operating income is a non-GAAP financial\nmeasure that excludes the same items that are described above and excluded from adjusted gross profit and adjusted\noperating expenses.  Adjusted operating income margin is the ratio of adjusted operating income to total revenue.\n Management believes that these non-GAAP financial measures are useful to investors as a supplemental way to evaluate the\nCompany\u2019s performance because the adjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in\nnature.\n Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "original_text": "Adjusted income before income taxes : Adjusted income before income taxes is a non-GAAP financial measure that excludes\n24", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "647bbc6809a24a8562ebcda19584f0485b6b1fb460d720434ad79fbd4bf4a81b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "acf44f2b-f418-4c4f-b056-181d17c79557", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. "}, "hash": "a299ea5435b0ee7a3279d254f1913ccbcbdf3f93d400cccc99b17a2fa350e900", "class_name": "RelatedNodeInfo"}}, "text": "the same items that are described above and excluded from adjusted operating income. ", "start_char_idx": 0, "end_char_idx": 85, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "acf44f2b-f418-4c4f-b056-181d17c79557": {"__data__": {"id_": "acf44f2b-f418-4c4f-b056-181d17c79557", "embedding": null, "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbc99c99-570d-465d-b7d7-70dbf6450a33", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "the same items that are described above and excluded from adjusted operating income. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "de2b8d62f6baed7de1edd375a7864f9652449367a8034a84933acb0016043212", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "024c427c-51fa-4cba-a964-803d03a1a732", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n"}, "hash": "d462a774473acfdeeaa84b1cd57a2cd4d03c12a4b547393de4981a7d56654b0f", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "start_char_idx": 85, "end_char_idx": 458, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "024c427c-51fa-4cba-a964-803d03a1a732": {"__data__": {"id_": "024c427c-51fa-4cba-a964-803d03a1a732", "embedding": null, "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "acf44f2b-f418-4c4f-b056-181d17c79557", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "original_text": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fdbe8e8fd69afad47213dda722338941d149340459dd98a043382b04764888b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2acc911-677f-4cec-98e1-f07eb5416e38", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. "}, "hash": "886b23ad4a82b7c2f9e00daddcc6c99bb12a4699529464b2779812b426346d91", "class_name": "RelatedNodeInfo"}}, "text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "start_char_idx": 458, "end_char_idx": 623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2acc911-677f-4cec-98e1-f07eb5416e38": {"__data__": {"id_": "a2acc911-677f-4cec-98e1-f07eb5416e38", "embedding": null, "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "024c427c-51fa-4cba-a964-803d03a1a732", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "original_text": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21341b3989cfd5ebe8b192ebf8833a43f1d54c091a614b2a8a3f2239e971e924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1f7a156-f25a-40c8-a348-ae89c28958b2", "node_type": "1", "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n"}, "hash": "bbd1f07b356c17b52f3c4c78674c42d10b4ea8028175fab9dba41ebd0eb7f299", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "start_char_idx": 623, "end_char_idx": 820, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1f7a156-f25a-40c8-a348-ae89c28958b2": {"__data__": {"id_": "b1f7a156-f25a-40c8-a348-ae89c28958b2", "embedding": null, "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2acc911-677f-4cec-98e1-f07eb5416e38", "node_type": "1", "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "original_text": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e586d5679b8370d22f36f4be4230377224efcaa6b1136479f19bc75076e2e868", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bfbdcdb-3821-4c17-ab51-5792f77fbd87", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n"}, "hash": "f3eb98b97d1fe7afa8a3f7e4a7a448485c5a6acf988f231477767c57104f258e", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "start_char_idx": 820, "end_char_idx": 1092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bfbdcdb-3821-4c17-ab51-5792f77fbd87": {"__data__": {"id_": "3bfbdcdb-3821-4c17-ab51-5792f77fbd87", "embedding": null, "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1f7a156-f25a-40c8-a348-ae89c28958b2", "node_type": "1", "metadata": {"window": "In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "original_text": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bfbf1b37b60100914d6b92ce138bada528da3069a10120a93f8e9b008d07f6f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9777dfaa-03e7-4034-8481-d406b9413329", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. "}, "hash": "b2d28a7c11fbb395ea3c65589b82cff65fcf54810bf5cddc139ac478d91231e8", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "start_char_idx": 1092, "end_char_idx": 1330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9777dfaa-03e7-4034-8481-d406b9413329": {"__data__": {"id_": "9777dfaa-03e7-4034-8481-d406b9413329", "embedding": null, "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bfbdcdb-3821-4c17-ab51-5792f77fbd87", "node_type": "1", "metadata": {"window": "Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "98b69d6891f896213f5a1ab4df54f709dfb164353c85188269f9b5c9298f0fde", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0b058c0-c3b8-4dcf-a108-f755e86c1076", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. "}, "hash": "f307774a30c6e07b4eb0d68f42f73588707389f3e54eaadd456780198e1fc6bb", "class_name": "RelatedNodeInfo"}}, "text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "start_char_idx": 1330, "end_char_idx": 1703, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0b058c0-c3b8-4dcf-a108-f755e86c1076": {"__data__": {"id_": "a0b058c0-c3b8-4dcf-a108-f755e86c1076", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9777dfaa-03e7-4034-8481-d406b9413329", "node_type": "1", "metadata": {"window": "Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes.  Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "original_text": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4809124c5749f1178b920b1a90d1e9507067b4743f5102c5f9802d473d0b185a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "e5e9e3c94f40d725e9881ac3735f3ecea812469912fc1a2d9388e112b8a3e5ec", "class_name": "RelatedNodeInfo"}}, "text": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "start_char_idx": 1703, "end_char_idx": 1887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c": {"__data__": {"id_": "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c", "embedding": null, "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0b058c0-c3b8-4dcf-a108-f755e86c1076", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial\nmeasure is useful to investors because it presents an effective tax rate that does not reflect unusual, non-operating,\nunpredictable, non-recurring, or non-cash amounts or items that are outside the control of the Company.\n Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "original_text": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a71bb7814fcff9b6f8a9fe4035b8538571e7f2db5935bf033c88fe57a640e23c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23eaf8f6-3034-4df1-b50f-222f4667e5fb", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. "}, "hash": "06a8a02be7e6a0fd27159412964b5be8fa18a6a7369bdc320519dd8922eac2d1", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 1887, "end_char_idx": 2131, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23eaf8f6-3034-4df1-b50f-222f4667e5fb": {"__data__": {"id_": "23eaf8f6-3034-4df1-b50f-222f4667e5fb", "embedding": null, "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c", "node_type": "1", "metadata": {"window": "Adjusted income tax expense : Adjusted income tax expense is a non-GAAP financial measure that excludes the income tax\nexpense associated with the same items that are described above and excluded from adjusted income before income taxes.\n Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "original_text": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec238cd05fd680996a2591c82821f77ae7dfadec3369a0fdc8e332a31c16578e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6db908e-3e45-416b-b5f1-7c69833f8115", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n"}, "hash": "edfd92fcf9eece6d08383f810c547f72c65844ecd3b96a161abc47a6c5a4054f", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "start_char_idx": 2131, "end_char_idx": 2401, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6db908e-3e45-416b-b5f1-7c69833f8115": {"__data__": {"id_": "c6db908e-3e45-416b-b5f1-7c69833f8115", "embedding": null, "metadata": {"window": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23eaf8f6-3034-4df1-b50f-222f4667e5fb", "node_type": "1", "metadata": {"window": "Certain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the Coronavirus Aid, Relief and Economic Security Act (the \"CARES Act\") are also\nexcluded from adjusted income tax expense for the three and nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021.  Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "original_text": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c6cc45b0fae01ca851b410e41c198204991e6d796aa7df7fc49976430df738f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a11e34df-566e-457e-aa06-20f59133dfb2", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. "}, "hash": "0f09971b6eb877004f953b1a38620f210a5a962b6d72a2f445d71ec712da1bfd", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "start_char_idx": 2401, "end_char_idx": 2564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a11e34df-566e-457e-aa06-20f59133dfb2": {"__data__": {"id_": "a11e34df-566e-457e-aa06-20f59133dfb2", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6db908e-3e45-416b-b5f1-7c69833f8115", "node_type": "1", "metadata": {"window": "Further, certain expenses relating to tax reform in the United Kingdom and Switzerland are excluded from\nadjusted income tax expense for the three and nine months ended June 30, 2021.  Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "original_text": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ef3bf06f30a0f5446cb0621c7ac61949aae1535cfdc63040aa68f7050ebf04d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e02659c-4951-446a-9111-3a0d23acec4b", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n"}, "hash": "6d44afd1bf0e4cdc81234c5e5c094a05cf091581a2c9ff2b72631d75468857e0", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "start_char_idx": 2564, "end_char_idx": 2733, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e02659c-4951-446a-9111-3a0d23acec4b": {"__data__": {"id_": "6e02659c-4951-446a-9111-3a0d23acec4b", "embedding": null, "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a11e34df-566e-457e-aa06-20f59133dfb2", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP\nfinancial measure is useful to investors as a supplemental way to evaluate the Company\u2019s performance because the\nadjustments are unusual, non-operating, unpredictable, non-recurring or non-cash in nature.\n Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "original_text": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e831a1e95fcb10ac688481349e37401029b00829abefd6eb294f1791cd63595", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. "}, "hash": "8fb27c6f23ed136c3c90c7647be3c260e37cc9ce5daaacf05fd34b7ce7645440", "class_name": "RelatedNodeInfo"}}, "text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "start_char_idx": 2733, "end_char_idx": 2978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5": {"__data__": {"id_": "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e02659c-4951-446a-9111-3a0d23acec4b", "node_type": "1", "metadata": {"window": "Adjusted net income/loss attributable to noncontrolling interests: Adjusted net income/loss attributable to noncontrolling\ninterests excludes the non-controlling interest portion of acquisition-related intangibles amortization and a contingent\nconsideration adjustment.  Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "original_text": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3877335cffeb6b03c7641439e6dac6bae9ef78ed158ab696e5ef9eadf363eda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d1370b6-5da8-4e89-8826-5e04c5bc7a48", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. "}, "hash": "d08ed0edd28998967286568fc0db798e4d172f96765ba5c57b19986689dc7c16", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "start_char_idx": 2978, "end_char_idx": 3553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d1370b6-5da8-4e89-8826-5e04c5bc7a48": {"__data__": {"id_": "7d1370b6-5da8-4e89-8826-5e04c5bc7a48", "embedding": null, "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to investors because it\nfacilitates the calculation of adjusted net income attributable to ABC.\n Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "original_text": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5687098133280da8b8d40c4446b46789f441941675e360f8df6dd85900e876b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ddaee0c8-d92a-458b-9b06-bf82ca3a374f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n"}, "hash": "4eaa10f462c6532d085bbe0024c3fe98ef619c05c78985e93d740d85b48f73c1", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "start_char_idx": 3553, "end_char_idx": 4060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ddaee0c8-d92a-458b-9b06-bf82ca3a374f": {"__data__": {"id_": "ddaee0c8-d92a-458b-9b06-bf82ca3a374f", "embedding": null, "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d1370b6-5da8-4e89-8826-5e04c5bc7a48", "node_type": "1", "metadata": {"window": "Adjusted net income attributable to ABC:  Adjusted net income attributable to ABC is a non-GAAP financial measure that\nexcludes the same items that are described above.  Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "original_text": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a815beeb057fde9ceb42b987d3b30c0a83ffefdca7e594347cd20ea0616bb05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "891bccfb-099d-49e3-a581-c0df87b2c5a0", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. "}, "hash": "1a902342c0c148c925dc8a42ba35b2826fe7b1c4ce212922670b22e779724890", "class_name": "RelatedNodeInfo"}}, "text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "start_char_idx": 4060, "end_char_idx": 4414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "891bccfb-099d-49e3-a581-c0df87b2c5a0": {"__data__": {"id_": "891bccfb-099d-49e3-a581-c0df87b2c5a0", "embedding": null, "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ddaee0c8-d92a-458b-9b06-bf82ca3a374f", "node_type": "1", "metadata": {"window": "Management believes that this non-GAAP financial measure is useful to\ninvestors as a supplemental way to evaluate the Company's performance because the adjustments are unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.\n Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "original_text": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b213e712161aaf0a1fe642a0c46fb8847d5e894cbc9e656730fee54dd8263671", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ef4e695-8cd3-46cf-a507-65abb6970e85", "node_type": "1", "metadata": {"window": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. "}, "hash": "800d0538e2ef3fe6099daae117685bfe4e292de79c412849a88777f324dfff74", "class_name": "RelatedNodeInfo"}}, "text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "start_char_idx": 4414, "end_char_idx": 4677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ef4e695-8cd3-46cf-a507-65abb6970e85": {"__data__": {"id_": "5ef4e695-8cd3-46cf-a507-65abb6970e85", "embedding": null, "metadata": {"window": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "891bccfb-099d-49e3-a581-c0df87b2c5a0", "node_type": "1", "metadata": {"window": "Adjusted diluted earnings per share: Adjusted diluted earnings per share excludes the per share impact of adjustments\nincluding gains from antitrust litigation settlements; LIFO expense (credit); PharMEDium shutdown and remediation costs;\nacquisition-related intangibles amortization; employee severance, litigation, and other; impairment of PharMEDium assets;\nthe loss on the currency remeasurement related to Swiss tax reform; and a contingent consideration adjustment, in each case\nnet of the tax effect calculated using the applicable effective tax rate for those items.  In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "original_text": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c480b0ad503afc21abaabdd373990736e235da3b77950f0a71b4bd0ba404c1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc0a49e3-51d6-4c70-b8a9-44164bb35d23", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. "}, "hash": "a52c9c52a8b6c34ba68aab001b3b4b10a0c3f946950f791c81d2f53189450c1d", "class_name": "RelatedNodeInfo"}}, "text": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "start_char_idx": 4677, "end_char_idx": 4982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc0a49e3-51d6-4c70-b8a9-44164bb35d23": {"__data__": {"id_": "cc0a49e3-51d6-4c70-b8a9-44164bb35d23", "embedding": null, "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ef4e695-8cd3-46cf-a507-65abb6970e85", "node_type": "1", "metadata": {"window": "In addition, the per share impact of\ncertain discrete tax benefits primarily attributable to the income tax deduction recognized in connection with the permanent\nshutdown of PharMEDium as well as the CARES Act for the nine months ended June 30, 2020 and the nine months ended\nJune 30, 2021, and the per share impact of certain expenses relating to tax reform in the United Kingdom and Switzerland are\nalso excluded from adjusted diluted earnings per share for the three and nine months ended June 30, 2021.  Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "original_text": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "009a9dec056ff5451f665756ffb72f2d909a35a7f11b99bea329b6ee8f5ec641", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2969592d-eeb4-4f21-b2b0-feefb08e5b7b", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. "}, "hash": "6702353d2746161ae489f6a3113ce148095c6b682cf876b4e9bfb27cf6921818", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "start_char_idx": 4982, "end_char_idx": 5269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2969592d-eeb4-4f21-b2b0-feefb08e5b7b": {"__data__": {"id_": "2969592d-eeb4-4f21-b2b0-feefb08e5b7b", "embedding": null, "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc0a49e3-51d6-4c70-b8a9-44164bb35d23", "node_type": "1", "metadata": {"window": "Management\nbelieves that this non-GAAP financial measure is useful to investors because it eliminates the per share impact of the items\nthat are outside the control of the Company or that we consider to not be indicative of our ongoing operating performance\ndue to their inherent unusual, non-operating, unpredictable, non-recurring, or non-cash nature.\n In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9dc74b514696715e9d8d391941d6eca83865c4705e31807b18e9fbe55755badc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fef3fa9-100a-47b5-9b12-2071062ac984", "node_type": "1", "metadata": {"window": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. "}, "hash": "0399bdd398e4688808194d672d6be03cdec669b0aee486760c3accd3cd3f2fe4", "class_name": "RelatedNodeInfo"}}, "text": "For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "start_char_idx": 5269, "end_char_idx": 5544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fef3fa9-100a-47b5-9b12-2071062ac984": {"__data__": {"id_": "2fef3fa9-100a-47b5-9b12-2071062ac984", "embedding": null, "metadata": {"window": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2969592d-eeb4-4f21-b2b0-feefb08e5b7b", "node_type": "1", "metadata": {"window": "In addition, the Company updated its non-GAAP fiscal year 2021 guidance for diluted earnings per share, operating expense,\noperating income and adjusted free cash flow, and has previously provided non-GAAP fiscal year 2021 guidance for effective\nincome tax rate.  The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc3cf3a3e98d48730f0784e107ccfabf68f77420fc6e27b68bcc52f5df2dba10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2384ec3f-0df3-459d-8c7c-67338b621162", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For example, LIFO expense (credit) is largely\n25"}, "hash": "761ff3e6caf2332fda5f511e73c3f1f6dcfe4c8261dfea0d7f797b604b2feefd", "class_name": "RelatedNodeInfo"}}, "text": "The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "start_char_idx": 5544, "end_char_idx": 5780, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2384ec3f-0df3-459d-8c7c-67338b621162": {"__data__": {"id_": "2384ec3f-0df3-459d-8c7c-67338b621162", "embedding": null, "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For example, LIFO expense (credit) is largely\n25", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67", "node_type": "4", "metadata": {"page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43574a271153994b1749e37b53c17f6e09bf98c30aae84f281063b2af6b1d953", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fef3fa9-100a-47b5-9b12-2071062ac984", "node_type": "1", "metadata": {"window": "The guidance for each metric excludes the same or similar items as those that are excluded from the historical non-\nGAAP financial measures, as well as significant items that are outside the control of the Company or inherently unusual, non-\noperating, unpredictable, non-recurring or non-cash in nature.  For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dfd367b367f69ed73a24a7dd287dbd4a37e4ff6b94004b0621f5082b0c4a7572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3", "node_type": "1", "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated. "}, "hash": "b2bdb6a1d0dd4c423c2606a7d1d5440893212b43559dd8720f5fefac5e0203d3", "class_name": "RelatedNodeInfo"}}, "text": "For example, LIFO expense (credit) is largely\n25", "start_char_idx": 5780, "end_char_idx": 5828, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3": {"__data__": {"id_": "da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3", "embedding": null, "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated. ", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f80cf58ba6354b982c5c339e925af81b6731f4fdfbacda4a4b44b9d9b7d499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2384ec3f-0df3-459d-8c7c-67338b621162", "node_type": "1", "metadata": {"window": "For fiscal year 2021, we have defined the non-GAAP financial\nmeasure of adjusted free cash flow as net cash provided by operating activities, excluding other significant unpredictable or non-\nrecurring cash payments or receipts relating to legal settlements, minus capital expenditures.  For the nine months ended June 30,\n2021 adjusted free cash flow of $1,235.9 million consisted of net cash provided by operating activities of $1,656.8 million minus\ncapital expenditures of $273.4 million and the gains from antitrust litigation settlements of $147.4 million.  The Company does not\nprovide forward looking guidance on a GAAP basis for such metrics because certain financial information, the probable significance\nof which cannot be determined, is not available and cannot be reasonably estimated.  For example, LIFO expense (credit) is largely\n25", "original_text": "For example, LIFO expense (credit) is largely\n25", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23b7e06ceaa2e8bc313465b7c98d89e779f79ba888b6801d6b2d4b7deb0485cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df", "node_type": "1", "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n"}, "hash": "45280da01e9fc78f08f762c77dbf5610bf7e5ddc9e1a01b9abc2fd91ca2f0829", "class_name": "RelatedNodeInfo"}}, "text": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated. ", "start_char_idx": 0, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df": {"__data__": {"id_": "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df", "embedding": null, "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f80cf58ba6354b982c5c339e925af81b6731f4fdfbacda4a4b44b9d9b7d499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3", "node_type": "1", "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated. ", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6908623a7f544d33ae311c7193c956c344d9a6e69503ad19258da8a7e44e8f25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbdc7274-69bc-46db-bba3-37b9ccb298cd", "node_type": "1", "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26"}, "hash": "4478f3a58824b1808b81d9d3661fa79ff3681bdf0a11eab9afd80f56b565f516", "class_name": "RelatedNodeInfo"}}, "text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "start_char_idx": 270, "end_char_idx": 365, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbdc7274-69bc-46db-bba3-37b9ccb298cd": {"__data__": {"id_": "cbdc7274-69bc-46db-bba3-37b9ccb298cd", "embedding": null, "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a", "node_type": "4", "metadata": {"page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42f80cf58ba6354b982c5c339e925af81b6731f4fdfbacda4a4b44b9d9b7d499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df", "node_type": "1", "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30b69baabb3b134a08d8428495439f5f59499f6f2981e3abb21da7d970a15734", "class_name": "RelatedNodeInfo"}}, "text": "View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "start_char_idx": 365, "end_char_idx": 614, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"9fe0fe7f-eabb-4cd7-8b9d-05d8aee52bd1": {"doc_hash": "9980b1930f5c514239a0d8a3a040ce4dd720066c0026420edb07d4d37faa03b2", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "9f19edc3-78bd-4060-b083-6d0421f272b0": {"doc_hash": "17300085cccb29a7f30349a3efe35ec868164866bd8f949a2360235193e3f838", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "86206a4c-9249-496c-a68f-057d20eb3cae": {"doc_hash": "7663bcc2207cc58194879399e77db21471bf318a7113e3f2f489a6d2a900e17b", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "d7310391-fadf-4911-822c-44ad0d3f2b2e": {"doc_hash": "b68b44eebe5075c5a7ef8537e741e21c04929e4c0cc15eaaf4c0395ace747b39", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "8e8526d6-be8e-485d-956e-f3c08e0dbccb": {"doc_hash": "951512d05f75672656a39ed9ba0d8ffba3dc641b2e75698edc176b8851e019a0", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "dc3002e3-b2a8-413b-bb08-1ae8412447ed": {"doc_hash": "1381909fbb2d66c706ddb8cc2c08777549839b1f817a862ce8207e0a3c9a3dba", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "9e7cd1ad-7035-4d60-99d3-4ba7d6905783": {"doc_hash": "3daaa469b1277059ec466dcc7b48ae3fa0594ca9c95413b74be77c9102ec55a6", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "4ad34148-97db-4a90-930f-b939088580a7": {"doc_hash": "d3b05efd7689cc2b6f7d27497d123293873247f0c1782f401fb6a31de3ed7106", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "aaa6ba74-7051-4cd0-a331-f655b65f9305": {"doc_hash": "58090854145de67e537007c9fce86aa732c180d7725b0c8e724289251965c3e0", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3": {"doc_hash": "de8bfab214670d1f00d591cc6d6304de0cea119b5bc633f2f5a7704dedfbd01c", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "551a1d30-2603-4420-9f57-65b20c4c4495": {"doc_hash": "ac5f26894659748dd0f79fd8fe5bb18242b31c1db25a350836bf755a0f35a3a6", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "ff643fb8-bb2a-4238-9a28-dd91d0155cc4": {"doc_hash": "80cc1fdaba267e3b0c0c93801af0585e769ceff5a73a683874855a9988309c7d", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "0139868c-d1b6-4659-844e-111de542b94c": {"doc_hash": "4b60266eb2027ff66a1b2a3e77d98600d851a33b8ce58618351dff65c53512cf", "ref_doc_id": "e56e4208-9f6b-406a-b7a7-a67ba6605aae"}, "c5f7487c-b63e-4090-a96d-74fb12a20122": {"doc_hash": "c929f95a0e8e8114e39d72950369d07a2a72faf7583304e81603d804ea26fdcd", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "7a3b634a-a999-43e5-9c81-797b25bd8c60": {"doc_hash": "4c96519a45e869f4a41a05c61c214ac4ba8cc5e59277e2f6cbef130e8dc06b49", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "85faab7a-2559-43f1-8102-97614f834458": {"doc_hash": "639846699befe8e702d0abb9b56045985b3f8155acdf2532a63e7cfeb620c878", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "d3c20500-a9a9-4072-bacc-768c963048f6": {"doc_hash": "a2a4929964cc3d9efd1ec6d8c4be55c92c08b7c8a319b0e73f1e329971283480", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "c2e93779-4977-4c64-9347-7d24c70bdf54": {"doc_hash": "a19fc7a8e457ecdd884d887338a42b8e2570362d89da20b80f485f05d396ca40", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "f7030fe7-1f1f-4a4d-993f-d03045062c93": {"doc_hash": "bb307beae84b1b4e52eb5459ca74bea64c5036919dc6f1961fd5e97e3872263d", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "514e0001-f72e-410c-8a84-6915524d8bd0": {"doc_hash": "ced11b5bbb4dcf20b585945b965a8cf6773304df98121ea466ca1542d5c45461", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "316d2dd3-e6f9-4249-8bd0-02b09f8a6650": {"doc_hash": "4419940bfd365883f01b5dbf969de7a599b0ea4159c975cb5779da2d5eb94674", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "13947e16-3f92-4418-ac00-24e61c66190a": {"doc_hash": "e0e88ee21aa6f0b5b47d5770042e0d8a0175bec3a41ed3395962dfe2e8f550ee", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "1c260ad0-9f08-4d28-8869-8f0ed8538a01": {"doc_hash": "9ce46196b3ff216520c083f854be12703894d6f2249370fd3e4b53180804e0d9", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "c410088b-f0df-46c1-b82b-548d821e5b85": {"doc_hash": "ac0a766bcdf237a1a46df756bc8b720a5f87e1bcbd1d8a628ea34c3550ea8c3f", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "78087d40-938e-4da0-9bf3-7bc66069f434": {"doc_hash": "202bf679649b8bcc70eccbc3bb9cdb856e00f654a5f090fba3e8d54d9c75c6a5", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "7b73b946-0c6d-4420-9809-531de5d60a28": {"doc_hash": "9d74aaa05144940c6b769f5af59309778112c1aede607a9181c620f4330bf95e", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c": {"doc_hash": "aa22fb175274c0422c83af51c28adc2622c952c30d54da683da4af445ac4a951", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "1c846acd-3fff-4317-ae6a-1f8ed8970998": {"doc_hash": "a7855e4177ccfacfab0e42d2e3f1c6b27d67885eb497c37b51bb2bfa9192abb6", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "639ec7ed-917e-45ef-9e1a-9d42b41a8b64": {"doc_hash": "aef55112c39fe975ab3baaf775d76c685979549ef379682279f0fc9c26b0899d", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "8a7d36bc-24a5-4269-a4d2-a277c7a99357": {"doc_hash": "ef6736f7459395dc00456c14879958b3ee3d849a9b5b999fa86200e5b9c3ca75", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "af65e123-f5ae-4883-9494-dacd8d927cd1": {"doc_hash": "98fbf80a739c4af25d8ed7e9edb691e29362521ffddfda779c94496d34312a41", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "f10c2628-e07c-46a1-bf04-ec088088aca7": {"doc_hash": "cafc74d1598f391f7eb2a37693c32bdf4dcdbb3dfcdfd6effde3f515ed82d8b7", "ref_doc_id": "09171313-4b13-48bb-9d5b-29c9710fa0be"}, "128b0472-8710-467f-95d8-e4ef4dfe131e": {"doc_hash": "cb96719b5f55fec47b8a90aeeeb3c6eff67865f2ae72fcfcc187296a0ad48d1a", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "a12841f1-6f65-49df-ba17-79b79f7c2052": {"doc_hash": "00158ee50cec97861c3ac91ce724137a2b9f758d385bbaaf5b4ae80a4ddb6566", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9": {"doc_hash": "727d44267656c6fa83b5687f2187475084bce64058d3dd4f9bf8fcfd15c0c0fd", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "c599e1c4-b7c8-498f-8242-550494ad53cd": {"doc_hash": "a2f5da5ae5e604588083ac93428de34c41c54482099a56a202d2a06101e092fd", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "6e652466-8a21-446d-b4af-6429e203e9af": {"doc_hash": "1f44f4e58f6fe79f6133fe1ab393919ebfc01952e0a544fd4db6936364913cda", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "7c062dfb-dc89-41f2-a5c0-a46be6d28acd": {"doc_hash": "a1d9a903a95b1917a35a7dbe57d5ae0a83437f177df7bed1e5a2b080d1f15011", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a": {"doc_hash": "b01474214cd0dd3b43abbb5b802ce228899e19800c5cd7badf517d924b28006a", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2": {"doc_hash": "37489d22d494319adec296a18d3e8c5458e4ff255a963903bb6097a155e21232", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "d33c8f13-f5f2-45a5-988d-456703b26f7d": {"doc_hash": "d55876727a8070faa5fc4e7b04f11a7e1cc785e6e8b2b2e16a00ebb40d67172e", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "87036aad-6ff2-44d3-a023-40589f58e4a3": {"doc_hash": "4945e3ec3f036aa6d0366e3134b435d6a37b6fa004620366bcfcdb83a3a12496", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "ee62b8c6-e3a9-4776-baff-f53fc71f1a04": {"doc_hash": "af4ff24074396fdb952fab049ed1d2337b0bee535a8dc3ae4ebb8a31a309e8b8", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "43f3fbd6-b089-4af8-9176-c9b13e2022e8": {"doc_hash": "20775c3cda4dc8add2a377d4dcd20b040bb7081ef4b4af75023e0788af70d7d8", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "0ebc3a1c-00f2-4afb-90ee-42b87299409c": {"doc_hash": "d90067de52d012cdecb5dc1a9ea0b537d03723091f83787367696dd5abe1b91f", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "ce11fdd8-d125-4428-bd77-de5ac414e1e6": {"doc_hash": "d0eff07ad22b9e882a83490a4f03f0c8d0d4355f94c7dc0d4a6c165ed9369802", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "73ad3fa7-adbb-4894-9aea-5d23bd02a7da": {"doc_hash": "ecb4ab41fde05f3b0f3fdb3a601ac2c0ab868e85418039131f059f0d4bca6d6a", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "a55f9745-0850-4d8f-bc71-b4cc8a85e552": {"doc_hash": "721bab1f1b68db82302d0a0838cbaf438ad218fec63595ee12ad92d57f93c830", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "ca9babee-8aeb-472f-953b-7a44b03cbd28": {"doc_hash": "daad4b95069911acd1d3445200ab7258fb57b982610c0dbcc8f2d33db40d3f6a", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "56338974-c21b-43bd-8b88-b54a4846df2d": {"doc_hash": "2cd32a1d38b1329f4e586fd53e000b3024081798b140015200171dec26d02cf5", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "dfd924ba-fedd-4a32-bd33-92a3feaf897a": {"doc_hash": "27e08299ac9600e3374553dc455f9808577f24cffd97a6d2835f3d41fc9b0216", "ref_doc_id": "ed807259-1b19-4feb-a664-384450cebb90"}, "1a5de5de-c080-448b-86ba-7618e50ab122": {"doc_hash": "712eddf8b42d41c25d3283b453e5f7b00017b208b687e27532adc59a2eefd7e4", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "71357bbb-c077-4ced-b88c-b783967484ec": {"doc_hash": "2992824178ab5fafa6ed8cfe875f4ffc8ec7e279e70c0234a0eeeef8400d49ba", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "1c80bd36-d297-4699-889e-12a6725b7d1c": {"doc_hash": "ed7caa3625984a9bfd0f2b14387d048e0aa5ac72da37502ca7d51950e12811aa", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "e5d17a5b-0263-4508-b859-b1333f03418f": {"doc_hash": "e07892b8bfcc9c1382a404d21822899d3175a339570e2e51694f9e0ea63889ef", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "f47fcdd9-123e-46ed-8bc6-973368750ac4": {"doc_hash": "c25e9367f60b9000d434935f5096a6a8fb8bde5cd0c466d02e68d565078a1043", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "3ae0c417-79ae-42db-9e14-488c20f59635": {"doc_hash": "d3b4228be62310f56c2004a6c4b2d417170237f1a8804d1058f13ee420e66de2", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "fd0f6610-475d-4452-b02e-049f3ed68a82": {"doc_hash": "7b2b48cc14d4771fb45a1a10a5c568964d8d0938160bdf5e797c4aa5fea830ab", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "a3dfcc09-c925-445b-b293-aa61380ed76d": {"doc_hash": "415a8c54396974ec313bf8a73c34ea2489436512114318d2658dffcf9214bafb", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "2f89555d-156a-4383-9bea-803750c1b62d": {"doc_hash": "1219c81fb80a18dccb0cb332f83112336f1adeb258f97296a3fd905401ffb121", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "0432da5b-1c0e-40a5-a443-09db63078961": {"doc_hash": "21234a19d06693eadfc5afbb581dba63eddb0b1444ab717b03899935a6d77978", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18": {"doc_hash": "c7caa145c8aa9eaf091d80a8192c4409792dba180113f3394e980f44bb0a26f3", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "8a335c69-0bd6-455a-a1ef-2d0b5f4da801": {"doc_hash": "2ce999a3772e5b850c6d42a387fdb2472df3723d2e191093e974534125ec33c7", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "0ca69835-2155-43c9-a4c9-cefdedf40ac6": {"doc_hash": "4998c4a4ae88626921d4f36753bd62ef28a611bd52f4381c5d9ea50ad8bc1e2f", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2": {"doc_hash": "018a98c5f1fd1d0dcda6f5ee637fb5b1ea8ba68b0f1e2ed4f2884f7ed2a01197", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "38179bd7-3014-45eb-9ee9-1efa25757c7e": {"doc_hash": "457ba0586468f7217de7ec391724dda4bbf963387958cd25876af90536271677", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "50922714-fc3f-46a0-bcca-1e42eb4f8544": {"doc_hash": "ae83ad109c2954af1f728facf813d719eee91da4e0ee1230eec1d3d2b68836d7", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "ce2aa9d1-cb77-4db0-bbce-03129c71266a": {"doc_hash": "e4c49062e5bd4883d3751f0d1c5c705f1ce0f39e8183a5939c257a5f0be3d70f", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "aec0db3f-3cff-4fa1-98a1-7d34968f12ce": {"doc_hash": "9c9637a115125fba2b9cfe41bd10a2b326f702d475fd47820c062d047d62d961", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "8b605f03-1350-4802-8fc9-0c2d5f358d07": {"doc_hash": "3a05a8d87f2da5cb65621b8b3b863b856a2fbd8e15d9aff69f205cfa85d4a59c", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "9f15c82a-be3a-476c-9d50-8ea2bef0c257": {"doc_hash": "0da57e2daa841117ae7cf699459a520db816ccfe97037a99c9a787262da4d3cd", "ref_doc_id": "97c40641-d845-4a7e-abff-6500dad1dd3a"}, "e0c2ed28-5ca9-492a-82db-f3ed6bd5da29": {"doc_hash": "594662c32a8cbf3d3a94521ea7bbd80d30538cda14b02488b3086ea845677787", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "982011cd-f125-4304-be01-15f6299cb210": {"doc_hash": "09aeb98dd483766a3c6e00af12c28526c3b011e4da5295fb72c7aa6d6738b1ee", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "8ad63680-be79-4528-b649-28a1333e17fb": {"doc_hash": "33037a4f19d6c01af80482a0de50b6c8055a27cd6ecb98d1bca4dd2438cd62a4", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "c5c39e25-8de7-49a4-bfd6-8aa744f8d482": {"doc_hash": "1fa5f74f37f5452c98d5ffbf91c9e2fb989eba590be311b9388ee75aa2dc5684", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "500703b2-b343-4c03-abc6-fe62c708fb10": {"doc_hash": "665514e35898d5acda0da2fa2560333ec34c1b4cca882468c00e8e775486ca1e", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "4bd51752-d7c2-4c42-9a80-16f64e068c21": {"doc_hash": "0374da85b0611b552de850365b0d6a4287f6d7a366f2d3188a8d7b046bd5110e", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "07c77af4-420b-43bc-a2b5-6070fd72963b": {"doc_hash": "b5dbe10a76b39441df3cddc3403e73126094568bdd2cb834da128d38e9a01c0a", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9": {"doc_hash": "33aa052332ca04a6778fd2c7dbd8276efe42d3f77431b22dfe0b6803b4ccc123", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "865a0a79-2c50-477e-8be7-95a45a732c97": {"doc_hash": "61aa0d3e0a7f8bb66badcde087c7cdf2b3f18f214aa089b1355a024d70a342fe", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "454e9184-0d20-4a23-a671-505044e0aaab": {"doc_hash": "de3ee89beb2d4f086fca5ab1ad0bd46389596dab6629c3604e19e0af2967f300", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9": {"doc_hash": "984f2f1b38e1be2fa31b399694de777cd8e1db48cf9d29cfe4f2baf0ce01130e", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa": {"doc_hash": "b844710df4d79f562bac772d057d5ff91a1e5a9930cd53d92249d8e24c298452", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "847614e7-e5de-41d0-b83c-ef77877a9627": {"doc_hash": "5191ec5bf3d1ffd08fd7cc9c57a65b508c0cd29c52add7d4bbd8eccc831d5529", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "8d2b5319-7dcd-447e-a56c-7c136e0d83a1": {"doc_hash": "c715e744688343f444365f76dfe1bf72b80b9ddd76fea3e400995217e87d16f8", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "fee81e8d-c164-4439-b7c0-e7f85da19d47": {"doc_hash": "37df8be813d8baa5ba45f91e19d2a75f430a8c590c8011d7feccdc9e36da64b7", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "2f3df2a9-7ed2-431f-9580-e870332f52c9": {"doc_hash": "239a213f6c941f5a27a140851491a70d2f593a33dc50782932fd31baafa0d518", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "269d6890-d057-4e2d-9757-3636f4e4f970": {"doc_hash": "5839074fa718cf6a67a470ecbf4c99b35f8ccce6b23c9e57cc05bce99bc3443c", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "0d4f0061-815c-40a6-a5f0-33dcbeaccda2": {"doc_hash": "94f6a6159329c1b1514c1f155fef922d46ad7bc8046460ee55422fcd7606883d", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "ef618df9-57d6-468b-a759-d0d703ebe523": {"doc_hash": "3a3f7fcd26ca7201519c6d9b17e1a55ebe91f66dfce78e618732211c65cdc202", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989": {"doc_hash": "f4d49a33d8d4678c3ba29a229d6d1be20bedeb60458e47560f2a198eb58533c8", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "b8ab4c5a-71b1-4e67-8978-4be77bb04790": {"doc_hash": "ff6de7d1d3d574bf716e43c5ef0da78c8d1627c428d45ee4b21621535acc74eb", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "58a092dc-d649-46de-abee-5e42d06efe84": {"doc_hash": "032e566dddde8c866a470113fc2f66d234fe2cd231b4d337a3950a1d97e4a757", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "be123ccd-fd45-4045-a4b7-ba65f4d3758a": {"doc_hash": "8315ef574a5aa96d9a30e91dcaca252daed59093d8fd1e5a34721ddad00c7368", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "df2e76a7-a758-480c-b71d-e353fc22a2d7": {"doc_hash": "664ab1ab2870821b3aec1c8a414bfb5863d0eef895e136ef53c94b7352da052d", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "1a879545-b589-4a25-84d6-f2e769414b47": {"doc_hash": "f34e83e3fc8b65616354c540ed5f9c584afe289991f0257697c20a80083e97bd", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "5408e699-cc5b-4597-8a3a-2212d7e64433": {"doc_hash": "89396b48142e01c91bcfb0409d044a082513962355d0e75acfc182bbe1a4c4f3", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "066d3668-8bd9-4138-93e4-f136c3cacf3d": {"doc_hash": "7ebc598b8d6d31fc08f329dd5dc5dae673b5440fa02e5390270c89b30fd1c1d8", "ref_doc_id": "f8954832-f6eb-4b5c-80b4-b87f9334e148"}, "16bddad9-31b4-439c-9c21-d55e7b2356bf": {"doc_hash": "2a961fc948372e9ff83e8b34902b36bcd6efb112aef56a8e8df0fd51dd73b191", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "1a70d733-ef47-4a31-84b9-b2ed4fe25edb": {"doc_hash": "f7418a6ecc43f5fe410f97a2d7a3a13f79315dcbf16607c5538c4b299217722f", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "d5166528-bef8-4d08-b33a-dea7f72c82e7": {"doc_hash": "8cc838dd8e8d40bf0790f79e989d3c1eaeecf0aa5f430bbf7a8948fbb49fe874", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e": {"doc_hash": "0ae0abd05446d60fc0a14b9d752b3cd613627cf8b23239a40f0ee58e2ced9ad1", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "e33daa0e-8845-478a-b62a-7fe1f5c392fd": {"doc_hash": "dd824e87f586cb5ee2e0ad8da6d625f75739cbcdf0d6fc78c307d2cf266aa87c", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "298e2635-81f6-4460-806e-8eede25c6a07": {"doc_hash": "25eddcbc13afafe20f2b2c399c8e11105078336dbc04de8c5b15aa6eefe233d8", "ref_doc_id": "80df82db-d2f4-4b2e-8063-0906751b03f3"}, "758fea22-bf78-423f-8bcb-f806429549c6": {"doc_hash": "e62f4bb4b07e5ea760326d0db7530ee692faf153e4d0906e3fb782361fb8b294", "ref_doc_id": "a03e3911-7a61-4832-b633-f79cfb15c989"}, "4348b828-f9c4-4b04-821d-7cdd2f4248f4": {"doc_hash": "50c268b9fc5988c773778ce3956fe77bc6b854776b84c6c28d5d57bccd0f4d41", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "749746c8-f7db-4d55-8c6a-99359e254a6d": {"doc_hash": "0e786fbd17a5ef3db1c98495bdad961092e1225e7df0a7e97ba0fcbb4c4e01ef", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b": {"doc_hash": "51111d75fd740a58017c56727d28022a5476f9840a016a00a755dd9764762e93", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "2613502a-191e-4276-bdd7-5263dcef6522": {"doc_hash": "936542f124cda60d8fd61e84859bf99c1c9bcacb560b0f0e87e283056d2fc7a4", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "25492582-915f-49f6-8852-0c1e12f68d81": {"doc_hash": "8f657395276a535b9e2f8b6f21e9d32c0785e0ff588149ead9bab18e77277cd6", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "eb106088-0256-4e24-8e25-4e6c3e23327f": {"doc_hash": "f88a5eb7a15aff5b01be4fec3c336bc1a79248b2159f48c2d995791081b1b0c3", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "b6c748b8-b2f0-4f08-904c-8c61111007dc": {"doc_hash": "7f005d8cda40e53769bd9bc1c287b9a3d2a23bb8346f7affe169e2acd3ae2676", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "0b94a360-0206-489d-87dd-c204d9748de1": {"doc_hash": "ec4f473f7b1a605b15874dd19fb7f62bc11be71b31c532de18bc5f1c68ccd940", "ref_doc_id": "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968"}, "93b972c7-0ab1-426b-8ff4-c57b5dc226ea": {"doc_hash": "f64354b40cfffc67889cac7e22928f77a6e108749213f90fad316eed3821aa48", "ref_doc_id": "6631f107-6f9c-4aff-9248-1e2814044903"}, "824dbe41-cb78-4353-9a70-c365c991dc75": {"doc_hash": "56a2d7b53bc1e534b00b3d9e0f865b5bac729685ba87e5db8696fc46045b4bd6", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "62847867-7ce0-4f9d-857a-79a3dd09c318": {"doc_hash": "c3417da8d3b608fe8f3db7e3635216f6daf9f5aca40091b3fbd773752574b0ce", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4": {"doc_hash": "1b54448823abccf48cb0bb24ecef49f1011fa168b32e5fa679ccc961ddd53fd0", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "23943697-d32a-40b3-891b-7043128dbbe5": {"doc_hash": "069daa56fc5fe5ef6d73fdeed9d983d72d7b5d97cc0f534c0089f1520bd28bf8", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "5054753b-44bf-413a-8837-cede99b1b5f0": {"doc_hash": "6413ba3b49ea5c2c023ea62b477ee27e0d5c005b1398fe90cae63789a943bd5a", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "52d913c3-1688-4f77-883d-e3286369c5dd": {"doc_hash": "15bec04e8b82d49326b4ad79e2747769eecdc804aad0098e240031664550121a", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "02bd7576-3bfb-45ad-89be-ef63cc9574d3": {"doc_hash": "575672f2eb1773c343971ffdd2fb6185ffad1c72c2ec6b6c8b530b04160eee4d", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "09812a40-cfd0-4c1e-bf72-4859ef1dcea1": {"doc_hash": "0e86b1201ffd7897e8bc4998f94316d1398bbb751afce1ba4d62409b611a1836", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14": {"doc_hash": "26b3dd76423ca6f3c46475a88e86b99832c570dd1a138f546b8b4f4c32ba0faf", "ref_doc_id": "9e378987-9a65-464b-b917-f2bca2db10cd"}, "a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f": {"doc_hash": "508a2c438db64cd0827ecf1c657fc42538f9a882e9cda0e6d6bc138ed7c7f988", "ref_doc_id": "3ac7718c-3947-40a7-b13c-7abc741cf8dc"}, "79eab791-fc24-4385-b6da-b9172ffc14b2": {"doc_hash": "8d7ed4883b976c446fb013a71fa1acef1cb3ec9c1a93f550ca27f4fc72b17fa8", "ref_doc_id": "3ac7718c-3947-40a7-b13c-7abc741cf8dc"}, "0b69928b-17a8-4db3-971a-a3ea5efd452e": {"doc_hash": "c38f1204e8df70d195480aa7c7abd28b8c0d5e1d5092ddd6a0c99a0f1bf7ea6c", "ref_doc_id": "dba5f8dd-9511-497a-98fb-43d691170379"}, "9637a46f-34d4-4795-b962-8ea8187ec0fb": {"doc_hash": "c08f55aee8d110308c608ba026f9341f30a9bbe34f330e373ea5da7e821f7068", "ref_doc_id": "dba5f8dd-9511-497a-98fb-43d691170379"}, "9b5f18f3-0caa-4033-a24c-e472a06b50f4": {"doc_hash": "cf020adda0abff1163405de87dbde4d084d7c86d590f26bd8acef16d61637fbe", "ref_doc_id": "dba5f8dd-9511-497a-98fb-43d691170379"}, "bba015a0-2c1c-4dff-8d65-a8b6cd263bce": {"doc_hash": "08f041b8ec2f59135c7899ebf9912fddc77908c68167b72ab69dd31b3aab9fcd", "ref_doc_id": "dba5f8dd-9511-497a-98fb-43d691170379"}, "f421cc4f-cdb9-4538-a2f2-b91016bbc77f": {"doc_hash": "b1e337714393ee95d296385cecf51bf7f0baf19898bc69d0de01c688f6dee687", "ref_doc_id": "dba5f8dd-9511-497a-98fb-43d691170379"}, "d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3": {"doc_hash": "775fc85aafe5ae5c94923f90a1ff3c4dfa640a45bd9401fe15b819371ff5bec3", "ref_doc_id": "6a3fea13-fa23-4c23-ad8a-0fab3e527b21"}, "be2e69d6-3882-4481-be54-a0d9c86a36d6": {"doc_hash": "c30b64420509b1f2e4acdb3e9f07f02722d33113656efacb42e391ed2907a90a", "ref_doc_id": "6a3fea13-fa23-4c23-ad8a-0fab3e527b21"}, "4a884a4b-6796-4b8e-a64c-b11fe1233a4c": {"doc_hash": "5d76cd39482fb7776d65889f9841804497a9fe9c9753cb5e4bbb6c1c9eeacc6e", "ref_doc_id": "426cba76-db19-4101-9255-d4fb1858ebb2"}, "a35f55b3-475b-4a7e-80cb-da6f3dfb406b": {"doc_hash": "6ad5521facf59cf52ae9f0662bc27ebed168e5fd49c67e52fa2fb4aa0548266e", "ref_doc_id": "426cba76-db19-4101-9255-d4fb1858ebb2"}, "6be0ccb8-531f-431d-8187-495bed6f57fd": {"doc_hash": "80e8e03d0f9ce1e2e258bf1e9202868e769ab012491cf2a01aa1678b11923652", "ref_doc_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a"}, "cc9b2ac1-fdf8-4db1-b934-435c14c6a515": {"doc_hash": "348015805861d9d8cf237c3fd7fba0b08ccc05a291c61e7cd34483e68490e47d", "ref_doc_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a"}, "d7c04171-35b3-4f82-a5dc-389219dfc5bb": {"doc_hash": "33005ecde5a7305a90567b75a554d23eeafb5517cc02c62cfa40335eea0665da", "ref_doc_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a"}, "521a7226-9b13-46f1-9fab-46b8c881187f": {"doc_hash": "cd12435e50e0978b974b017e0e2131223b8c465bb2bae6d72d44c44d959c3a2e", "ref_doc_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a"}, "5e9b4b43-6dec-4c66-abd5-895712cf8136": {"doc_hash": "aed1c5bf1639b8eda798314b4c96e335af9e841031b99244355841f737ec6731", "ref_doc_id": "c8c5766a-f18b-443e-8d64-94c3b01dca8a"}, "d3f376b3-078a-4c17-a082-10aaa482a11b": {"doc_hash": "ea7c6e595da48dfbc4f9097a5a370fac601d8ba30b695b0221dfd494c293e549", "ref_doc_id": "1f22f2bf-33b7-4b90-b536-cf1e31629f88"}, "e469e068-19d6-45b0-a8bf-4a3a260e6e99": {"doc_hash": "e84ea66431d668e4ec89b40642fe9ef7ba09ff6d413abd2e9644f23f4edd92d8", "ref_doc_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041"}, "b28ba5c4-63c6-4286-9272-003d6f9a126d": {"doc_hash": "7254dda95307ea4b85f60024effee9f5edad1f887a9fd7f43b25ab422dd1fe71", "ref_doc_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041"}, "3f4b2768-b288-4a3e-b77d-0fc08fa33025": {"doc_hash": "44d4aaaaed2755a2fe5b3ea6dd12b04b9bbe983063787a03403e8f4e52410c21", "ref_doc_id": "ff4c4e77-cafe-4534-814c-3ad8aa2c9041"}, "5b71840d-7f4c-4773-9eba-8c98a9753df9": {"doc_hash": "fac23c97885ba5848d9bbd138949d97e3d8d477626e34291d47f67ef47c6b228", "ref_doc_id": "c780a895-f794-4666-8259-cada8c3ff3f5"}, "d1d4d66f-0993-4009-9755-d864305b3d74": {"doc_hash": "2698fca430e26c143ef9e9cf7ffe815596bffc8e90b115e723277b7f440bdd64", "ref_doc_id": "c780a895-f794-4666-8259-cada8c3ff3f5"}, "1648d99d-e901-4f47-a595-19d87421fd7b": {"doc_hash": "e4ef5d4c22cea9305234e21aead5f9a62371d1afdd56a431daead319e80aedfb", "ref_doc_id": "7d1a231b-11f1-4500-9ed3-84383fc945ed"}, "070c2aed-83ea-4ecb-9047-3b74693a2626": {"doc_hash": "fa0d38df4b7d402450ac0e137055a3728159d9586992dae923c373a10b1d86b9", "ref_doc_id": "dd3484f2-8c0b-4b1d-92a2-d188850dc10d"}, "cbc53efc-6495-498a-be3f-b7cfbacb8360": {"doc_hash": "94fbb8f907d95aba795bc0a33a647f26ad6be1f6693e312d0e30035dc43eb8e1", "ref_doc_id": "dd3484f2-8c0b-4b1d-92a2-d188850dc10d"}, "7e1deeb3-c6b7-4d52-a15a-794a00f514d9": {"doc_hash": "ddffd4e18d22e16ef503ee3185c018d89a34a7459d677d01c1aa6a228abd6213", "ref_doc_id": "3dfc97ef-e4e0-4ca9-842c-540aca825314"}, "51c7f25e-43f6-4deb-a450-be956a0a71e1": {"doc_hash": "45572e57d087a6386b52503e27bdcb5410ae5230d3aa883fa4676e60081f741c", "ref_doc_id": "0f7a4cae-8fec-42b4-bd7a-d29f10ee3849"}, "4707c0eb-b7e4-41ea-ba2a-30d86cc62287": {"doc_hash": "79017e04d43ba9a7e281285fc35c991b9b38fb50d004bc03cbc07b18a531aa62", "ref_doc_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3"}, "7a39f68e-7898-4978-b840-60071077090e": {"doc_hash": "cf3ae3c8e38f19a284c8d5c8b7b3c4132fb7b56a3e502fa64f4619e73eb31c13", "ref_doc_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3"}, "d3b437de-82fa-44f9-b58d-71755b7c72aa": {"doc_hash": "46876527c2eeb2fa381425d3c99b769a17893dd5de0f099979ef20a2ff3a426a", "ref_doc_id": "74388ca1-192d-449a-97e9-9c50c8cd9dd3"}, "36c35b28-cedc-4e26-88cd-76ecddd57d06": {"doc_hash": "20c1d99e8ed9a6a775c778276a3e7afee534ca9f41bfef54bdbd27993b2f1ee7", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "0b3732d9-f301-45cf-8534-abb0db7c1b18": {"doc_hash": "d8cf56cb0eb478edf7253700df12446c218e091a692ed2e087f312d541711cc1", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "66803499-28a2-4be4-9a75-6303460a167d": {"doc_hash": "719017dbd5bd5fd4190082ed4e3355b88c1176705ee2f9200c981d39edf0fb3d", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "31bf0499-f754-4e46-b7a6-329f0f9e27a8": {"doc_hash": "78b0b455696c4270a822cdbe59d7b4643f5273bcc99784dc00860c3cda0b107e", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "fffefa91-0a17-4e23-ba3a-4715eac1ced3": {"doc_hash": "5dbd40a4dceaeb383214ad844bc81252fa726c222011b1d48e3d358637523200", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab": {"doc_hash": "b9c1dcf36a5a75a0c2c79904fe79245aac5c3c0a8a20d2b6a2faea7d0d65c6ec", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "d1fdf0dd-064a-4e86-8a1c-b22d206796ad": {"doc_hash": "6ea7fd064b4abf9ac876e210eed03d5e050a760df1da330260d6cdd3fb6568b2", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "b9afe04f-8167-4299-927c-d323f74b81f8": {"doc_hash": "bf7f200160a1e71103e9f028a30485129820a04f43c069544496110d19748cd7", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "60e9fe26-5af6-4409-8648-b9374aa8c30e": {"doc_hash": "5d2862efef484647c0c3d3b34f57f642261b982152a131fd477fa54bbedfb48f", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "b53d66d1-017c-4a2d-a409-5cde11d712d5": {"doc_hash": "bbac374c0598812914b28e46bef0b83afdb47ddf0c6a24cda2d25f30b234ca75", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "1c293633-80d3-4936-befd-8fcaf47aa9ed": {"doc_hash": "c9794e86879398f0082a3074ffd810ed03eb07f4a70ab080632450e50ad22c7b", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "6b3f3b03-e89f-49ef-954a-7650b4ce3a14": {"doc_hash": "5645f80599f7573f60595bb46a084e9b34c90657e3af953e451f54326327eaf9", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "f6fafac4-6596-487d-a16c-f3a136557ec0": {"doc_hash": "9945bc84ca2978692014934ae9d62a1ed2de1a6a5015db83416f97904e46bfc3", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4": {"doc_hash": "70da23f7fcc8d4b1463807cc99563a0639b319bece19c38d1b4e2e46f07de0d2", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "68bac126-a580-41c1-9ac8-7b21e7d0bd7c": {"doc_hash": "dcb5ba03bf54ea700884234aaf0d0c3728871f46e7b3df3042dc9c7cb0a766f4", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "025c4c7f-9ed5-4187-bfef-c3e22b86bf89": {"doc_hash": "2ec40a0cae906b3cf8d75f196444374eec317e26f298e9c2cd2dcdbff8792c39", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b": {"doc_hash": "a217cf7e351b0fb2259016ca31a2ddc14e22dd558cae0bd91b584a8a68c423ce", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "59704da3-0b55-4c9f-8ed5-a70672a4ca7a": {"doc_hash": "4263498c82bf90afc4d1a1a302fdd7f29ab07c5a6ec71a50b6cf8862a09059ef", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "4ec40243-9deb-4ecb-951c-f691669e00d6": {"doc_hash": "792d2d2b5186c3aef78525ee3b29937ce848cf6eb90e7726710e57bc2d8a8245", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "50efce9d-4e95-4d06-8839-991b205eed1e": {"doc_hash": "5f149926ea1e7380b487d8e5cc47b714a28da9ab9588cb2723a139fe4b96209e", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "c6c53c5b-b148-4c79-8a45-de56b842022f": {"doc_hash": "7ec1d2141fb11542ff0d262482067a7f4f6fde1cd2f7a35e0b8f2baa6f6892e2", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "1fed0e71-6c86-44eb-87f5-6433ca3a68fe": {"doc_hash": "d1c18fd6305c9fcaa5016ea414291b0fd0716d5a9fd5e9f04796bd0510c656b5", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea": {"doc_hash": "8022413b149b2826dc562fb4bd52d0f70450acc3848df0bd843777cc9693993e", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "ed2e65d4-795c-4fc0-a70b-4e0686807ae7": {"doc_hash": "1e1a12158ea25cc09e8cc1a028020ebdf788068115efe2db87b1fce5c8d35ab6", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f": {"doc_hash": "008ae12386d730df0a9f3d71300be134f76cc6212a7e098439fe2406d5de726c", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "e66ffe97-16ee-4933-978a-ea7720481782": {"doc_hash": "c7c58bd191d407417803adfacf6d6077c1654e791ab4d6a1a439ff320a3794be", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "d944e562-2afa-4197-96ad-ac896417dd38": {"doc_hash": "1c53edfc2eff7835f5db3f995bdb6625657eb696a91dc96c2582e89ae76bda4e", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "4834dd80-ae60-47af-8f81-15f9580b1a68": {"doc_hash": "44eb1d85df20e1e54f590331fa693f9b7c2df69d841a399b2c9da3ca78438311", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "af5aaf3a-b375-4561-bad1-24e4b4550e26": {"doc_hash": "647bbc6809a24a8562ebcda19584f0485b6b1fb460d720434ad79fbd4bf4a81b", "ref_doc_id": "7171fa27-94f2-418f-83e9-6b9aa8af453c"}, "cbc99c99-570d-465d-b7d7-70dbf6450a33": {"doc_hash": "de2b8d62f6baed7de1edd375a7864f9652449367a8034a84933acb0016043212", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "acf44f2b-f418-4c4f-b056-181d17c79557": {"doc_hash": "0fdbe8e8fd69afad47213dda722338941d149340459dd98a043382b04764888b", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "024c427c-51fa-4cba-a964-803d03a1a732": {"doc_hash": "21341b3989cfd5ebe8b192ebf8833a43f1d54c091a614b2a8a3f2239e971e924", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "a2acc911-677f-4cec-98e1-f07eb5416e38": {"doc_hash": "e586d5679b8370d22f36f4be4230377224efcaa6b1136479f19bc75076e2e868", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "b1f7a156-f25a-40c8-a348-ae89c28958b2": {"doc_hash": "5bfbf1b37b60100914d6b92ce138bada528da3069a10120a93f8e9b008d07f6f", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "3bfbdcdb-3821-4c17-ab51-5792f77fbd87": {"doc_hash": "98b69d6891f896213f5a1ab4df54f709dfb164353c85188269f9b5c9298f0fde", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "9777dfaa-03e7-4034-8481-d406b9413329": {"doc_hash": "4809124c5749f1178b920b1a90d1e9507067b4743f5102c5f9802d473d0b185a", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "a0b058c0-c3b8-4dcf-a108-f755e86c1076": {"doc_hash": "a71bb7814fcff9b6f8a9fe4035b8538571e7f2db5935bf033c88fe57a640e23c", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c": {"doc_hash": "ec238cd05fd680996a2591c82821f77ae7dfadec3369a0fdc8e332a31c16578e", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "23eaf8f6-3034-4df1-b50f-222f4667e5fb": {"doc_hash": "0c6cc45b0fae01ca851b410e41c198204991e6d796aa7df7fc49976430df738f", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "c6db908e-3e45-416b-b5f1-7c69833f8115": {"doc_hash": "8ef3bf06f30a0f5446cb0621c7ac61949aae1535cfdc63040aa68f7050ebf04d", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "a11e34df-566e-457e-aa06-20f59133dfb2": {"doc_hash": "5e831a1e95fcb10ac688481349e37401029b00829abefd6eb294f1791cd63595", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "6e02659c-4951-446a-9111-3a0d23acec4b": {"doc_hash": "a3877335cffeb6b03c7641439e6dac6bae9ef78ed158ab696e5ef9eadf363eda", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5": {"doc_hash": "5687098133280da8b8d40c4446b46789f441941675e360f8df6dd85900e876b7", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "7d1370b6-5da8-4e89-8826-5e04c5bc7a48": {"doc_hash": "6a815beeb057fde9ceb42b987d3b30c0a83ffefdca7e594347cd20ea0616bb05", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "ddaee0c8-d92a-458b-9b06-bf82ca3a374f": {"doc_hash": "b213e712161aaf0a1fe642a0c46fb8847d5e894cbc9e656730fee54dd8263671", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "891bccfb-099d-49e3-a581-c0df87b2c5a0": {"doc_hash": "8c480b0ad503afc21abaabdd373990736e235da3b77950f0a71b4bd0ba404c1e", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "5ef4e695-8cd3-46cf-a507-65abb6970e85": {"doc_hash": "009a9dec056ff5451f665756ffb72f2d909a35a7f11b99bea329b6ee8f5ec641", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "cc0a49e3-51d6-4c70-b8a9-44164bb35d23": {"doc_hash": "9dc74b514696715e9d8d391941d6eca83865c4705e31807b18e9fbe55755badc", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "2969592d-eeb4-4f21-b2b0-feefb08e5b7b": {"doc_hash": "bc3cf3a3e98d48730f0784e107ccfabf68f77420fc6e27b68bcc52f5df2dba10", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "2fef3fa9-100a-47b5-9b12-2071062ac984": {"doc_hash": "dfd367b367f69ed73a24a7dd287dbd4a37e4ff6b94004b0621f5082b0c4a7572", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "2384ec3f-0df3-459d-8c7c-67338b621162": {"doc_hash": "23b7e06ceaa2e8bc313465b7c98d89e779f79ba888b6801d6b2d4b7deb0485cd", "ref_doc_id": "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67"}, "da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3": {"doc_hash": "6908623a7f544d33ae311c7193c956c344d9a6e69503ad19258da8a7e44e8f25", "ref_doc_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a"}, "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df": {"doc_hash": "30b69baabb3b134a08d8428495439f5f59499f6f2981e3abb21da7d970a15734", "ref_doc_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a"}, "cbdc7274-69bc-46db-bba3-37b9ccb298cd": {"doc_hash": "3f6694365003f8ac349deeb9ee3f3296eba47370c924e3873d2e64e3c666fba8", "ref_doc_id": "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a"}}, "docstore/ref_doc_info": {"e56e4208-9f6b-406a-b7a7-a67ba6605aae": {"node_ids": ["9fe0fe7f-eabb-4cd7-8b9d-05d8aee52bd1", "9f19edc3-78bd-4060-b083-6d0421f272b0", "86206a4c-9249-496c-a68f-057d20eb3cae", "d7310391-fadf-4911-822c-44ad0d3f2b2e", "8e8526d6-be8e-485d-956e-f3c08e0dbccb", "dc3002e3-b2a8-413b-bb08-1ae8412447ed", "9e7cd1ad-7035-4d60-99d3-4ba7d6905783", "4ad34148-97db-4a90-930f-b939088580a7", "aaa6ba74-7051-4cd0-a331-f655b65f9305", "8ec56a4f-6d61-41d2-8d3c-4586b86b61f3", "551a1d30-2603-4420-9f57-65b20c4c4495", "ff643fb8-bb2a-4238-9a28-dd91d0155cc4", "0139868c-d1b6-4659-844e-111de542b94c"], "metadata": {"window": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion.  On the basis of U.S.  generally\naccepted accounting principles (GAAP), diluted earnings per share (EPS) was $1.40 for the June quarter of fiscal 2021, compared to\n$1.41 in the prior year quarter.  Adjusted diluted EPS, which is a non-GAAP measure that excludes items described below, increased\n16.8 percent to $2.16 in the fiscal third quarter.\n", "original_text": "Amerisour ceBer gen R epor ts Fiscal 2021 Thir d Quar ter Results\n8/4/2021\nRevenues of $53.4 billion for the Third Quarter, a 17.7 Percent Increase Year-Over-Year \n Third Quarter GAAP Diluted EPS of $1.40 and Adjusted Diluted EPS of $2.16 \n Adjusted Diluted EPS Guidance Range Raised to $9.15 to $9.30 for Fiscal 2021\nCONSHOHOCKEN, Pa.--(BUSINESS WIRE)-- AmerisourceBergen Corporation (NYSE: ABC) today reported that in its fiscal year 2021\nthird quarter ended June 30, 2021, revenue increased 17.7 percent year-over-year to $53.4 billion. ", "page_label": "1", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "09171313-4b13-48bb-9d5b-29c9710fa0be": {"node_ids": ["c5f7487c-b63e-4090-a96d-74fb12a20122", "7a3b634a-a999-43e5-9c81-797b25bd8c60", "85faab7a-2559-43f1-8102-97614f834458", "d3c20500-a9a9-4072-bacc-768c963048f6", "c2e93779-4977-4c64-9347-7d24c70bdf54", "f7030fe7-1f1f-4a4d-993f-d03045062c93", "514e0001-f72e-410c-8a84-6915524d8bd0", "316d2dd3-e6f9-4249-8bd0-02b09f8a6650", "13947e16-3f92-4418-ac00-24e61c66190a", "1c260ad0-9f08-4d28-8869-8f0ed8538a01", "c410088b-f0df-46c1-b82b-548d821e5b85", "78087d40-938e-4da0-9bf3-7bc66069f434", "7b73b946-0c6d-4420-9809-531de5d60a28", "6dd1cfce-a6db-4f92-9d1c-50c785bd7a8c", "1c846acd-3fff-4317-ae6a-1f8ed8970998", "639ec7ed-917e-45ef-9e1a-9d42b41a8b64", "8a7d36bc-24a5-4269-a4d2-a277c7a99357", "af65e123-f5ae-4883-9494-dacd8d927cd1", "f10c2628-e07c-46a1-bf04-ec088088aca7"], "metadata": {"window": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results.  In\nthe tables that follow, GAAP results and GAAP to non-GAAP reconciliations are presented.  For more information related to non-\nGAAP financial measures, including adjustments made in the periods presented, please refer to the \"Supplemental Information\nRegarding non-GAAP Financial Measures\" following the tables.\n Third Quar ter GAAP R esults\nRevenue:  In the third quarter of fiscal 2021, revenue was $53.4 billion, up 17.7 percent compared to the same quarter in the\nprevious fiscal year, reflecting a 13.2 percent increase in Pharmaceutical Distribution Services revenue and a 128.0 percent\nincrease in revenue within Other primarily driven by the June 2021 acquisition of Alliance Healthcare.\n", "original_text": "Net Income A ttributable t o ABC $292M $452M\nDilut ed Earnings P er Shar e $1.40 $2.16\nDilut ed Shar es Outstanding 209M 209M\nBelow, AmerisourceBergen presents descriptive summaries of the Company\u2019s GAAP and adjusted (non-GAAP) quarterly results. ", "page_label": "2", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ed807259-1b19-4feb-a664-384450cebb90": {"node_ids": ["128b0472-8710-467f-95d8-e4ef4dfe131e", "a12841f1-6f65-49df-ba17-79b79f7c2052", "7f7501bf-7cda-4fa4-871f-6c7d0bc1b7d9", "c599e1c4-b7c8-498f-8242-550494ad53cd", "6e652466-8a21-446d-b4af-6429e203e9af", "7c062dfb-dc89-41f2-a5c0-a46be6d28acd", "3d6e4520-6809-4f8a-bf78-c90ec0f46e1a", "0db8b80e-6ada-4c0e-bf1d-29f2dfb4e0b2", "d33c8f13-f5f2-45a5-988d-456703b26f7d", "87036aad-6ff2-44d3-a023-40589f58e4a3", "ee62b8c6-e3a9-4776-baff-f53fc71f1a04", "43f3fbd6-b089-4af8-9176-c9b13e2022e8", "0ebc3a1c-00f2-4afb-90ee-42b87299409c", "ce11fdd8-d125-4428-bd77-de5ac414e1e6", "73ad3fa7-adbb-4894-9aea-5d23bd02a7da", "a55f9745-0850-4d8f-bc71-b4cc8a85e552", "ca9babee-8aeb-472f-953b-7a44b03cbd28", "56338974-c21b-43bd-8b88-b54a4846df2d", "dfd924ba-fedd-4a32-bd33-92a3feaf897a"], "metadata": {"window": "June 2021 acquisition of Alliance Healthcare.\n Adjusted Gross Profit:  Adjusted gross profit in the fiscal 2021 third quarter was $1.6 billion, which was up 32.0 percent\ncompared to the same period in the previous fiscal year due to the Alliance Healthcare acquisition and increases in gross\nprofit in Pharmaceutical Distribution Services and Other.  Adjusted gross profit as a percentage of revenue was 3.05 percent in\nthe fiscal 2021 third quarter, an increase of 33 basis points when compared to the prior year quarter primarily driven by the\nAlliance Healthcare acquisition, an increase in sales of specialty products in Pharmaceutical Distribution Services and growth\nin some of the Company's higher margin businesses.\n Adjusted Operating Expenses:  In the third quarter of fiscal 2021, adjusted operating expenses were $996.2 million, an increase\nof 37.5 percent compared to the same period in the previous fiscal year due to the acquisition of Alliance Healthcare and an\nincrease in payroll-related operating costs to support the Company's current and future revenue growth. ", "original_text": "June 2021 acquisition of Alliance Healthcare.\n", "page_label": "3", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "97c40641-d845-4a7e-abff-6500dad1dd3a": {"node_ids": ["1a5de5de-c080-448b-86ba-7618e50ab122", "71357bbb-c077-4ced-b88c-b783967484ec", "1c80bd36-d297-4699-889e-12a6725b7d1c", "e5d17a5b-0263-4508-b859-b1333f03418f", "f47fcdd9-123e-46ed-8bc6-973368750ac4", "3ae0c417-79ae-42db-9e14-488c20f59635", "fd0f6610-475d-4452-b02e-049f3ed68a82", "a3dfcc09-c925-445b-b293-aa61380ed76d", "2f89555d-156a-4383-9bea-803750c1b62d", "0432da5b-1c0e-40a5-a443-09db63078961", "8af6deb1-30e6-4dc9-9fe5-77a0c7936a18", "8a335c69-0bd6-455a-a1ef-2d0b5f4da801", "0ca69835-2155-43c9-a4c9-cefdedf40ac6", "b0fed0ce-b29f-41b7-b7ae-5520ef2647b2", "38179bd7-3014-45eb-9ee9-1efa25757c7e", "50922714-fc3f-46a0-bcca-1e42eb4f8544", "ce2aa9d1-cb77-4db0-bbce-03129c71266a", "aec0db3f-3cff-4fa1-98a1-7d34968f12ce", "8b605f03-1350-4802-8fc9-0c2d5f358d07", "9f15c82a-be3a-476c-9d50-8ea2bef0c257"], "metadata": {"window": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS.  Operating income in Other increased 77.2 percent to $146.9 million in the third quarter of fiscal 2021 primarily\ndue to the acquisition of Alliance Healthcare and growth at MWI and World Courier.\n Recent Comp any Highlights & Milest ones\nAmerisourceBergen announced the completion of its acquisition of the majority of Walgreens Boots Alliance\u2019s Alliance\nHealthcare businesses.  The acquisition extends AmerisourceBergen\u2019s pharmaceutical distribution presence and global\nplatform of manufacturer services to support pharmaceutical innovation.\n", "original_text": "Revenue in Other was $4.1 billion in the third quarter of fiscal 2021, an increase of 128.0 percent compared to the same period in\nthe prior fiscal year primarily due to the acquisition of Alliance Healthcare and growth in the other operating segments: MWI, World\nCourier, and ABCS. ", "page_label": "4", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "f8954832-f6eb-4b5c-80b4-b87f9334e148": {"node_ids": ["e0c2ed28-5ca9-492a-82db-f3ed6bd5da29", "982011cd-f125-4304-be01-15f6299cb210", "8ad63680-be79-4528-b649-28a1333e17fb", "c5c39e25-8de7-49a4-bfd6-8aa744f8d482", "500703b2-b343-4c03-abc6-fe62c708fb10", "4bd51752-d7c2-4c42-9a80-16f64e068c21", "07c77af4-420b-43bc-a2b5-6070fd72963b", "a7e4da64-3f1f-49d4-b6a3-64b7f496ceb9", "865a0a79-2c50-477e-8be7-95a45a732c97", "454e9184-0d20-4a23-a671-505044e0aaab", "3f37e1ac-2c25-4ef7-9d7f-80b07a4e30f9", "d0b0f10c-5abb-4e89-9dad-3bdd4570c9aa", "847614e7-e5de-41d0-b83c-ef77877a9627", "8d2b5319-7dcd-447e-a56c-7c136e0d83a1", "fee81e8d-c164-4439-b7c0-e7f85da19d47", "2f3df2a9-7ed2-431f-9580-e870332f52c9", "269d6890-d057-4e2d-9757-3636f4e4f970", "0d4f0061-815c-40a6-a5f0-33dcbeaccda2", "ef618df9-57d6-468b-a759-d0d703ebe523", "6eeb7541-bcab-43ee-8dc0-e4d2ec0a2989", "b8ab4c5a-71b1-4e67-8978-4be77bb04790", "58a092dc-d649-46de-abee-5e42d06efe84", "be123ccd-fd45-4045-a4b7-ba65f4d3758a", "df2e76a7-a758-480c-b71d-e353fc22a2d7", "1a879545-b589-4a25-84d6-f2e769414b47", "5408e699-cc5b-4597-8a3a-2212d7e64433", "066d3668-8bd9-4138-93e4-f136c3cacf3d"], "metadata": {"window": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n Opioid Litigation\nOn July 21, 2021, AmerisourceBergen announced that it and the two other national pharmaceutical distributors have negotiated a\ncomprehensive proposed settlement agreement that, if all conditions are satisfied, would result in the resolution of a substantial\nmajority of opioid lawsuits filed by state and local governmental entities.\n Confer ence Call & Slide Pr esentation\nThe Company will host a conference call to discuss the results at 8:30 a.m.  ET on August 4, 2021. ", "original_text": "The Company's Board of Directors declared a quarterly cash dividend of $0.44 per common share, payable September 7, 2021, to\nstockholders of record at the close of business on August 16, 2021.\n", "page_label": "5", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "80df82db-d2f4-4b2e-8063-0906751b03f3": {"node_ids": ["16bddad9-31b4-439c-9c21-d55e7b2356bf", "1a70d733-ef47-4a31-84b9-b2ed4fe25edb", "d5166528-bef8-4d08-b33a-dea7f72c82e7", "8df8d6ad-a9cb-4c48-98d4-c74abd2b510e", "e33daa0e-8845-478a-b62a-7fe1f5c392fd", "298e2635-81f6-4460-806e-8eede25c6a07"], "metadata": {"window": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc.  and the Company, including with respect to the pharmaceutical distribution\nagreement and/or the global generic purchasing services arrangement; managing foreign expansion, including non-compliance with\nthe U.S.  Foreign Corrupt Practices Act, anti-bribery laws, economic sanctions and import laws and regulations; financial market\nvolatility and disruption; changes in tax laws or legislative initiatives that could adversely affect the Company's tax positions and/or\nthe Company's tax liabilities or adverse resolution of challenges to the Company's tax positions; substantial defaults in payment,\nmaterial reduction in purchases by or the loss, bankruptcy or insolvency of a major customer, including as a result of COVID-19; the\nloss, bankruptcy or insolvency of a major supplier, including as a result of COVID-19; financial and other impacts of COVID-19 on\nour operations or business continuity; changes to the customer or supplier mix; malfunction, failure or breach of sophisticated\ninformation systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of\npersonal data; natural disasters or other unexpected events, such as additional pandemics, that affect the Company\u2019s operations; the\nimpairment of goodwill or other intangible assets (including any additional impairments with respect to foreign operations),\nresulting in a charge to earnings; the Company's ability to manage and complete divestitures; the disruption of the Company's cash\nflow and ability to return value to its stockholders in accordance with its past practices; interest rate and foreign currency exchange\nrate fluctuations; declining economic conditions in the United States and abroad; and other economic, business, competitive, legal,\ntax, regulatory and/or operational factors affecting the Company's business generally.  Certain additional factors that management\nbelieves could cause actual outcomes and results to differ materially from those described in forward-looking statements are set\nforth (i) in Item 1A (Risk Factors), in the Company\u2019s Annual Report on Form 10-K for the fiscal year ended September 30, 2020 and\nelsewhere in that report and (ii) in other reports filed by the Company pursuant to the Securities Exchange Act. ", "original_text": "governmental regulations regarding the pharmaceutical supply channel; declining reimbursement rates for pharmaceuticals;\ncontinued federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances\nand the diversion of controlled substances; continued prosecution or suit by federal, state and other governmental entities of\nalleged violations of laws and regulations regarding controlled substances, including due to failure to achieve a global resolution of\nthe multi-district opioid litigation and other related state court litigation, and any related disputes, including shareholder derivative\nlawsuits; increased federal scrutiny and litigation, including qui tam litigation, for alleged violations of laws and regulations\ngoverning the marketing, sale, purchase and/or dispensing of pharmaceutical products or services, and associated reserves and\ncosts; failure to comply with the Corporate Integrity Agreement; material adverse resolution of pending legal proceedings; the\nretention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or\nother dispute with customers or suppliers; changes to customer or supplier payment terms, including as a result of the COVID-19\nimpact on such payment terms; the integration of the Alliance Healthcare business into the Company being more difficult, time\nconsuming or costly than expected; the Company\u2019s or Alliance Healthcare\u2019s failure to achieve expected or targeted future financial\nand operating performance and results; the effects of disruption from the acquisition and related strategic transactions on the\nrespective businesses of the Company and Alliance Healthcare and the fact that the acquisition and related strategic transactions\nmay make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; the\nacquisition of businesses, including the acquisition of the Alliance Healthcare businesses and related strategic transactions, that do\nnot perform as expected, or that are difficult to integrate or control, or the inability to capture all of the anticipated synergies related\nthereto or to capture the anticipated synergies within the expected time period; risks associated with the strategic, long-term\nrelationship between Walgreens Boots Alliance, Inc. ", "page_label": "6", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a03e3911-7a61-4832-b633-f79cfb15c989": {"node_ids": ["758fea22-bf78-423f-8bcb-f806429549c6"], "metadata": {"window": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "original_text": "Cost of goods sold \u00a051,517,489 \u00a0\u00a0\u00a0\u00a0 \u00a044,141,061 \u00a0\u00a0\u00a0 \u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit 1 \u00a01,888,206 \u00a0\u00a0\u00a03.54 %\u00a01,225,716 \u00a0\u00a02.70 %\u00a054.0 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a0913,414 \u00a0\u00a0\u00a01.71 %\u00a0666,885 \u00a0\u00a01.47 %\u00a037.0 %\nDepreciation and amortization \u00a0127,101 \u00a0\u00a0\u00a00.24 %\u00a095,415 \u00a0\u00a00.21 %\u00a033.2 %\nEmployee severance, litigation, and other 3 \u00a0226,964 \u00a0\u00a0\u00a0\u00a0 \u00a058,585 \u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a01,267,479 \u00a0\u00a0\u00a02.37 %\u00a0820,885 \u00a0\u00a01.81 %\u00a054.4 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a0620,727 \u00a0\u00a0\u00a01.16 %\u00a0404,831 \u00a0\u00a00.89 %\u00a053.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther (income) loss, net 4 \u00a0(4,141 )\u00a0\u00a0\u00a0 \u00a01,073 \u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a051,338 \u00a0\u00a0\u00a0\u00a0 \u00a037,748 \u00a0\u00a0\u00a0 \u00a036.0 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a0573,530 \u00a0\u00a0\u00a01.07 %\u00a0343,835 \u00a0\u00a00.76 %\u00a066.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense 5 \u00a0278,082 \u00a0\u00a0\u00a0\u00a0 \u00a056,567 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a0295,448 \u00a0\u00a0\u00a00.55 %\u00a0287,268 \u00a0\u00a00.63 %\u00a02.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet (income) loss attributable to noncontrolling interests \u00a0(3,326 )\u00a0\u00a0\u00a0 \u00a02,171 \u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$292,122 \u00a0\u00a0\u00a00.55 %\u00a0$289,439 \u00a0\u00a00.64 %\u00a00.9 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n7", "page_label": "7", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6d6a1ee9-ce2c-4fc2-a4c7-03f6b7923968": {"node_ids": ["4348b828-f9c4-4b04-821d-7cdd2f4248f4", "749746c8-f7db-4d55-8c6a-99359e254a6d", "4e046adf-b8d9-43d2-84bd-8f97c1d4e97b", "2613502a-191e-4276-bdd7-5263dcef6522", "25492582-915f-49f6-8852-0c1e12f68d81", "eb106088-0256-4e24-8e25-4e6c3e23327f", "b6c748b8-b2f0-4f08-904c-8c61111007dc", "0b94a360-0206-489d-87dd-c204d9748de1"], "metadata": {"window": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021.  Includes a $6.1 million LIFO expense in the three months ended June 30, 2020.\n 2 Includes $12.5 million of PharMEDium shutdown costs in the three months ended June 30, 2020.\n 3 Includes a $6.7 million of employee severance, a $124.3 million legal accrual related to our proposed opioid litigation settlement,\n$28.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $67.0 million of other\ncosts in connection with acquisition-related deal and integration costs, business transformation efforts, and other restructuring\ninitiatives in the three months ended June 30, 2021. ", "original_text": "Basic \u00a0$1.42 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.42 \u00a0\u00a0\u00a0 \u00a0\u2014 %\nDiluted \u00a0$1.40 \u00a0\u00a0\u00a0\u00a0 \u00a0$1.41 \u00a0\u00a0\u00a0 \u00a0(0.7 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0206,156 \u00a0\u00a0\u00a0\u00a0 \u00a0203,654 \u00a0\u00a0\u00a0 \u00a01.2 %\nDiluted \u00a0208,912 \u00a0\u00a0\u00a0\u00a0 \u00a0205,544 \u00a0\u00a0\u00a0 \u00a01.6 %\n________________________________________\n1 Includes a $113.9 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the three months ended June\n30, 2021. ", "page_label": "8", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6631f107-6f9c-4aff-9248-1e2814044903": {"node_ids": ["93b972c7-0ab1-426b-8ff4-c57b5dc226ea"], "metadata": {"window": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "original_text": "Gross profit 1 \u00a04,873,817 \u00a0\u00a0\u00a03.14 %\u00a03,845,037 \u00a0\u00a0\u00a02.73 %\u00a026.8 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating expenses: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nDistribution, selling, and administrative 2 \u00a02,378,563 \u00a0\u00a0\u00a01.53 %\u00a02,046,251 \u00a0\u00a0\u00a01.45 %\u00a016.2 %\nDepreciation and amortization \u00a0327,451 \u00a0\u00a0\u00a00.21 %\u00a0293,725 \u00a0\u00a0\u00a00.21 %\u00a011.5 %\nEmployee severance, litigation, and other 3 \u00a0375,501 \u00a0\u00a0\u00a0\u00a0 \u00a0165,626 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a0361,652 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nTotal operating expenses \u00a03,081,515 \u00a0\u00a0\u00a01.99 %\u00a02,867,254 \u00a0\u00a0\u00a02.04 %\u00a07.5 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOperating income \u00a01,792,302 \u00a0\u00a0\u00a01.16 %\u00a0977,783 \u00a0\u00a0\u00a00.70 %\u00a083.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther loss, net  4 \u00a04,901 \u00a0\u00a0\u00a0\u00a0 \u00a02,806 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\nInterest expense, net \u00a0119,478 \u00a0\u00a0\u00a0\u00a0 \u00a0103,176 \u00a0\u00a0\u00a0\u00a0 \u00a015.8 %\nLoss on early retirement of debt \u00a0\u2014 \u00a0\u00a0\u00a0\u00a0 \u00a022,175 \u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome before income taxes \u00a01,667,923 \u00a0\u00a0\u00a01.08 %\u00a0849,626 \u00a0\u00a0\u00a00.60 %\u00a096.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nIncome tax expense (benefit) 5 \u00a0559,763 \u00a0\u00a0\u00a0\u00a0 \u00a0(595,321 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income \u00a01,108,160 \u00a0\u00a0\u00a00.71 %\u00a01,444,947 \u00a0\u00a0\u00a01.03 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to noncontrolling interests \u00a0(5,926 )\u00a0\u00a0\u00a0 \u00a0(7,591 )\u00a0\u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nNet income attributable to AmerisourceBergen Corporation \u00a0$1,102,234 \u00a0\u00a0\u00a00.71 %\u00a0$1,437,356 \u00a0\u00a0\u00a01.02 %\u00a0(23.3 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nEarnings per share: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0$5.37 \u00a0\u00a0\u00a0\u00a0 \u00a0$7.01 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.4 )%\n9", "page_label": "9", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "9e378987-9a65-464b-b917-f2bca2db10cd": {"node_ids": ["824dbe41-cb78-4353-9a70-c365c991dc75", "62847867-7ce0-4f9d-857a-79a3dd09c318", "90f7eab6-58e4-4103-ba0c-3e4c251dbfc4", "23943697-d32a-40b3-891b-7043128dbbe5", "5054753b-44bf-413a-8837-cede99b1b5f0", "52d913c3-1688-4f77-883d-e3286369c5dd", "02bd7576-3bfb-45ad-89be-ef63cc9574d3", "09812a40-cfd0-4c1e-bf72-4859ef1dcea1", "cd0aebec-b5a3-4a7e-8647-a5f741d1cb14"], "metadata": {"window": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021.  Includes a $43.2 million LIFO expense, $12.6 million of PharMEDium remediation and shutdown costs, and an $8.5 million\ngain from antitrust litigation settlements in the nine months ended June 30, 2020.\n 2 Includes $49.0 million of PharMEDium remediation and shutdown costs and a $12.2 million adjustment to Profarma's estimate of\ncontingent consideration related to the purchase price of one of its prior business acquisitions in the nine months ended June 30,\n2020.\n 3 Includes $6.7 million of employee severance, a $141.4 million legal accrual related to our proposed opioid litigation settlement,\n$85.9 million of litigation costs related to legal fees in connection with opioid lawsuits and investigations, and $141.5 million of\nother costs in connection with acquisition-related deal and integration costs, business transformation efforts, and other\nrestructuring initiatives in the nine months ended June 30, 2021. ", "original_text": "Diluted \u00a0$5.31 \u00a0\u00a0\u00a0\u00a0 \u00a0$6.95 \u00a0\u00a0\u00a0\u00a0 \u00a0(23.6 )%\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nWeighted average common shares outstanding: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nBasic \u00a0205,255 \u00a0\u00a0\u00a0\u00a0 \u00a0205,017 \u00a0\u00a0\u00a0\u00a0 \u00a00.1 %\nDiluted \u00a0207,679 \u00a0\u00a0\u00a0\u00a0 \u00a0206,714 \u00a0\u00a0\u00a0\u00a0 \u00a00.5 %\n________________________________________\n1 Includes a $160.6 million LIFO credit and a $147.4 million gain from antitrust litigation settlements in the nine months ended June\n30, 2021. ", "page_label": "10", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3ac7718c-3947-40a7-b13c-7abc741cf8dc": {"node_ids": ["a4b43a4d-d5d5-4fcd-b24d-a31be6ff7f0f", "79eab791-fc24-4385-b6da-b9172ffc14b2"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a032.0 % \u00a037.5 % \u00a024.3 % \u00a023.1 % \u00a037.3 % \u00a0\u00a0 \u00a018.8 % \u00a016.8 %\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.54%\u00a03.05 %\nOperating expenses \u00a02.37%\u00a01.87 %\nOperating income \u00a01.16%\u00a01.18 %\n11", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.63 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(113,920 )\u00a0\u2014 \u00a0\u00a0(113,920 )\u00a0(113,920 )\u00a0(6,692 )\u00a0\u2014 \u00a0\u00a0(107,228 )\u00a0(0.51 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(44,282 )\u00a044,282 \u00a0\u00a044,282 \u00a0\u00a0(4,355 )\u00a0(890 )\u00a047,747 \u00a0\u00a00.23 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(226,964 )\u00a0226,964 \u00a0\u00a0226,964 \u00a0\u00a06,034 \u00a0\u00a0\u2014 \u00a0\u00a0220,930 \u00a0\u00a01.06 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 2\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0(6,243 )\u00a0(136,588 )\u00a0\u2014 \u00a0\u00a0130,345 \u00a0\u00a00.62 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$1,626,854 \u00a0\u00a0$996,233 \u00a0\u00a0$630,621 \u00a0\u00a0$577,181 \u00a0\u00a0$121,215 \u00a0\u00a0$(4,216 )\u00a0$451,750 \u00a0\u00a0$2.16 \u00a03\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "11", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "dba5f8dd-9511-497a-98fb-43d691170379": {"node_ids": ["0b69928b-17a8-4db3-971a-a3ea5efd452e", "9637a46f-34d4-4795-b962-8ea8187ec0fb", "9b5f18f3-0caa-4033-a24c-e472a06b50f4", "bba015a0-2c1c-4dff-8d65-a8b6cd263bce", "f421cc4f-cdb9-4538-a2f2-b91016bbc77f"], "metadata": {"window": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Includes $127.6 million of expense relating to UK tax reform, $9.0 million of expense relating to Swiss tax reform, and $6.2 million\nof income on the currency remeasurement of the related deferred tax assets, which is recorded within Other (Income) Loss.\n 3 The sum of the components does not equal the total due to rounding.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "________________________________________\n1 Includes a $124.3 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "12", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "6a3fea13-fa23-4c23-ad8a-0fab3e527b21": {"node_ids": ["d0ca7b1e-7fc8-4847-a3bf-1075cd578fe3", "be2e69d6-3882-4481-be54-a0d9c86a36d6"], "metadata": {"window": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n GAAP TO NON-GAAP RECONCILIATIONS \n (in thousands, except per share data) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30, 2021 \u00a0\nIncome \nfNet Income Dilut ed \n13", "original_text": "litigation, and\nother \u00a0\u2014 \u00a0(58,585 )\u00a058,585 \u00a058,585 \u00a014,583 \u00a0\u00a0\u2014 \u00a0\u00a044,002 \u00a0\u00a00.21 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment of\nPharMEDium\nassets \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0638 \u00a0\u00a0\u2014 \u00a0\u00a0(638 )\u00a0\u2014 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u2014 \u00a0(22 )\u00a0(1,833 )\u00a0(1,811 )\u00a0(0.01 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a022,175 \u00a05,449 \u00a0\u00a0\u2014 \u00a0\u00a016,726 \u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted Non-\nGAAP \u00a0$1,232,209 \u00a0$724,687 \u00a0\u00a0$507,522 \u00a0$468,701 \u00a0$88,295 \u00a0\u00a0$ (99 )\u00a0$380,307 \u00a0\u00a0$1.85 \u00a0\u00a0\n\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.70% \u00a02.72%\nOperating expenses \u00a01.81% \u00a01.60%\nOperating income \u00a00.89% \u00a01.12%\n________________________________________\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "13", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "426cba76-db19-4101-9255-d4fb1858ebb2": {"node_ids": ["4a884a4b-6796-4b8e-a64c-b11fe1233a4c", "a35f55b3-475b-4a7e-80cb-da6f3dfb406b"], "metadata": {"window": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs.  prior\nyear \u00a017.3 % \u00a017.8 % \u00a016.7 % \u00a016.7 % \u00a022.9 % \u00a0\u00a0 \u00a014.8 % \u00a014.3 %\u00a0\n\u00a0\n14", "original_text": "\u00a0 \u00a0Gross Pr ofit\u00a0Operating \n Expenses \u00a0Operating \n Income \u00a0Befor e \n Income\nTaxes \u00a0Income\nTax\nExpense \u00a0Attributable t o\nNoncontr olling\nInterests \u00a0Net Income\nAttributable\nto ABC \u00a0Earnings\nPer\nShare \u00a0\nGAAP \u00a0$4,873,817 \u00a0\u00a0$3,081,515 \u00a0\u00a0$1,792,302 \u00a0\u00a0$1,667,923 \u00a0\u00a0$559,763 \u00a0\u00a0$(5,926 )\u00a0$1,102,234 \u00a0\u00a0$5.31 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nGains from\nantitrust\nlitigation\nsettlements \u00a0(147,432 )\u00a0\u2014 \u00a0\u00a0(147,432 )\u00a0(147,432 )\u00a0(15,266 )\u00a0\u2014 \u00a0\u00a0(132,166 )\u00a0(0.64 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLIFO credit \u00a0(160,565 )\u00a0\u2014 \u00a0\u00a0(160,565 )\u00a0(160,565 )\u00a0(16,625 )\u00a0\u2014 \u00a0\u00a0(143,940 )\u00a0(0.69 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0(94,289 )\u00a094,289 \u00a0\u00a094,289 \u00a0\u00a03,043 \u00a0\u00a0(1,764 )\u00a089,482 \u00a0\u00a00.43 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other 1\u00a0\u2014 \u00a0\u00a0(375,501 )\u00a0375,501 \u00a0\u00a0375,501 \u00a0\u00a036,502 \u00a0\u00a0\u2014 \u00a0\u00a0338,999 \u00a0\u00a01.63 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 2 \u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a020,425 \u00a0\u00a0\u2014 \u00a0\u00a0(20,425 )\u00a0(0.10 )\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nTax reform 3\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a0\u2014 \u00a0\u00a01,086 \u00a0\u00a0(191,607 )\u00a0\u2014 \u00a0\u00a0192,693 \u00a0\u00a00.93 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$4,565,820 \u00a0\u00a0$2,611,725 \u00a0\u00a0$1,954,095 \u00a0\u00a0$1,830,802 \u00a0\u00a0$396,235 \u00a0\u00a0$(7,690 )\u00a0$1,426,877 \u00a0\u00a0$6.87 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP\n% change\nvs. ", "page_label": "14", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c8c5766a-f18b-443e-8d64-94c3b01dca8a": {"node_ids": ["6be0ccb8-531f-431d-8187-495bed6f57fd", "cc9b2ac1-fdf8-4db1-b934-435c14c6a515", "d7c04171-35b3-4f82-a5dc-389219dfc5bb", "521a7226-9b13-46f1-9fab-46b8c881187f", "5e9b4b43-6dec-4c66-abd5-895712cf8136"], "metadata": {"window": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n 2 Represents an adjustment of discrete tax benefits primarily attributable to the income tax deductions resulting from the\npermanent shutdown of the PharMEDium business.\n 3 Includes $127.6 million of expense relating to UK tax reform, $64.0 million of expense relating to Swiss tax reform, and a $1.1\nmillion loss on the currency remeasurement of the related deferred tax assets, which is recorded within Other Loss.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "original_text": "Percentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a03.14% \u00a02.94%\nOperating expenses \u00a01.99% \u00a01.68%\nOperating income \u00a01.16% \u00a01.26%\n________________________________________\n1 Includes a $141.4 million legal expense accrual related to our proposed opioid litigation settlement.\n", "page_label": "15", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "1f22f2bf-33b7-4b90-b536-cf1e31629f88": {"node_ids": ["d3f376b3-078a-4c17-a082-10aaa482a11b"], "metadata": {"window": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "original_text": "and\nremediation\ncosts \u00a012,556 \u00a0\u00a0\u00a0(49,015 )\u00a0\u00a061,571 \u00a0\u00a0\u00a061,571 \u00a0\u00a0\u00a015,128 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a046,443 \u00a0\u00a0\u00a00.22 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAcquisition-\nrelated\nintangibles\namortization \u00a0\u2014 \u00a0\u00a0\u00a0(85,345 )\u00a0\u00a085,345 \u00a0\u00a0\u00a085,345 \u00a0\u00a0\u00a020,971 \u00a0\u00a0\u00a0(1,308 )\u00a0\u00a063,066 \u00a0\u00a0\u00a00.31 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nEmployee\nseverance,\nlitigation,\nand other \u00a0\u2014 \u00a0\u00a0\u00a0(165,626 )\u00a0\u00a0165,626 \u00a0\u00a0\u00a0165,626 \u00a0\u00a0\u00a040,697 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0124,929 \u00a0\u00a0\u00a00.60 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nImpairment\nof\nPharMEDium\nassets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0361,652 \u00a0\u00a0\u00a0361,652 \u00a0\u00a0\u00a088,865 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0272,787 \u00a0\u00a0\u00a01.32 \u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nContingent\nconsideration\nadjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0(12,153 )\u00a0\u00a0(12,153 )\u00a0\u00a0(2,987 )\u00a0\u00a05,678 \u00a0\u00a0\u00a0(3,488 )\u00a0\u00a0(0.02 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nLoss on early\nretirement of\ndebt \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a022,175 \u00a0\u00a0\u00a05,449 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a016,726 \u00a0\u00a0\u00a00.08 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nCertain\ndiscrete tax\nbenefits 1 \u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0741,015 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0(741,015 )\u00a0\u00a0(3.58 )\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\nAdjusted\nNon-GAAP \u00a0$3,892,242 \u00a0\u00a0\u00a0$2,217,769 \u00a0\u00a0\u00a0$1,674,473 \u00a0\u00a0\u00a0$1,568,491 \u00a0\u00a0\u00a0$322,331 \u00a0\u00a0\u00a0$(3,221 )\u00a0\u00a0$1,242,939 \u00a0\u00a0\u00a0$6.01\u00a0\u00a0\u00a0\nPercentages o f Revenue: \u00a0GAAP \u00a0Adjust ed\nNon-GAAP\nGross profit \u00a02.73% \u00a02.77%\nOperating expenses \u00a02.04% \u00a01.58%\n16", "page_label": "16", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ff4c4e77-cafe-4534-814c-3ad8aa2c9041": {"node_ids": ["e469e068-19d6-45b0-a8bf-4a3a260e6e99", "b28ba5c4-63c6-4286-9272-003d6f9a126d", "3f4b2768-b288-4a3e-b77d-0fc08fa33025"], "metadata": {"window": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n Note: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Three Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$49,312,013 \u00a0\u00a0\u00a0$43,579,119 \u00a0\u00a0\u00a013.2 %\nOther \u00a04,128,266 \u00a0\u00a0\u00a01,810,533 \u00a0\u00a0\u00a0128.0 %\nIntersegment eliminations \u00a0(34,584 )\u00a0\u00a0(22,875 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$53,405,695 \u00a0\u00a0\u00a0$45,366,777 \u00a0\u00a0\u00a017.7 %\n\u00a0\n\u00a0 \u00a0Three Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$483,914 \u00a0\u00a0\u00a0$426,643 \u00a0\u00a0\u00a013.4 %\nOther \u00a0146,869 \u00a0\u00a0\u00a082,875 \u00a0\u00a0\u00a077.2 %\nIntersegment eliminations \u00a0(162 )\u00a0\u00a0(1,996 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a0630,621 \u00a0\u00a0\u00a0507,522 \u00a0\u00a0\u00a024.3 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a0\u2014 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0113,920 \u00a0\u00a0\u00a0(6,061 )\u00a0\u00a0\u00a0\nPharMEDium shutdown costs \u00a0\u2014 \u00a0\u00a0\u00a0(12,936 )\u00a0\u00a0\u00a0\n17", "original_text": "Operating income \u00a00.70% \u00a01.19%\n________________________________________\n1 Includes $741.0 of discrete tax benefits primarily attributable to the income tax deductions resulting from the shutdown of the\nPharMEDium business.\n", "page_label": "17", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "c780a895-f794-4666-8259-cada8c3ff3f5": {"node_ids": ["5b71840d-7f4c-4773-9eba-8c98a9753df9", "d1d4d66f-0993-4009-9755-d864305b3d74"], "metadata": {"window": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n 18", "original_text": "Acquisition-related intangibles amortization \u00a0(44,282 )\u00a0\u00a0(25,109 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(226,964 )\u00a0\u00a0(58,585 )\u00a0\u00a0\u00a0\nOperating income \u00a0$620,727 \u00a0\u00a0\u00a0$404,831 \u00a0\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.14 \u00a0%\u00a02.08 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.16 \u00a0%\u00a01.10 \u00a0%\u00a0\u00a0\nOperating income \u00a00.98 \u00a0%\u00a00.98 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a013.92 \u00a0%\u00a018.17 \u00a0%\u00a0\u00a0\nOperating expenses \u00a010.37 \u00a0%\u00a013.59 \u00a0%\u00a0\u00a0\nOperating income \u00a03.56 \u00a0%\u00a04.58 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.54 \u00a0%\u00a02.70 \u00a0%\u00a0\u00a0\nOperating expenses \u00a02.37 \u00a0%\u00a01.81 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.89 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a03.05 \u00a0%\u00a02.72 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.87 \u00a0%\u00a01.60 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.18 \u00a0%\u00a01.12 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "18", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7d1a231b-11f1-4500-9ed3-84383fc945ed": {"node_ids": ["1648d99d-e901-4f47-a595-19d87421fd7b"], "metadata": {"window": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "original_text": "AMERISOURCEBERGEN CORPORATION \n SUMMARY SEGMENT INFORMATION \n (dollars in thousands) \n (unaudited)\n\u00a0 \u00a0Nine Months Ended June 30,\nRevenue \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$146,905,854 \u00a0\u00a0\u00a0$135,178,617 \u00a0\u00a0\u00a08.7 %\nOther \u00a08,273,312 \u00a0\u00a0\u00a05,534,110 \u00a0\u00a0\u00a049.5 %\nIntersegment eliminations \u00a0(102,744 )\u00a0\u00a0(63,569 )\u00a0\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nRevenue \u00a0$155,076,422 \u00a0\u00a0\u00a0$140,649,158 \u00a0\u00a0\u00a010.3 %\n\u00a0\n\u00a0 \u00a0Nine Months Ended June 30,\nOperating\u00a0income \u00a02021 \u00a0\u00a0\u00a02020 \u00a0\u00a0\u00a0%\u00a0Change\nPharmaceutical Distribution Services \u00a0$1,569,014 \u00a0\u00a0\u00a0$1,381,434 \u00a0\u00a0\u00a013.6 %\nOther \u00a0391,696 \u00a0\u00a0\u00a0295,614 \u00a0\u00a0\u00a032.5 %\nIntersegment eliminations \u00a0(6,615 )\u00a0\u00a0(2,575 )\u00a0\u00a0\u00a0\nTotal segment operating income \u00a01,954,095 \u00a0\u00a0\u00a01,674,473 \u00a0\u00a0\u00a016.7 %\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGains from antitrust litigation settlements \u00a0147,432 \u00a0\u00a0\u00a08,546 \u00a0\u00a0\u00a0\u00a0\nLIFO credit (expense) \u00a0160,565 \u00a0\u00a0\u00a0(43,195 )\u00a0\u00a0\u00a0\nPharMEDium shutdown and remediation costs \u00a0\u2014 \u00a0\u00a0\u00a0(61,571 )\u00a0\u00a0\u00a0\nAcquisition-related intangibles amortization \u00a0(94,289 )\u00a0\u00a0(85,345 )\u00a0\u00a0\u00a0\nEmployee severance, litigation, and other \u00a0(375,501 )\u00a0\u00a0(165,626 )\u00a0\u00a0\u00a0\nImpairment of PharMEDium assets \u00a0\u2014 \u00a0\u00a0\u00a0(361,652 )\u00a0\u00a0\u00a0\nContingent consideration adjustment \u00a0\u2014 \u00a0\u00a0\u00a012,153 \u00a0\u00a0\u00a0\u00a0\nOperating income \u00a0$1,792,302 \u00a0\u00a0\u00a0$977,783 \u00a0\u00a0\u00a0\u00a0\n19", "page_label": "19", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "dd3484f2-8c0b-4b1d-92a2-d188850dc10d": {"node_ids": ["070c2aed-83ea-4ecb-9047-3b74693a2626", "cbc53efc-6495-498a-be3f-b7cfbacb8360"], "metadata": {"window": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n AMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED BALANCE SHEETS \n (in thousands) \n (unaudited)\n20", "original_text": "\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPercentages of revenue: \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nPharmaceutical Distribution Services \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a02.19 \u00a0%\u00a02.11 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.12 \u00a0%\u00a01.09 \u00a0%\u00a0\u00a0\nOperating income \u00a01.07 \u00a0%\u00a01.02 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nOther \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a016.39 \u00a0%\u00a018.78 \u00a0%\u00a0\u00a0\nOperating expenses \u00a011.65 \u00a0%\u00a013.44 \u00a0%\u00a0\u00a0\nOperating income \u00a04.73 \u00a0%\u00a05.34 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nGross profit \u00a03.14 \u00a0%\u00a02.73 \u00a0%\u00a0\u00a0\nOperating expenses \u00a01.99 \u00a0%\u00a02.04 \u00a0%\u00a0\u00a0\nOperating income \u00a01.16 \u00a0%\u00a00.70 \u00a0%\u00a0\u00a0\n\u00a0 \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAmerisourceBergen Corporation (Non-GAAP) \u00a0\u00a0 \u00a0\u00a0 \u00a0\u00a0\nAdjusted gross profit \u00a02.94 \u00a0%\u00a02.77 \u00a0%\u00a0\u00a0\nAdjusted operating expenses \u00a01.68 \u00a0%\u00a01.58 \u00a0%\u00a0\u00a0\nAdjusted operating income \u00a01.26 \u00a0%\u00a01.19 \u00a0%\u00a0\u00a0\nNote: For more information related to non-GAAP financial measures, refer to the section titled \"Supplemental Information\nRegarding Non-GAAP Financial Measures\" of this release.\n", "page_label": "20", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3dfc97ef-e4e0-4ca9-842c-540aca825314": {"node_ids": ["7e1deeb3-c6b7-4d52-a15a-794a00f514d9"], "metadata": {"window": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "original_text": "\u00a0 June 30, \u00a0September 30,\n\u00a0 2021 \u00a02020\nASSETS \u00a0 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent assets: \u00a0 \u00a0\u00a0\nCash and cash equivalents $2,553,217 \u00a0\u00a0$4,597,746 \u00a0\nAccounts receivable, net 17,695,170 \u00a0\u00a013,846,301 \u00a0\nInventories 14,996,364 \u00a0\u00a012,589,278 \u00a0\nRight to recover assets 1,215,839 \u00a0\u00a01,344,649 \u00a0\nIncome tax receivable 254,065 \u00a0\u00a0488,428 \u00a0\nPrepaid expenses and other 545,111 \u00a0\u00a0189,300 \u00a0\nTotal current assets 37,259,766 \u00a0\u00a033,055,702 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nProperty and equipment, net 2,143,080 \u00a0\u00a01,484,808 \u00a0\nGoodwill and other intangible assets 14,570,548 \u00a0\u00a08,592,826 \u00a0\nDeferred income taxes 289,040 \u00a0\u00a0361,640 \u00a0\nOther long-term assets 1,668,502 \u00a0\u00a0779,854 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal assets $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLIABILITIES AND STOCKHOLDERS\u2019 EQUITY (DEFICIT) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCurrent liabilities: \u00a0 \u00a0\u00a0\nAccounts payable $36,502,816 \u00a0\u00a0$31,705,055 \u00a0\nOther current liabilities 2,631,413 \u00a0\u00a01,646,763 \u00a0\nShort-term debt 455,609 \u00a0\u00a0501,259 \u00a0\n21", "page_label": "21", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0f7a4cae-8fec-42b4-bd7a-d29f10ee3849": {"node_ids": ["51c7f25e-43f6-4deb-a450-be956a0a71e1"], "metadata": {"window": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "original_text": "Total current liabilities 39,589,838 \u00a0\u00a033,853,077 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nLong-term debt 6,647,183 \u00a0\u00a03,618,261 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nAccrued income taxes 283,735 \u00a0\u00a0284,845 \u00a0\nDeferred income taxes 1,671,696 \u00a0\u00a0686,485 \u00a0\nOther long-term liabilities 1,058,767 \u00a0\u00a0472,855 \u00a0\nAccrued litigation liability 6,271,276 \u00a0\u00a06,198,943 \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal equity (deficit) 408,441 \u00a0\u00a0(839,636) \u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nTotal liabilities and stockholders' equity (deficit) $55,930,936 \u00a0\u00a0$44,274,830 \u00a0\nAMERISOURCEBERGEN CORPORATION \n CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS \n (in thousands) \n (unaudited)\n\u00a0 Nine Months Ended June 30,\n\u00a0 2021 \u00a0\u00a02020 \u00a0\nOperating Activities: \u00a0 \u00a0\u00a0\nNet income $1,108,160 \u00a0\u00a0\u00a0$1,444,947 \u00a0\u00a0\nAdjustments to reconcile net income to net cash provided by operating activities 1599,953 \u00a0\u00a0\u00a0822,005 \u00a0\u00a0\nChanges in operating assets and liabilities, excluding the effects of acquisitions: \u00a0 \u00a0\u00a0\nAccounts receivable (116,845 )\u00a0\u00a0(436,237 )\u00a0\nInventories (594,708 )\u00a0\u00a0(910,828 )\u00a0\nAccounts payable 242,419 \u00a0\u00a0\u00a0824,105 \u00a0\u00a0\nOther, net 2 417,790 \u00a0\u00a0\u00a0(836,184 )\u00a0\nNet cash provided by operating activities 1,656,769 \u00a0\u00a0\u00a0907,808 \u00a0\u00a0\n22", "page_label": "22", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "74388ca1-192d-449a-97e9-9c50c8cd9dd3": {"node_ids": ["4707c0eb-b7e4-41ea-ba2a-30d86cc62287", "7a39f68e-7898-4978-b840-60071077090e", "d3b437de-82fa-44f9-b58d-71755b7c72aa"], "metadata": {"window": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n 2 Includes a $590.2 million increase in income tax receivable for the nine months ended June 30, 2020 primarily as a result of\nrecognizing certain discrete tax benefits.\n 3 Includes proceeds from the issuance of the Company's $1,525 million of 0.737% senior notes, $1,000 million of 2.700% senior\n23", "original_text": "\u00a0 \u00a0 \u00a0\u00a0\nInvesting Activities: \u00a0 \u00a0\u00a0\nCapital expenditures (273,407 )\u00a0\u00a0(251,101 )\u00a0\nCost of acquired companies, net of cash acquired (5,536,717 )\u00a0\u00a0\u2014 \u00a0\u00a0\nCost of equity investments (162,620 )\u00a0\u00a0(34,830 )\u00a0\nOther, net 2,516 \u00a0\u00a0\u00a07,824 \u00a0\u00a0\nNet cash used in investing activities (5,970,228 )\u00a0\u00a0(278,107 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nFinancing Activities: \u00a0 \u00a0\u00a0\nNet borrowings (repayments) 3 2,620,315 \u00a0\u00a0\u00a0(10,960 )\u00a0\nPayment of premium on early retirement of debt \u2014 \u00a0\u00a0\u00a0(21,448 )\u00a0\nPurchases of common stock (82,150 )\u00a0\u00a0(420,449 )\u00a0\nExercises of stock options 164,297 \u00a0\u00a0\u00a0137,748 \u00a0\u00a0\nCash dividends on common stock (274,041 )\u00a0\u00a0(256,764 )\u00a0\nOther (30,965 )\u00a0\u00a0(11,750 )\u00a0\nNet cash provided by (used in) financing activities 2,397,456 \u00a0\u00a0\u00a0(583,623 )\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\n(Decrease) increase in cash and cash equivalents (1,916,003 )\u00a0\u00a046,078 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at beginning of period 4,597,746 \u00a0\u00a0\u00a03,374,194 \u00a0\u00a0\n\u00a0 \u00a0 \u00a0\u00a0\nCash, cash equivalents, and restricted cash at end of period $2,681,743 \u00a0\u00a0\u00a0$3,420,272 \u00a0\u00a0\n________________________________________\n1 Includes an impairment of PharMEDium assets of $361.7 million in the nine months ended June 30, 2020.\n", "page_label": "23", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "7171fa27-94f2-418f-83e9-6b9aa8af453c": {"node_ids": ["36c35b28-cedc-4e26-88cd-76ecddd57d06", "0b3732d9-f301-45cf-8534-abb0db7c1b18", "66803499-28a2-4be4-9a75-6303460a167d", "31bf0499-f754-4e46-b7a6-329f0f9e27a8", "fffefa91-0a17-4e23-ba3a-4715eac1ced3", "68ba87d9-d1f3-4fc0-8783-56d7c9cf33ab", "d1fdf0dd-064a-4e86-8a1c-b22d206796ad", "b9afe04f-8167-4299-927c-d323f74b81f8", "60e9fe26-5af6-4409-8648-b9374aa8c30e", "b53d66d1-017c-4a2d-a409-5cde11d712d5", "1c293633-80d3-4936-befd-8fcaf47aa9ed", "6b3f3b03-e89f-49ef-954a-7650b4ce3a14", "f6fafac4-6596-487d-a16c-f3a136557ec0", "7293e5fd-9eb4-4947-b0ab-5fb06bdf6ad4", "68bac126-a580-41c1-9ac8-7b21e7d0bd7c", "025c4c7f-9ed5-4187-bfef-c3e22b86bf89", "ccf06800-89eb-4b1b-8dd3-a888f85f8b9b", "59704da3-0b55-4c9f-8ed5-a70672a4ca7a", "4ec40243-9deb-4ecb-951c-f691669e00d6", "50efce9d-4e95-4d06-8839-991b205eed1e", "c6c53c5b-b148-4c79-8a45-de56b842022f", "1fed0e71-6c86-44eb-87f5-6433ca3a68fe", "6f3b167d-827b-4e3d-b4e0-9936ae2d0fea", "ed2e65d4-795c-4fc0-a70b-4e0686807ae7", "e2ec1c3d-2ca4-474e-b053-18f1a3140e9f", "e66ffe97-16ee-4933-978a-ea7720481782", "d944e562-2afa-4197-96ad-ac896417dd38", "4834dd80-ae60-47af-8f81-15f9580b1a68", "af5aaf3a-b375-4561-bad1-24e4b4550e26"], "metadata": {"window": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n SUPPLEMENT AL INFORMA TION REGARDING \n NON-GAAP FINANCIAL ME ASURES\nTo supplement the financial measures prepared in accordance with U.S.  generally accepted accounting principles (GAAP), the\nCompany uses the non-GAAP financial measures described below.  The non-GAAP financial measures should be viewed in addition\nto, and not in lieu of, financial measures calculated in accordance with GAAP. ", "original_text": "notes, and $500 million of term loan, all of which were used to finance a portion of the June 2021 acquisition of Alliance Healthcare.\n", "page_label": "24", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "5cfc11b6-6ece-4619-9cc6-f02e1b69cf67": {"node_ids": ["cbc99c99-570d-465d-b7d7-70dbf6450a33", "acf44f2b-f418-4c4f-b056-181d17c79557", "024c427c-51fa-4cba-a964-803d03a1a732", "a2acc911-677f-4cec-98e1-f07eb5416e38", "b1f7a156-f25a-40c8-a348-ae89c28958b2", "3bfbdcdb-3821-4c17-ab51-5792f77fbd87", "9777dfaa-03e7-4034-8481-d406b9413329", "a0b058c0-c3b8-4dcf-a108-f755e86c1076", "6400c47e-a9a7-4998-b1cf-0e1c0c6d691c", "23eaf8f6-3034-4df1-b50f-222f4667e5fb", "c6db908e-3e45-416b-b5f1-7c69833f8115", "a11e34df-566e-457e-aa06-20f59133dfb2", "6e02659c-4951-446a-9111-3a0d23acec4b", "2670cb43-b7e5-499e-8c4d-fd4ed0a754f5", "7d1370b6-5da8-4e89-8826-5e04c5bc7a48", "ddaee0c8-d92a-458b-9b06-bf82ca3a374f", "891bccfb-099d-49e3-a581-c0df87b2c5a0", "5ef4e695-8cd3-46cf-a507-65abb6970e85", "cc0a49e3-51d6-4c70-b8a9-44164bb35d23", "2969592d-eeb4-4f21-b2b0-feefb08e5b7b", "2fef3fa9-100a-47b5-9b12-2071062ac984", "2384ec3f-0df3-459d-8c7c-67338b621162"], "metadata": {"window": "the same items that are described above and excluded from adjusted operating income.  In addition, the loss on the currency\nremeasurement of the deferred tax asset relating to Swiss tax reform in the three and nine months ended June 30, 2021 and\nthe loss on the early retirement of debt in the three and nine months ended June 30, 2020 are excluded from adjusted\nincome before income taxes because these amounts are unusual, non-operating, and non-recurring.  Management believes\nthat this non-GAAP financial measure is useful to investors because it facilitates the calculation of the Company\u2019s adjusted\neffective tax rate.\n Adjusted effective tax rate:  Adjusted effective tax rate is a non-GAAP financial measure that is determined by dividing adjusted\nincome tax expense/benefit by adjusted income before income taxes. ", "original_text": "the same items that are described above and excluded from adjusted operating income. ", "page_label": "25", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "13c320f3-2b7f-43b1-a5c3-ae2a04ead40a": {"node_ids": ["da867c2e-ebf3-4b31-b7ce-a5ee0228f6b3", "58d1aaaa-8cb5-4dba-8f8d-2d9751eb58df", "cbdc7274-69bc-46db-bba3-37b9ccb298cd"], "metadata": {"window": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated.  Similarly, the timing and amount of litigation settlements is unpredictable and non-recurring.\n View source version on businesswire.com : https://www.businesswire.com/news/home/20210804005182/en/\nBennett S. Murphy \n Senior Vice President, Investor Relations \n 610-727-3693 \n bmurphy@amerisourcebergen.com\nSource: AmerisourceBergen Corporation\n26", "original_text": "dependent upon the future inflation or deflation of brand and generic pharmaceuticals, which is out of the Company\u2019s control, and\nacquisition-related intangibles amortization depends on the timing and amount of future acquisitions, which cannot be reasonably\nestimated. ", "page_label": "26", "file_name": "CEN-Q3-FY21-ECT.pdf", "file_path": "pdfs\\CEN-Q3-FY21-ECT.pdf", "file_type": "application/pdf", "file_size": 224188, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}